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Abstract 
 
Carbohydrates are one of the most abundant biomolecules and are fundamental to 
the correct function of many biological processes. The monosaccharide ʟ-fucose is 
incorporated into biological polymers including oligo and polysaccharides, and 
glycoproteins. ʟ-fucose is often appended to the end of a glycan chain, and as such 
is recognised by lectins in a number of molecular recognition events. Due to this, 
the monosaccharide plays a critical role in the immune response, the colonisation of 
bacteria in mammals, and cancer. Two enzymes regulate homeostasis  of ʟ-
fucosylated biomolecules, GDP-ʟ-fucosyltransferases append the sugar to nascent 
biomolecules while α-ʟ-fucosidases catalyse its cleavage . Two α-ʟ-fucosidases exist 
in the human genome. Deficiency of one of these enzymes causes the lysosomal 
storage disorder fucosidosis, and the enzyme is upregulated in a number of cancers. 
Meanwhile, the other enzyme has been shown to play a critical role in enabling the 
adhesion of the pathogen Helicobacter pylori  to mammals. Thus, inhibition of α -ʟ-
fucosidase activity is clinically relevant. In this work, the 1.6 - 2.1 Å X-ray crystal 
structures of α-ʟ-fucosidase inhibitors complexed with a bacterial α -ʟ-fucosidase 
are presented and discussed. Of the inhibitors discussed, the majority comprise 5 -
membered iminocyclitols, a potent yet infrequently used framework for inhibition 
of glycoside hydrolases, and their mode of binding to the enzyme in an E3  
conformation is elaborated from crystal structures. Further, the crystallographic 
observation of the interaction between a 6-membered ring inhibitor comprising an 
aziridine moiety as an electrophilic trap and a glycoside hydrolase is reported for 
the first time. Finally, efforts towards the purification and crystallisation of α -ʟ-
fucosidases from Homo sapiens  are documented. The results reported herein may 
aid in the rational design of more potent inhibitors of α -ʟ-fucosidase in the future 
and may help direct future efforts towards the crystallisation and structure solution 
of the clinically important human enzymes.  
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Chapter 1: Introduction 
 
Abstract  
Carbohydrates are one of the most abundant biological polymers and are critical to 
many biological processes. Monosaccharides are catabolised as an energy source 
while polysaccharides have numerous important biological roles, both structural 
such as in the plant cell wall and functional e.g. in cell-cell interactions, signal 
transduction and protein folding and function. ʟ-fucose is one of the series of ʟ-
configured monosaccharides and is unusual in its lack of a hydroxyl group at the C6 
carbon; the sugar is incorporated into a number of biologically important polymers 
including those from plant and animal extracellular matrices, and many 
immunogens such as blood group ABO and Lewis antigens. GDP-ʟ-
fucosyltransferases and α-ʟ-fucosidases catalyse the transfer of ʟ-fucosyl moieties 
to nascent polysaccharides, and the cleavage in an exo-fashion of an α-ʟ-fucoside 
from such a polymer, respectively. Deficiency in either of these enzymes causes 
disease phenotypes in mammals, reflecting the importance of ʟ-fucosylated 
carbohydrates in nature. While deficiency in various GDP-ʟ-fucosyltransferase 
activities leads to a range of outcomes due to the diverse roles of ʟ-fucosyl moieties 
in biology, deficiency in α-ʟ-fucosidase activity causes the lysosomal storage 
disorder fucosidosis, which causes severe neuronal and psychomotor defects  and 
early death. Herein, the role of carbohydrates in nature, and particularly the role of 
the monosaccharide ʟ-fucose, will be discussed.  
  
  
2 
 
1.1 The role of carbohydrates in nature 
In the post-genomic revolution era, i t is perhaps often overlooked how important 
carbohydrates are in the biochemical context.  Carbohydrates are one of the most 
abundant species in nature, are found in every kingdom of life and are pivotal in 
many biological processes such as energy storage, the formation of durable 
biological structures such as the plant cell wall, and the immune response. It is been 
estimated that more than half of all mammalian proteins are glycoproteins
1
 and it is 
thus no surprise that the attachment of carbohydrates to these proteins often serves 
a critical role in affecting the way they perform their functions
2
.  A great number of 
disease states are also related to carbohydrate metabolism
2,3
, and many pathogens 
effect their adhesion by exploitation of carbohydrate-mediated interactions
4-6
.  
Historically, the etymology of the term carbohydrate (also sugars, saccharides) was 
a literal chemical definition, ‘hydrates of carbon’ i.e. describing compounds that 
have the general chemical structure  Cx(H2O)y. Many carbohydrates e.g. sialic acids, 
N-acetylhexosamines and deoxyribose, however, deviate from this general formula, 
and a more correct definition for a carbohydrate is a polyhydroxy aldehyde (aldose 
sugar) or ketone (ketose sugar). The simplest form of a carbohydrate is a 
monosaccharide, while polymerisation of monosaccharides with other carbohydrates 
leads to the formation of  di, tri, oligo and polysaccharides (also glycans) .  
Carbohydrates are typified by their large number of chiral centres, and many 
biological systems have evolved to specifically recognise and interact with a single 
stereoisomer from the large number present in nature. The large number of chiral 
centres in these compounds poses a significant challenge for their chemical 
syntheses, or synthesis of related compounds in vitro. Thus, chemical syntheses of 
carbohydrate-related compounds typically involve the use of carbohydrates already 
containing the complex chirality required as a feedstock .  
Carbohydrate monomers (monosaccharides) are named to represent their open-chain 
length, aldose or ketose nature, and stereochemistry. ʟ- and ᴅ- nomenclature for all 
other than the shortest carbohydrate, glyceraldehyde, is not, as one would expect, 
based on the direction in which a carbohydrate epimer rotates the orientation of 
plane-polarised light, but is based on the chirality of the highest -order chiral centre 
in the open-chain form of the carbohydrate, and whether it is on the same side of 
the Fischer projection (Figure 1.1) as that of ʟ- or ᴅ-glyceraldehyde.  
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Figure 1.1. Carbohydrate nomenclature and ring-closing reactivity. Panel A: Both 
isomers of glyceraldehyde, the shortest chain carbohydrate, shown in Fischer 
projection. Panel B: Mutarotation of ᴅ-glucose. ʟ- and ᴅ- nomenclature of 
carbohydrates other than glyceraldehyde is based on the highest number chiral 
centre (shown in red), and whether this is on the same side of the Fischer projection 
of ʟ- or ᴅ- glyceraldehyde. α and β nomenclature  is dictated by whether the 
endocyclic bond formed is on the same (α) or opposite (β) side of the Fischer 
projection as the newly formed, anomeric hydroxyl.  
 
The carbonyl groups in carbohydrates are labile to nucleophilic attack from the ir 
internal hydroxyls and these compounds exist in equilibrium of their open-chain 
form with multiple closed ring forms (Figure 1.1 shows this for glucose).  The ring 
strain of smaller heterocycles typically favours the formation of larger ring 
structures, up to the most favourable 6-cycles, which have the lowest strain energy. 
Thus, the most prevalent ring structures of carbohydrates are furanose and pyranose  
rings (5- or 6- membered ring structures, respectively, comprising a single O atom).  
Ring-closing reactivity can occur towards either the Re- or Si- face of the 
electrophilic carbonyl group leading to α - or β-products, with nomenclature being 
based on the chirality of the newly-formed (anomeric) chiral centre (Figure 1.1). 
Reaction is typically favoured from the face of the carbonyl which places hydroxyls 
in an equatorial conformation, in order to minimise trans -diaxial steric clashing. 
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Nomenclature dictates that the β-anomer of a carbohydrate is that where the 
anomeric hydroxyl has the same absolute stereochemistry as  that of the highest-
order chiral centre of the carbohydrate, whilst the α-anomer has different absolute 
stereochemistry between these two chiral centres .  
 
1.1.1 Enzymes that act on carbohydrates  
Further reactivity of carbohydrates occurs in nature through enzymatic catalysis . 
Glycosyltransferase enzymes catalyse the formation of glycosidic bonds between 
activated donor sugars and nucleophilic acceptor moieties to form polysaccharides, 
glycolipids or glycoproteins (Figure 1.2, A).
7
 An important point of nomenclature is 
that of the reducing vs. the non-reducing end of a polysaccharide; reducing sugars 
contain free aldehyde groups or are able to form these moieties through 
mutarotation. While no free aldehyde group typically exists in biomolecules, the 
distinction of the reducing vs. non-reducing end of the polysaccharide chain is often 
made. Glycosyltransferases catalyse the appendage of saccharides to the non-
reducing end of a nascent polysaccharide.  
Hydroxyls of carbohydrates may further be sulfated or phosph orylated (Figure 1.2, 
B-C). The sulfation of oligosaccharides occurs by the action of sulfotransferases in 
the golgi compartment and drastically alters the physical and biological properties 
of the oligosaccharide.
8
 In sulfated glycosaminoglycans such as heparin, sulfation 
is critical to biological function in mediating molecular interactions through 
electrostatics; sulfation patterns of this biomolecule have been shown to be 
important e.g. for its sequestration of growth factors
9
, interaction with chemokines 
during leukocyte migration
10
 and uptake by various cell types
11
. Oligosaccharide 
phosphorylation on the other  hand is involved in enzyme trafficking. The 
incorporation of mannose-6-phosphate into N-glycans acts as a signalling sequence 
for transport of the nascent glycoprotein to the lysosome by its recognition with 
mannose-6-phosphate receptors and subsequent vesicular transport; whilst other 
mechanisms exist, this is the predominant means for lysosomal targetting
12
.  
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Figure 1.2. Schematic of some of the reactions catalysed by carbohydrate -
processing enzymes. Glucose is used as a representative monosaccharide.  Substrate 
specificities for these reactions may be slightly altered i.e. C2-C6 OH groups may 
already be modified. A: Glycosyltransferases catalyse the transfer of glycosyl 
moieties to acceptor moieties through activated donor sugars. B: Sulfotransferases 
(B) and kinases (C) may append sulfate or phosphate moieties to the free hydroxyls 
on glycosides. D: glycoside hydrolases catalyse the cleavage of the energetically 
stable glycoside bond.  
 
Glycosidic bonds are incredibly stable, indeed even more so than other biological 
polymers such as DNA and proteins
13-15
; cleavage of the glycosidic bond is thus 
catalysed by glycoside hydrolase enzymes which enhance the rate of hydrolys is by 
as much as a factor of 10
17 13
. Glycoside hydrolases catalyse the hydrolysis of 
glycosylated structures such as polysaccharides, glycoproteins and glycolipids, to 
yield mono-, di- or oligosaccharides, and may act in either an exo- or endo- manner 
i.e. hydrolyse a terminal or non-terminal glycosidic bond respectively (Figure 1.2 
D). 
Carbohydrates have many biological roles, inter alia, in energy transfer
16
, their 
incorporation in extracellular matrices such as the plant cell wall  and animal mucin 
proteins
17
, protein folding
18
, their mediation of cell-cell interaction events and 
signal transduction
19
.   
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1.2 Fucose 
Fucose (6-deoxy-ʟ-galactose, below) is a deoxyhexose sugar that is present in all 
domains of life, and belongs to the rare series of ʟ-sugars. The α-anomer of fucose 
is the most thermodynamically favourable due to the anomeric effect; the C1 
hydroxyl preferentially lies in an axial position (α-fucose) rather than an equatorial 
position (β-fucose).  
 
Fucose is incorporated into a number of polysaccharide structures throughout 
nature; often, the sugar is appended to the non-reducing end of glycans and forms 
part of a molecular recognition and signalling moiety, however a number of fucose-
rich structural polysaccharide structures also exist.
20
 As a structural polysaccharide, 
ʟ-fucose is a component of the extracellular matrices of brown seaweed and some 
marine invertebrates
21,22
, and is also incorporated as a side-chain component in the 
hemicellulosic portion of xyloglucan of some plants
23
. Fucose is also a component 
of both N-linked and O-linked glycans, and as such a number of fucosyltransferase 
enzymes are involved in appending ʟ-fucosyl moieties to nascent oligosaccharides 
during the biosynthesis of these structures.
20
 The homeostasis of fucosylated 
structures also requires the action of exo-acting α-ʟ-fucosidases which cleave ʟ-
fucose residues from the non-reducing end of a polysaccharide chain.  What follows 
is a description of some of the many places throughout nature that this 
monosaccharide may be found.  A number of the more esoteric biological structures 
containing ʟ-fucose will be discussed first, followed by a more in-depth discussion 
of the sugar’s incorporation in carbohydrate structures important  to human health. 
 
1.2.1 ʟ-Fucose as a component of plant and animal extracellular matrices 
Holothurians, or sea cucumbers,  incorporate fucosylated chondroitin sulfate 
(FucCS) into their body walls. These carbohydrates are glycosaminoglycans 
comprising branched ʟ-fucose moieties that were first described in 1988, when 
extracted from the holothurian Ludwigothurea grisea .
24
 The molecular architecture 
of FucCS has since been elucidated; the polysaccharide has a repeating main chain 
of β(1,4)-linked glucuronic acid and β(1,3)-linked N-acetyl galactosamine, with a 
large number of sulfated Fucα(1,3) branches appended to the main chain glucuronic 
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acid (Figure 1.3).
22,25
 The analysis of FucCS extracts after chondroitinase treatment 
by Vieira et al . showed that the polysaccharide is incorporated into proteoglycans 
with a wide molecular weight range, however all products reported displayed a 
similar protein to carbohydrate ratio.
26
 FucCS has been shown to have a number of 
beneficial effects to human physiology, including its activity as an anticoagulant 
and anti-thrombotic. The anticoagulant activity of FucCS is attributed to the 
sulfated fucose present in its structure, as de-sulfation or de-fucosylation of the 
carbohydrate abolishes its anticoagulant activity.
27
 Likewise, the anti-thrombotic 
effectiveness of the polysaccharide is dependent on its branched fucosyl moieties.
28
 
Other described therapeutic effects of FucCS include, inter alia , its attenuation of 
tumour metastasis and inflammation through blocking the binding between selectins 
and sialyl-Le
x
, vide infra
29
, and its ability to ameliorate hyperglycemia in skeletal 
muscle through effects likely arising from activation of gen es in the PKB/GLUT4 
signalling pathway
30
.  
Brown seaweed, and a number of marine invertebrates, produce polysaccharides 
comprising mostly highly sulfated branched chains of ʟ-fucose, termed 
fucoidans.
21,31
 Following the trend of sulfated fucose-containing polysaccharides, 
these compounds have also been shown to have a number of beneficial effects to 
human physiology. As with FucCS, this includes their activity as anti -inflammatory 
agents
32
, anti-coagulants
32,33
, and anti-proliferatives against cancer cells
32,34
, and 
due to this, the polysaccharide is marketed as a dietary supplement. Fucoidan has 
also been shown to have a marked inhibitory effect on human, hamster and guinea 
pig sperm binding to oocyte zona pellucida reflecting the roles of ʟ-fucose in 
fertility, vide infra .
35
 
Fucoidans from different organisms have diverse structures; linear ʟ-fucose chains 
may be α(1,3) linked or built from repeating α(1,3) and α(1,4) linkages, different 
sulfation patterns exist between different organisms , acetylation may be present at 
positions 2, 3 or 4 of fucose residues, and some fucoidans also incorpora te xylose, 
mannose, galactose, glucose, glucuronic acid and α(1,2)-linked fucose branches in 
their structures (Figure 1.3).
21,31
  
ʟ-Fucose is incorporated as a side-chain component in the pectic and hemicellulosic 
material of plant cell walls.  In pectins, fucose is incorporated in the side -chains of 
rhamnogalactouronans I and II, though the sugar makes up a very small proportion 
of the overall carbohydrate content of these polysaccharides.
36
 Xyloglucan 
comprises a large portion of the hemi-cellulosic biomass present in plant cell walls, 
and ʟ-fucose is incorporated into xyloglucan side -chains in a genetically diverse 
subset of plants, inter alia, pines, legumes and onions, in XXFG and XLFG 
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subunits (Figure 1.4, for nomenclature see Fry et al . 1993
37
).
23
 As the sugar is 
incorporated into xyloglucan in species which are evolutionarily unrelated, there 
was speculation about the importance of the sugar in plant development, leading to 
a number of studies to address  this question. 
 
Figure 1.3. Strucures of fucose-rich carbohydrates from seaweed and sea 
cucumbers. Panel A: Structure of fucosylated chondroitin sulfate from the body 
wall of sea cucumbers, adapted from Pomin et al . 2014
22
. Panel B: Molecular 
architectures of selected fucoidans from brown seaweed and marine invertebrates  to 
represent their marked structural heterogeneity , adapted from Ale et al . 2013
31
.  
 
Molecular dynamics simulations, supported by in vitro assays, of pea and 
nasturtium xyloglucans, differing in nasturtium xyloglucan’s lac k of α(1,2)-linked 
fucose residues, revealed that fucosylation of xyloglucan markedly increased its 
affinity for cellulose
38
; as the binding of xyloglucan to cellulose is thought to 
modulate cell growth, this result would seem to indicate a role of fucose in 
modulating plant growth.  
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Figure 1.4. Fucose as a side-chain component of hemicellulose in the plant cell 
wall.  
 
The characterisation of mur1, an Arabidopsis thaliana mutant strain completely 
deficient in ʟ-fucose, revealed that the lack of ʟ-fucose causes dwarfism and low 
cell wall strength in planta.
39
 Later, an A. thaliana mur2  mutant, lacking the α(1,2)-
fucosyltransferase that appends fucose to the Galβ(1,2)-Xylα(1,6)-Glc sidechain of 
xyloglucan (Figure 1.4) was characterised; this mutant strain has a 50 % reduction 
in fucose content of the plant’s cell wall, indicating that half of the extracellular 
matrix fucose content in A. thaliana  is from xyloglucan.
40
 Whilst mur1 mutant 
plants display low cell wall strength, mur2  mutants were shown to have similar 
growth and cell wall strength to wild type plants under a variety of growth 
conditions, leading to speculation that the loss of fucose from fucosylated pectin is 
to be attributed for the lower growth and cell wall strength of the mur1 mutant.
40
 
This may be explained by the fact that mur2 mutant plants incorporate galactose 
where fucose would be appended in about one half of their xylogluc an side-
chains
41
; the results of Levy and co-workers indicated that it is the presence of 
trisaccharide side-chains that influence the binding of xyloglucan to ce llulose
38
.  
In 2003, a third A. thaliana  mutant with influence on carbohydrate composition in 
the cell wall, mur3, was identified; this mutant is deficient in β(1,2)-galactosyl 
transferase activity, therefore the normally fucosylated side -chains of xyloglucan 
are lacking in both Fuc and Gal, and comprise only a single Xyl residue.
42
 Tensile 
strength measurements taken on wild-type, mur2, and mur3 mutants revealed that 
the galactosylation, rather than fucosylation, of xyloglucan is critical to cell wall 
strength.
43
 It is thus uncertain what the role of α(1,2)-fucosyl moieties in 
xyloglucan are.  
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In addition to its incorporation into structural components of the eukaryotic 
extracellular matrix, fucose is incorporated into both N-linked and O-linked glycan 
structures in animals, and N-linked glycans in plants. 
 
1.2.2 Fucose in N-linked and O-linked glycans  
In N-linked glycans and O-linked glycans, ʟ-fucose is incorporated via Fucα(1,2)-
Gal, Fucα(1,3)-GlcNAc, Fucα(1,4)-GlcNAc or Fucα(1,6)-GlcNAc linkages, or 
directly appended to protein serine or threonine r esidues.
20
 For N-linked glycans, 
the monosaccharide represents a non-reducing end of the final oligosaccharide 
product. Thus, fucose is exposed to the biological microenvironment, and many 
cellular signalling processes involve the recognition of fucosylated glycans such as 
the ABO and Lewis antigens (Figure 1.5).  
Lewis antigens are synthesised in various cell types by the action of numerous 
fucosyltransferase enzymes present in the human genome. These antigens have  
important roles in the immune response during leukocyte rolling and 
extravasation
44,45
, and in the colonisation of xenobiotics spanning a spectrum of 
interactions with the host from symbiogenesis to pathogenicity
46
. The blood group 
antigens Le
x
, H and Le
y
 are thought to be involved in carbohydrate -mediated 
cellular adhesion processes during signal transduction by type 1 g lycosynapses.
47-49
 
O-linked glycosylation involves the attachment of a  sugar moiety or oligosaccharide 
to a protein serine or threonine residue. O-linked fucosylation occurs solely in 
eukaryotes, in the endoplasmic reticulum, and involves the addition of ʟ-fucose or a 
fucosylated oligosaccharide to proteins containing a cysteine -rich motif.
50
 Two 
fucosyltransferases are known to be involved in O -fucosylation, POFUT1 and 
POFUT2.  
 
11 
 
 
Figure 1.5. Examples of ABO and Lewis oligosaccharide structures containing ʟ-
fucose. Monosaccharides are displayed by the standard proposed by Varki et al. in 
2009 (Yellow circle = galactose, yellow square = GalNAc, blue square = GlcNAc, 
purple diamond = sialic acid, red triangle = fucose).
51
  
 
Human POFUT1 was first isolated and its biological function characterised in 
2001.
52
 The enzyme catalyses the addition of fucose to EGF repeats of, inter alia, 
Notch receptors. These receptors are large type I transmembrane proteins that are 
involved in intercellular signalling in a variety of cellular contexts  during 
development and are conserved between metazoan species.
53
 Genetic abnormalities 
leading to deficiency in the Notch pathway are linked to a number of developmental  
diseases such as Alagille syndrome, which is caused by deficiency in either the 
Notch ligand Jagged1
54
 or the Notch2 receptor 
55
. The Notch signalling mechanism 
is an elegant example of the use of regulated proteolysis by nature and was recently 
reviewed by Kopan and Ilagan
53
. Signal transduction by the mature Notch receptor 
is initiated by its binding to Notch ligands, which are often other transmembrane 
proteins, expressed on the surface of the signal-sending cell
56
. This binding event 
induces a conformational change in Notch, opening it to sequential proteolytic 
attack by ADAM metalloproteases and γ-secretase yielding the Notch intracellular 
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domain fragment.
57
 This fragment is subsequently trafficked to the nucleus where it 
complexes with the DNA-binding protein CSL;  in the absence of Notch this protein 
is involved in the formation of a co-repressor complex blocking gene 
transcription.
58
 Finally, the CSL-Notch intracellular domain complex is recognised 
by Mastermind and the ternary complex formed causes transcriptional activation of 
target genes (Figure 1.6).
58
 
Notch is O-fucosylated by POFUT1 between the second and third cysteines of its 
epidermal growth factor repeats in the consensus sequence Cys
2
-X-X-X-X-
(Ser/Thr)-Cys
3
.
59,60
 Further glycosylation of this core fucose occurs in mammalian 
Notch; extension of Notch core fucose occurs through the addition of GlcNAc by 
Fringe, and subsequent addition of galactose and sialic acid leading to the mature 
mammalian tetrasaccharide Siaα(2,3)-Galβ(1-4)-GlcNAcβ(1-3)-Fuc.59,61,62 Studies 
have shown that Pofut1
- / -
 mice display embryonic lethality
63
, and that RNA 
interference of Ofut1 in Drosophila melanogaster  leads to loss of Notch function 
and drastic phenotypic defects
64
, thus these fucosyltransferases are critical in Notch 
function and organism viability.  
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Figure 1.6. Mechanism of the Notch signalling pathway. Adapted from Kopan et al. 
2009
53
.   
 
1.2.2.1 Fucose in the immune response 
Lewis antigens (Figure 1.5) act as ligands for selectins and are involved in a 
number of molecular recognition events throughout the body, such as those 
occurring during leukocyte rolling, a critical part of the leukocyte adhesion cascade 
and the innate immune system.
44, 45
 For the correct localisation of leukocytes at a 
site of injury of infection, the immune cells must first escape the high shear forces 
exerted in the intravascular compartment before their extravasation across the 
endothelial cell membrane. During this first, ‘slow rolling’ stage of the leukocyte 
adhesion cascade, leukocytes tether with low affinity to the endothelial cell surface 
14 
 
by the interaction between C-type lectins called selectins and a number of selectin 
ligands, both of which are expressed on leukocytes, platelets, and the endotheli al 
cell surface. A plethora of research undertaken in the early 1990s identified selectin 
ligands as glycoproteins that express the fucosylated sialyl -Le
x
 tetrasaccharide.
65
 
Fucosylation is indeed critical to leukocyte function; genetic disruption of the 
α(1,3)-fucosyltransferase FUTVII has been shown to markedly impair leukocyte 
function in vivo in mice
66
, and treatment of a chemokine-activated Monocytic cell 
line with α-ʟ-fucosidase was shown to reduce leukcoyte migration to a background 
level
67
.  
In 1992, a novel disease related to deficiency in leukocyte adhesion was 
characterised; tests run on samples from two unrelated boys displaying mental 
retardation, short stature, and recurrent contraction of bacterial infections showed 
that the patients did not correctly express Lewis antigens, along with having the 
non-Secretor and Bombay phenotypes.
68
 As all of these characteristics represent a 
lack of fucosylated glycan production  by distinct fucosyltransferase enzymes, the 
authors hypothesised deficiency in fucose metabolism is responsible for the disease, 
which is termed either leukocyte adhesion deficiency type II (LADII), or congenita l 
disorder of glycosylation-IIc.
68
  
More recently, genetic evidence has shown that LADII results from deficiency in 
the activity of a GDP-fucose specific transporter, which transports GDP -fucose 
across the cytosol and into the golgi compartment prior to glycosyltransferases 
incorporating the activated sugar into glycans.
69,70
 The genetic abnormalities 
causing LADII can be due to either deficiency in activity of a properly lo calised 
GDP-fucose transporter, or its improper localisation in the endoplasmic reticulum.
71
 
In either case, this results in deficiency of sialyl -Le
x
 and other antigens required for 
leukocyte rolling, disrupting the leukocyte adhesion cascade at an early stage.  
 
1.2.2.2 Fucose in cancer 
As it is approximated that more than half of all mammalian proteins are post-
translationally glycosylated
1
, it is perhaps not surprising that aberrant glycosylation 
is associated with cancer adhesion and metastasis.  Of course, as the disease remains 
one of the leading causes of death in both developing and developed countries
72
, a 
great deal of research has been aimed at the study of protein glycosylation in 
cancer. Changes in protein glycosylation, and in particular fucosylation, have been 
reported in various cancer types, predominantly with upregulation of cell surface 
glycan expression in neoplastic cell lines, however downregulation of some of these 
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species has also been reported in some cases , excellently reviewed by Christiansen 
et al.
73
.  
As many experiments studying the aberrant glycosylation of cancer cells utilise 
neoplastic cell lines in in vitro culture conditions, it is important to note that the 
glycosylation patterns displayed by cells may be influenced by the cell culture 
environment
74
 and changes in glycosylation patterns may therefore not necessarily 
represent changes of neoplastic cells over healthy ones. Thus, it is important to 
support data gained from culture -based experiments with that from clinical cancer 
tissue samples. While significant correlations exist between the differences 
observed in both cell lines and tissues in lung cancer
75
, this is not the case for all 
tumour types. For example,  significant differences have been reported  in the DNA 
methylation profile of ovarian cancer cell lines and tissues
76
,  and observations have 
shown that a panel of ovarian cancer cell lines from various origins more closely 
resemble themselves than the tissues they are supposed to model
77
.  
Nevertheless, upregulated core fucosylation i.e. α(1,6)-fucosylation of interior  
GlcNAc residues on N-glycans appears to be a common feature of cancers 
excluding melanoma.
73
 This is supported by the increased expression of the α(1,6) -
fucosyltransferase FUT8 in tissues from liver and breast cancers
78,79
 and the 
increased intracellular GDP-fucose levels observed in hepatocellular carcinoma
80
.  
The core fucosylation of serum alpha-fetoprotein proves a potent biomarker for 
early diagnosis of hepatocellular carcinoma.
81
 α-ʟ-fucosidase also has potential as a 
biomarker for this cancer, both in diagnosis and prognosis,  and when used in 
combination with alpha-fetoprotein the two biomarkers provide greater specificity 
for tracking the disease
82,83
. Serum α-ʟ-fucosidase activity has also been shown to 
correlate with progression-free survival for breast cancer patients treated with 
trastuzumab, with a greater FUCA2 activity correlating with higher sensitivity to 
trastuzumab treatment.
84
 
Fucosylation in ABO and Lewis type linkages may also be either up or 
downregulated in neoplastic cells.
73
 Le
x
 and sialyl-Le
x
 expression has been 
observed to correlate with poor survival  in patients with colon
85
 and breast 
cancers
86
. Evidence suggests that FUT6 expression correlates with sialyl-Le
x
 
expression and adhesion potential of neoplastic cells in a number of breast cancers
87
 
while a similar correlation has been shown on overexpression of FUT7 in colon 
cancer cell line HT-29
88
. The metastatic potential of human pancreatic tumour cell 
line BxPC-3 was inhibited after expression of FUT3 antisense mRNA
89
, indicating 
that this α(1,3/4)-fucosyltransferase may be important in pancreatic cancer 
viability.  
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The Le
y
 antigen appears to be upregulated in serous forms of ovarian cancer.
90
 
Transfection of the FUT1 α(1,2)-fucosytransferase gene into ovarian cancers was 
further observed to lead to increased Le
y
 expression and to promote neoplastic cell 
proliferation.
91,92
 It has been postulated that the increased biosynthesis of selectin -
associated Lewis antigens such as sialyl-Le
x
 is important for cancer metastasis as 
the metastatic cascade may mirror the leukocyte adhesion cascade, requiring 
binding of cell -surface associated selectin ligands with selectins on a target cell 
surface for cancer metastasis .
93
 Aberrant regulation of fucosyltransferases does not 
appear to be limited to their overexpression; extracts from hepatocellular carcinoma 
tissues have been observed to have downregulated α(1,2) and α(1,3)-fucosylation94 
and FUT1 and FUT4 mRNA were observed to be absent in almost 25% of over 100 
tested melanoma cell lines
95
.  
As neoplastic cells typically require more ʟ-fucose for proliferation than healthy 
cells, they uptake the monosaccharide with a greater efficiency. This may be 
exploited for the selective uptake of drugs to the site of neoplasia. For example , 
Yoshida et al. have reported the success of ʟ-fucose bound liposomes containing the 
anti-cancer drug Cisplatin in inhibiting proliferation of pancreatic cancer in vivo in 
mice.
96
 More recently, Babiuch and co-workers designed glycopolymers capable of 
self-assembling into nanoscale micelles.
97
 These micelles were decorated with β-ʟ-
fucose and/or β-ᴅ-glucose moieties in varying ratios from 100% β -ʟ-fucose to 100% 
β-ᴅ-glucose. The micelles richer in β-ʟ-fucose were shown to have a greater uptake 
into pancreatic, lung and ovarian carcinoma cell lines , hence ʟ-fucose may provide 
a valuable means for active targeting of these drug carriers.  Although these 
compounds were not tested for drug transport into neoplastic cells , if this is 
possible they should provide a delivery mechanism with tuneable pharmacokinetic 
and pharmacodynamic properties along with low toxicity
98
.  
Interestingly, in 2001 a fucose-binding lectin was isolated from serum of the sea 
bass Dicentrarchus labrax
99
; this lectin was subsequently transfected into a variety 
of cancer cells through an adenovirus vector, and shown to have an anti-
proliferative effect  due to suppression of anti-apoptotic factors in the neoplastic 
cells
100
. This lectin may prove a novel means for cancer therapy.   
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1.2.2.3 Fucose in fertility 
ʟ-fucose and α-ʟ-fucosidase have been shown to play critical roles in fertility across 
diverse species. The importance of ʟ-fucose in this event was first described in 
1982, when Huang et al. observed potent inhibition of human, hamster and guinea 
pig sperm-oocyte binding by the ʟ-fucose rich polysaccharide fucoidan.35  Human 
semen contains two α-ʟ-fucosidase isoforms.101 The majority of seminal α -ʟ-
fucosidase activity is found in the seminal fluid, less than ca. 3% of total activity is 
associated to the membranes of spermatozoa.  Both seminal fluid and sperma tozoa 
α-ʟ-fucosidases from different donors have been observed to have a number of 
further isoforms (3-6 and 2, respectively) and these enzymes have different activity 
profiles; whilst seminal plasma samples have a broad activity profile with a number 
of maxima between pH 4.8 and 7.0, the spermatozoan isoform has a more acidic pH 
optimum between pH 3.4 and 4.0
101
.  
Seminal α-ʟ-fucosidases have also been discovered in many mammals such as 
mice
102
, hamsters
103
 and also in diverse species such as Unio elongatulus
104
,  
Ascidiacea
105
and Drosophilidae
106
, suggesting a key role for the enzyme during 
fertilisation.  
Analysis of the effects of α -ʟ-fucosidase activity on spermatozoa fertility has been 
reported for hamsters
103
 and mice
102
. In hamsters, pre-incubation of spermatozoa 
with the competitive α-ʟ-fucosidase inhibitor deoxyfuconojirimycin  (DFJ107) was 
observed not to inhibit sperm binding to oocyte zona p ellucida, the glycoprotein 
layer surrounding the egg cell.
103
 Pretreatment of spermatozoa with DFJ was, 
however, shown to reduce fertilisation success, preventing development of the 
embryo past the 2-cell stage. In mice, treatment of sperm with DFJ was shown not 
to inhibit binding to the zona pellucida or the oocyte membrane, and had no effect 
on fusion or binding. Pre-incubation of sperm with anti -fucosidase antibody, or pre-
treatment of oocytes with purified human liver α -ʟ-fucosidase, however, 
significantly impaired these events.  
Thus, in mice, sperm α-ʟ-fucosidase activity has little or no effect on fertility, 
however its glycan structures are critical. This is supported by the observation of 
Oh et al. that introduction of the neoglycoprotein BSA-fucose to mouse oocytes 
inhibits the interaction between their zona pellucida and sperm
108
, thus it is likely 
that this binding event requires the interaction between fucosylated glycans present 
on mouse sperm α-ʟ-fucosidase and zona pellucida lectins. The fucosylated 
immunodeterminant sialyl-Le
x
 has been shown to be the highest abundance glycan  
expressed on human oocyte zona pellucida; present in both N-linked and O-linked 
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glycans, the epitope appears to be critical for spermatozoa-oocyte binding, as 
glycoconjugates bearing this motif or antibodies raised against it inhibit 
spermatozoa-oocyte binding.
109
  
 
1.2.2.4 Fucose in bacterial colonisation 
Many bacteria mediate their colonisation by decoration of their cell surfaces with 
lectins, allowing binding to glycan epitopes such as the fucosylated A, B, H, Le
a
, 
Le
b
, sialyl-Le
a
, Le
x
, Le
y
 and sialyl-Le
x 
antigens (Figure 1.5) expressed on cell 
surfaces in the gastrointestinal tract.
110
  
Mucin proteins are thought to have a role in forming a protective barrier to 
invading bacteria; these proteins are the main macromolecular component of the 
mucus that creates a barrier between the eye, trachea, stomach and intestines and 
pathogens.
17
 Mucins are repeat proteins comprising a large number of serine and 
threonine residues for O-glycan attachment, and are heavily glycosylated, typically 
comprising more than 70% O-glycans by mass. The O-glycans in mucins include 
fucosylated structures such as the ABO and Lewis
 
antigens.
17
 The role of mucins in 
defence against pathogens is supported by studies of Mucin knockout in mice, 
Muc1
- / -
 and Muc2
- / -
 have been shown to have susceptibility to infection by 
pathogens.
111, 112
 
An example of fucosylated antigens playing a role in bacterial adhesion is in the 
colonisation of the pathogen Campylobacter jejuni into the gastrointestinal tract. C. 
jejuni  is a commensal in poultry, but  is also the most common cause of 
gastroenteritis in the developed world,  causing mild to severe diarrhea which may 
be concomitant with a fever
113
. The pathogen effects its colonisation with the host 
by interacting with cell surface glycans, including fucosylated Le
a
 and Le
x
 epitopes, 
and when grown under mammalian-like growth conditions, is a poor binder of non -
fucosylated glycans
5
.  Further evidence corroborates the importance of ʟ-fucose to 
the viability of C. jejuni  as a pathogen; ʟ-fucose acts as a chemoattractant towards 
the organism
114
, and the presence of ʟ-fucose in its environment confers it a 
competitive advantage 
115
.  A gene encoding a fucose permease has been identified 
in C. jejuni
115
, making it likely that the organism is able to ut ilise ʟ-fucose as an 
energy source. The introduction of human milk oligosaccharides comprising 
fucosylated O-glycans abolishes C. jejuni  adhesion to the mucosa, presumably 
through competitive inhibition of C. jejuni lectins, allowing clearance of the 
bacterium through the gastrointestinal tract .
116
 Finally, mice deficient in Muc1 
show susceptibility to Campylobacter jejuni infection.
112
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Fucosylated glycans also play an important role in the pathogenicity of 
Pseudomonas aeruginosa . This bacterium is an opportunistic pathogen that 
typically infects immunocompromised patients  with chronic lung diseases, such as 
sufferers of cystic fibrosis , for whom infection with P. aeruginosa  may be fatal. P. 
aeruginosa colonisation of the airway is partially dependent on its interaction with 
mucin glycans, particularly the sialyl -Lewis
x
 antigen.
6
 This interaction is effected 
by the P. aeruginosa fucose-binding lectin PAII-L, which has a micromolar affinity 
for free ʟ-fucose.117 The X-ray crystal structure of PAII-L complexed with ʟ-
fucose
118
 explains the basis for this unusually high affinity of a lectin for its ligand; 
a pair of calcium ions in the fucose binding site aid in complexation of ʟ-fucose 
through electrostatic interaction.  
Some pathogens have adapted systems in order to take advantage of the host 
immune defence; an example of this is Helicobacter pylori , a stomach pathogen 
infecting approximately one half of the global human population . Colonisation 
density of this pathogen in chronic gastritis patients is related to  the expression of 
Le
x/y
 antigens on its cell surface, with strains expressing more Le
x/y
 antigens having 
higher colonisation density.
119
 An insightful study by Liu et al. found that H. pylori 
infection stimulates the host immune response, causing production of secreted 
human α-ʟ-fucosidase (FUCA2).4 The response of H. pylori is to utilise the ʟ-fucose 
moieties thus released from gastric epithelial cells , both as an energy source and in 
order to further decorate their cell surface with Le
x/y
 antigens for continued 
adhesion to epithelial cells;  FUCA2 appears to be essential for H. pylori  adhesion 
to human gastric cancer cells.
4
  
Due to the importance of fucosylated glycan -mediated interactions to successful 
adhesion and colonisation of a number of pathogenic bacteria  alluded to above, the 
use of fucosylated carbohydrates has been suggested as a n alternative treatment for 
bacterial infection.
120
 In this approach, fucosylated glycans would compete for host 
lectins, weakening the adhesion between pathogens and the host  and allowing 
clearance of the pathogens through the gastrointestinal tract . This approach is 
already used by nature; human breast milk contains free ʟ-fucose as well as a large 
number of fucosylated oligosaccharides which appear to supplement the nursing 
infant’s resistance to pathogens .121-123 For example, human milk oligosaccharides 
have been shown to provide resistance to the diarrheagenic symptoms after 
Escherichia coli  heat-stable enterotoxin infection in suckling mice
124
, and 
resistance to Campylobacter jejuni as discussed above
116
. The oligosaccharide 
profile of bovine milk is different to that of human milk, having higher levels of 
sialylation but lower levels of fucosylation.
121
 Due to the lack of ʟ-fucose, bovine 
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milk formulae may be less beneficial to the development of neonatal infants than 
human milk, and ʟ-fucose has been proposed as a supplement to infant formulae.  
The mucin MUC1 is expressed on normal and malignant T -cells, and has a 
modulatory role in function of these immune cells
125
, further, high levels of serum 
MUC1 suppress the T cell response
126
. MUC1 co-localises with other mucin-type 
glycoproteins and signal transducer molecules on the cell surface of T-cell 
lymphomas
127
;  these mucin-rich microdomains form type 2 glycosynapses where 
signal transduction by e.g. Src family kinases is effected after carbohydrate-protein 
mediated interaction likely between O-glycan linked structures such as sialyl -Le
x
 
and sialyl-Le
a
, and selectins
49
. 
It would be unfair to paint such a one-sided picture of host-microbe interactions; 
microbe interactions with their host in fact span a spectrum between pathogenicity 
and symbiosis, and while it is estimated that 90% of the cells in the human body are 
microbial in nature, the vast majority of these  organisms have a commensal or 
symbiotic relationship with their host
46,128
.  Of all of the mammalian organs, the gut 
has by far the highest microbial density
128
, and many microbes that reside in the gut 
act as symbiotes, serving an important role in supplementing the host’s enzymatic 
machinery for degradation of dietary plant polysaccharides
129
.  Our own enzymatic 
machinery is indeed limited to utilisation of monosaccharides, s ome disaccharides, 
and starch. Residents of the gut microbiota thus allow us to digest plant 
polysaccharides such as xylan, pectin and alginate
130
, with bacterial metabolism of 
otherwise indigestible dietary biomass generating short chain fatty -acids that 
account for 5-10% of the human daily caloric intake 
131
.  
One of the most widely studied gut symbiotes is Bacteroides thetaiotaomicron , an 
obligate anaerobe and one of the most abundant microbial members of the healthy 
human intestinal tract .
132
 Bacteroides thetaiotaomicron  has numerous documented 
beneficial effects on its host. Angiogenesis of the intestinal tract is stimulated by 
the organism; germ-free adult mice, which display arrested capillary formation, 
were shown to have their capillary network restored within 10 days of colonisation 
with Bacteroides thetaiotaomicron .
133
 Bacteroides thetaiotaomicron  also promotes 
the development of a strong mucosal barrier , as colonisation of the organism in 
mice induces upregulation of ang4,  which produces a ribonuclease that is 
bactericidal to some Gram-positive enteropathogens.
134
  
In return for providing beneficial effects to its host, Bacteroides thetaiotaomicron  
ensures its own fitness by helping to shape the glycan profile of mucins in the gut  
to provide nutrition for its growth. Bacteroides thetaiotaomicron  is able to digest a 
21 
 
number of glycans for growth
130
, including fucosylated glycans , which are 
particularly important to the organism; of the 24 oligosaccharide transporters 
present in its genome, eight are fucose permeases
135
. Germ-free mice actually lack 
α1,2 and α1,6-fucosyltransferase activity, which can be reintroduced by the ir 
inoculation with Bacteroides thetaiotaomicron  or extracts from conventionally 
grown mouse gut microflora.
136
 The fucosyltransferase activity thus restored is due 
to microbiota affecting expression of host enzymes which are downregulated as a 
function of mammalian development after the weaning stage .
136
 Hence, gut 
microbiota such as Bacteroides thetaiotaomicron  alter expression levels of their 
host’s enzymatic machinery in order to survive in the competitive environment of 
the gastrointestinal tract , both by stimulating the host to produce more nutrients 
required for their growth and by reducing the viability of pathogens that may 
compete for these nutrients.  
Bacterial utilisation of glycans is effected by their expression of genes encoding 
glycoside hydrolases and glycan processing enzymes, in some bacteria, such as 
Bacteroides thetaiotaomicron , these are organised into polysaccharide utilisation 
loci (PULs). These PULs allow bacteria to efficiently forage for available nutrients 
and eliminate the need for constitutive expression of many of their enzymes. The 
archetypal PUL of Bacteroides thetaiotaomicron  is the starch utilisation system 
(sus, reviewed by Martens et al. (Figure 1.7).
137
 The sus gene locus contains eight 
genes, five of which transcribe outer membrane-associated proteins. SusDEF are 
carbohydrate binding proteins that interact with starch while SusG is an endo-acting 
α-amylase that breaks the polysaccharide down into smaller carbohydrates. These 
smaller glycans are transported across the outer membrane by the TonB-dependent 
receptor SusC and further degraded by glycoside hydrolases SusA and SusB, which 
have neopullulanase and α -glucosidase activities, respectively. 138 Finally, SusR is a 
hybrid two-component sensor/regulator that, in the presence of starch degradation 
products in the periplasm, transduces a signal for up-regulation of expression of 
susABCDEFG.
138
 The presence of consecutive susC and susD-like genes are the 
minimum features needed to identify a sus -like PUL, and using these features, 88 
sus-like PULs have been identified in Bacteroides thetaiotaomicron
139
. PULs likely 
provide an evolutionary advantage to Bacteroides thetaiotaomicron  by allowing its 
adaptation to the rapidly changing environment of the distal intestine by 
coordination of the energy-intensive process of protein production with the 
available nutrient pool.  
A sus-like system of Bacteroides thetaiotaomicron  that is induced in response to 
free fucose was identified by Hooper et al.
140
 This operon comprises 5 genes, 
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fucRPIAK. The fucPIAK genes encode, respectively, an ʟ-fucose permease, ʟ-fucose 
isomerase, ʟ-fuculose-1-phosphate aldolase and ʟ-fuculose kinase. In parallel to 
susR, fucR acts as a repressor of the fucRIAK  genes until displaced by the presence 
of ʟ-fucose, but does not regulate its own expression. Evidence also suggested that 
fucR acts as an ʟ-fucose inducible co-repressor at another gene locus, which 
stimulates α(1,2)-fucosyltransferase activity by the host, corroborating the findings 
of Bry et al. discussed above
136
. Reflecting the evolution of Bacteroides 
thetaiotaomicron  as a symbiote, the bacterium appears to ensure that there remains 
a source of dietary fucose in its environment, while also limiting the pressure it 
exerts on its host. 
 
 
Figure 1.7. Schematic of the Bacteroides thetaiotaomicron  starch utilisation system.   
 
Interestingly, stress induced in mice through application of lipopolysaccharides  has 
been correlated with a rapid increase in α(1,2)-fucosylaton of intestine epithelial 
cells by Fut2
141
; Fut2
- / -
 mice were shown to require significantly more time for 
recovery of body weight after induced stress.  Gnotobiotic mice under induced 
stress, or antibiotic-treated normal mice also showed slow recovery, indicating the 
importance of the microbiota in supplementing the host’s immune system during 
systemic stress. This is supported by the observation that Fut2
- / -
 mice subjected to a 
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non-lethal pathogenic bacterium before induction of stress showed significantly 
slower weight recovery than Fut2-sufficient mice. Taken together , these results 
would seem to indicate that up-regulation of α(1,2)-fucosylation is a measure taken 
by the host to maintain the viability of its gut commensals  as a response to systemic 
stress.
141
 
Due to the myriad roles of carbohydrates in nature, vide supra , it is clear that 
carbohydrate metabolism and homeostasis are critical biological processes. Correct 
homeostasis of glycan structures requires the concerted action of two key classes of 
enzymes; glycosyltransferases, which form glycosidic bonds, and glycoside 
hydrolases, which cleave those bonds.  Both fucosyltransferases and fucosidases are 
of clinical importance due to various disease phenotypes which occur due to their 
malfunctioning or absence.  
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1.3  Glycosyltransferases 
Glycosyltransferases catalyse the transfer of sugar donors, activated in a nucleoside 
phosphate, lipid phosphate, or un-substituted phosphate form, to acceptor moieties. 
Saccharides may in this way be appended to , inter alia , other sugars, proteins, and 
lipids.
7
 The glycosyltransferase genes expressed by an organism, and their 
expression levels, are subject to change as a result of transition through 
developmental stages and environmental effects such as the onset of disease , and 
changes in the expression levels of glycosyltransferases contribute to the 
diversification of glycans.
142
 Owing to their biologically critical nature , 1 % to 2 % 
of the genomes of an organism, regard less of domain, encode glycosyl transferase 
enzymes.
7
  
Catalysis by glycosyltransferases leads to either inversion or retention of the 
chirality at the anomeric carbon of the donor sugar. While the mechanism of 
inverting glycosyltransferases is well understood and proceeds via an SN2-like 
mechanism, that of retaining glycosyltransferases is less clear, but may proceed 
through an oxocarbenium ion-like intermediate with basic assistance of the donor 
phosphate group.
7
  
 
1.3.1 Fucosyltransferases 
Fucosyltransferases (EC numbers 2.4.1.65, 2.4.1.68, 2.4.1.69, 2.4.1.152, 2.4.1.214) 
catalyse the transfer of an activated GDP-fucose donor to an acceptor moiety, which 
can be a protein Ser or Thr residue through an α1-(S/T)-linkage, Galactose through 
an α(1,2)-linkage or N-Acetylglucosamine through an α(1,3), α(1,4) or α(1,6)-
linkage.
143
 A large repertoire of fucosyltransferases exists in the human genome due 
to the requirement to produce a diverse array of fucose -containing glycans. Each 
enzyme is thus adapted for the synthesis of a specific glycosidic bond from GDP -
fucose to a specific or small subset of  potential acceptor moieties, and expression in 
different cell types.
144
  
Activation of fucose to a GDP-fucose form, which is required for fucosyltransferase 
reactivity, takes place through two pathways in mammals.
20,145
 The major, de novo  
pathway accounts for more than 90 % of GDP-fucose biosynthesis; this pathway 
involves conversion of GDP-mannose to GDP-fucose through the action of two key 
enzymes and a GDP-4-keto-6-deoxymannose intermediate.  The alternative pathway 
for GDP-fucose biosynthesis is termed the Salvage pathway and involves 
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phosphorylation of free fucose and subsequent condensation with GTP  to yield 
GDP-fucose.  
Currently, thirteen ORFs from the human genome have been annotated as coding for 
translation of proteins with fucosyltransferase activity. Th e majority of these 
proteins are grouped into glycosyltransferase family 10  according to the 
Carbohydrate Active Enzymes database, CAZy, available at http://www.cazy.org 
(GT10, FUT3-7, FUT9-11).
146, 147
  
FUT1 and 2 are α(1,2)-fucosyltransferases involved in biosynthesis of the blood 
group H antigen as described above.
148,149
 The α(1,3)-fucosyltransferases FUT3-7 
and FUT9 are differentially expressed in various cell types, leading  to different 
patterns of fucosylated ligand biosynthesis in these cells; three distinct fucosylation 
patterns exist, myeloid-type patterns in leukocytes and brain, plasma -type patterns 
in plasma and liver, and Lewis-type patterns in bladder, kidney and milk.
144
    
Fucosyltransferases 3, 5 and 6 only exist in higher-order mammals and evolved 
relatively recently; these proteins have a high sequence similarity with each  other 
and are clustered together on chromosome 19 in humans.
150
 These enzymes, along 
with fucosyltransferases 4, 7 and 9 all transfer ʟ-fucose to GlcNAc in α(1,3) or 
α(1,4) linkages in various cell types.151 FUT3 is also called the Lewis gene and has 
both α(1,3) and α(1,4)-fucosyltransferase activity; this enzyme is involved in the 
biosynthesis of Lewis antigens in epithelial cells.
152
 FUT5 is also expressed in 
epithelial cells, but only has α(1,4)-fucosyltransferase activity. In gastric cancer 
cells, FUT3 has been shown to be involved in the synthesis of the Le wis b, a and y 
antigens, while FUT5 synthesises the Lewis x antigen; the combined action of these 
two enzymes appears to be necessary for biosynthesis of the sialylated antigens 
sialyl-Le
x
 and sialyl-Le
a  153
.  
FUT4 and FUT7 are α(1,3)-fucosyltransferases involved in the biosynthesis of 
selectin ligands in leukocytes and endothelial cells
154,155
; FUT7 deficiency has been 
shown to cause leukocytosis in mouse
66
, and the enzyme only appears to catalyse 
the transfer of ʟ-fucose to oligosaccharide acceptors already containing sialic 
acid
156
. FUT6 is a plasma-type α(1,3)-fucosyltransferase.157  
FUT8 is unique in that it catalyses the transfer of ʟ-fucose in an α(1,6)-linkage to 
the internal GlcNAc in biantennary glycans terminating with  the same 
monosaccharide.
158,159
 This fucosylation is also known as core fucosylation, and t he 
expression of FUT8 appears to have an effect on tumour viability in liver
160
 and 
prostate cancer
161
 and indeed is upregulated in most cancers
73
. The substrate 
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specificity of FUT9 is different from the α(1,3)-fucosyltransferases FUT3-7, as the 
enzyme preferentially fucosylates the distal GlcNAc moiety of a polylactosamine 
acceptor, while FUT3-7 preferentially glycosylate an internal GlcNAc.
156
 FUT10 
may have a role in maintaining stem cell populations; overexpression of the α(1,3)-
fucosyltransferase was shown to enhance the self -renewal of neural stem cells, 
whilst knockdown of the enzyme induced their differentiation.
162
 To the author’s 
knowledge, nothing is known about the substrate specificity or tissue distribution of 
FUT11.  
Finally, POFUT1 and POFUT2 catalyse the transfer of ʟ-fucosyl moieties to serine 
or threonine residues on the polypeptide repeat of proteins. POFUT1 is involved in 
the addition of fucose to epidermal growth factor type repeats of proteins such as 
Notch, vide supra, while POFUT2 transfers the unit to thrombospondin 1 type 
repeats.
163
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1.4  Glycoside hydrolases 
Glycoside hydrolases effect the enzymatic cleavage of glycosidic bonds. The 
glycosidic bond is incredibly stable without catalytic aid, and is indeed more stable 
to degradation than the bonds present in such biological polymers such as DNA and 
proteins.
13-15
 The rate enhancement provided by glycoside hydrolase involvement in 
cleavage of the glycosidic bond is huge , e.g. comparison of the rate of catalysis of 
starch by sweet potato β-amylase and the un-catalysed rate yields a rate 
enhancement of 10
17
.
13
 
Glycoside hydrolases, as with glycosyltransferases, may proceed with either 
inversion or retention of chirality at the sugar substrate’s anomeric centre. Whilst 
other mechanisms exist , the majority of glycoside hydrolases utilise two catalytic 
carboxylates and proceed through either a single SN2-like displacement (inverting) 
or two consecutive SN2-like displacements (retaining) as originally proposed by 
Koshland.
164
 In the canonical inverting mechanism,  a basic carboxylate 
deprotonates water on the bottom of the glycoside ring (Figure 1.8 A). The 
activated hydroxyl then performs in -line nucleophilic attack on the anomeric 
carbon, whilst the leaving group is stabilised by protonation by the catalytic acid 
(Figure 1.8 A). The protonation states of the catalytic base and acid may then be 
regenerated through solvent.  The product released thus has inverted stereochemistry 
compared to that of the substrate glycoside. A distance of ca. 10 Å typically exists 
between the catalytic base and acid residues , reflecting the steric requirements of 
allowing enough space to accommodate a water molecule on the bottom face of the 
glycoside ring.
165
 
The canonical retaining glycoside hydrolase mechanism involves two SN2-like 
displacements, and formation of a covalent enzyme intermediate. Here, the catalytic 
nucleophile itself performs in-line nucleophilic attack to a bound glycoside , with 
leaving group departure aided by the catalytic acid/base, leading to the formation of 
a covalent glycosyl-enzyme intermediate (Figure 1.8 B). Subsequently, the catalytic 
acid/base acts as a base, activating a water molecule as a hydroxyl nucleophile to 
act on the trapped glycoside and release the catalytic nucleophile (Figure 1.8 B). In 
retaining glycoside hydrolases with this mechanism, a distance of ca. 5.5 Å is 
observed between the catalytic residues, and the reaction product has the same 
stereochemistry as the substrate glycoside.  
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Figure 1.8. Canonical inverting (A) and retaining (B) mechanisms of glycoside 
hydrolases. Figures are drawn with the configuration of and conformatio n adopted 
by ʟ-fucose. 
 
Carbohydrates adopt a variety of conformations in vitro. For pyranose ring 
structures, a single chair form of the pyranose is  typically the most energetically 
favourable and represents the conformational majority of the sugar in solution. The 
enzymatic transition states in glycoside hydrolases (there are two in retaining 
enzymes and one in inverting enzymes)  contain susbstantial oxocarbenium ion-like 
character, with a degree of positive charge at the anomeric carbon due to cleavage 
of the glycosidic bond. The glycosyl carbocation is incredibly unstable  in solution, 
it is believed that this species only exists through stabilisation of the oxocarbenium 
ion intermediate through electron donation by the endocyclic oxygen.
166
 For this to 
occur, the glycosidic bond must be situated anti-periplanar to an sp
3
 lone pair on 
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the endocyclic oxygen; this geometry requires co -planarity of the endocyclic 
oxygen, the anomeric carbon, and the atoms adjacent to these i.e. the C2 and C5 
atoms. Thus, only four possible conformations whereby nucleophilic substitution 
may occur exist for pyranose sugars, namely the two boat and four half -chair 
conformations 
3
H4,  
4
H3,  
2,5
B and B2,5  (Figure 1.9).
166
  
 
Figure 1.9. The transition state in glycoside hydrolases. The glycoside hydrolase 
transition state contains substantial oxocarbenium ion -like character and is 
stabilised by electron donation from the endocyclic oxygen sp
3
 lone pair to the 
anomeric carbon. While only the glycosylation step of retaining glycoside 
hydrolysis is displayed, the electronic character of the deglycosylation step of this 
reaction and that of the inverting reaction are identical.  
 
Glycoside hydrolases have evolved the capacity to stabilise conformations close to 
the enzymatic transition state  by electronic and steric means, and the evolution of 
each glycoside hydrolase family appears to be directed towards the stabilisation of 
a particular reaction pathway involving a discrete 
3
H4, 
4
H3, 
2,5
B or B2,5 transition 
state.
167
 As early as the 1940’s, it was postulated by Pauling that the most potent 
inhibitors of an enzyme would be those that mimicked the ‘strained activated 
complex’ formed during  catalysis.168 Indeed, the distortion of the glycoside to be 
cleaved in glycoside hydrolase catalysis has been exploited both by nature and man 
through the generation of enzyme inhibitors that are able to mimic the geometrical 
and electronic properties of the enzymatic transition state .
169
  
 
1.4.1 α-ʟ-fucosidases 
α-ʟ-fucosidases (EC numbers 3.2.1.51, 3.2.1.63 and 3.2.1.111) catalyse the 
hydrolysis of the glycosidic bond of an α -ʟ-fucoside from the non-reducing end of a 
glycoconjugate. These enzymes primarily exist in the GH29 and GH95 families of 
the CAZy system for classification of carbohydrate active enzymes , which groups 
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carbohydrate-active enzymes into families based on their primary sequence .
170
 
Some α-ʟ-fucosidases have been reported which do not belong to GH29 or GH95 
families, in 2002 an α-ʟ-fucosidase was identified from A. thaliana with activity 
against 2’-fucosyl-lactitol and xyloglucan XXFG polysaccharide but no homology 
to GH29 or GH95 enzymes, this enzyme is indeed currently ‘non -classified’ 
according to CAZy
171
.  More recently a novel α-ʟ-fucosidase from Paenibacillus 
thiaminolyticus  was characterised and reported to have no homology with GH29 or 
GH95, this enzyme does not currently have an entry in the CAZy database .
172
  
Two α-ʟ-fucosidases exist in the human genome, FUCA1 and FUCA2. While 
FUCA1 is localised in the lysosome, FUCA2 is a secreted protein localised in 
plasma; both enzymes are classified in the GH29 family. Lack of α-ʟ-fucosidase 
(FUCA1) activity in the human lysosome can lead to the rare (ca.  100 cases known 
worldwide) storage disorder fucosidosis  in man.
173
 This disorder leads to 
accumulation of fucosylated N-glycan structures which cannot be broken down by 
the host’s impaired catabolic pathway, the disease causes severe neurodegenerative 
symptoms, cachexia and low life expectancy
174
. Fucosidosis has also been reported 
in canines
175
 and felines
176
, and a wide spectrum of genetic FUCA1 mutations 
leading to fucosidosis in humans has been reported
177
. Gene therapy by retroviral 
insertion of FUCA1 into both canine and human fucosidotic fibroblasts was able to 
not only restore normal levels of α-ʟ-fucosidase function, but indeed such 
fibroblasts were able to hydrolyse radionuclide -labelled ʟ-[5,6-3H]-fucosylated 
glycans with greater efficiency than non-fucosidotic fibroblasts.
178
  
 
1.4.1.1 GH95 α-ʟ-fucosidases 
The catalytic mechanism for GH95 enzymes is thought to be less canonical than 
that typical of inverting glycoside hydrolases. During the study of Bifidobacterium 
bifidum 1,2-α-ʟ-fucosidase, Nagae et al. found that while residue Glu 566  was 
identified by X-ray crystal structure to lie in an appropriate position to act as the 
catalytic acid, and further confirmed by mutagenesis experiments, no carboxylate 
was observed in an appropriate position in X-ray crystal structure to act as the 
enzymatic base.
179
 Rather, the authors concluded that a conserved structural motif 
creates an electrostatic relay in the enzyme to modulate the p Ka  of Asn
423
 for its 
deprotonation of water (Figure 1.10). Further, this water molecule was shown to be 
held in the correct position and orientation for in -line attack on the anomeric 
carbon by hydrogen bonding interactions by the catalytic base Asn
423
 and another 
asparagine residue Asn
421
.
179
  
31 
 
 
Figure 1.10. Schematic of the proposed electrostatic relay and catalytic mechanism 
postulated for GH95 enzymatic catalysis.
179
 ʟ-fucose ring substituents other than 
that at the anomeric carbon are omitted for clarity.  
 
1.4.1.2 GH29 α-ʟ-fucosidases 
GH29 α-ʟ-fucosidases act with net retention of the anomeric configuration  after 
hydrolysis of a fucosylated substrate . In 2003, two research groups 
contemporaneously identified the catalytic nucleophile of α-ʟ-fucosidases from 
Thermotoga maritima  and the archaea Sulfolobus solfataricus .
180,181
 This was 
achieved for the archaeal enzyme by chemical rescue of α-ʟ-fucosidase activity of 
an inactive Asp
242
 mutant using sodium azide
181
. For the bacterial enzyme, 
identification of the catalytic nucleophile was achieved through covalent 
inactivation of the enzyme using an irreversible α-ʟ-fucosidase inhibitor 2-deoxy-2-
fluoro-α-ʟ-fucosyl fluoride, enabling identification of the catalytic nucleophile 
Asp
224
 by peptic digest and mass spectrometry.
180
 The fact that a covalent  enzyme 
intermediate could be trapped is evidence that GH29 enzymes act through a 
classical Koshland double-displacement mechanism
164
 involving, first, the attack of 
a nucleophilic carboxylate residue to form a covalent enzyme-substrate intermediate 
in the ‘fucosylation’  step (Figure 1.8 B). Aglycon departure is aided by a catalytic 
acid/base Glu residue. The catalytic acid/base Glu then activates water to 
regenerate fucose and the catalytic nucleophile  in the ‘defucosylation’ step. 
Notably, the first X-ray crystal structure of an α-ʟ-fucosidase was determined using 
the Thermotoga maritima  enzyme (TmGH29) in 2004; the catalytic, N-terminal 
domain of TmGH29 adopts a (βα)8 TIM barrel fold and forms a hexamer in both 
crystal structure and solution (as determined by size exclusion chromatography , 
Figure 1.11).
182
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Figure 1.11. 3 dimensional fold of the GH29 α-ʟ-fucosidase from Thermotoga 
maritima as solved by X-ray crystal structure (PDB code 1HL8). The figure was 
drawn in wall-eye stereo with model colour blended through the protomer chain, 
from the blue N-terminus to the red C-terminus. The figure was drawn using 
CCP4MG
183
.  
 
Subsequently, a number of crystal structures from other members of the GH29 
family have been reported, i.e. those from Bacteroides thetaiotaomicron  (two have 
been reported, gene products from genes 2970
184
 and 2192
185
), Bifidobacterium 
longum subsp. infantis
186,187
,  and the eukaryotic plant pathogen Fusarium 
graminearum
188
. Further, two GH29 crystal structures have been deposited  in the 
protein databank but have not been supported by literature as of yet, i.e. those with 
PDB codes 4ZRX and 3GZA.  
From the availability of GH29 crystal structures and related kinetic data, a number 
of observations can be made. First, the enzymes typically form dimers or higher 
order oligomers both in solution and in crystal structure (however the eukaryotic 
enzyme was observed not to form oligomers
188
). Second, while the catalytic 
nucleophile in GH29 enzymes is an Asp residue that is conserved by sequence, the 
catalytic acid/base Glu residue is not.
189
 Third, the conserved catalytic (βα)8 α-ʟ-
fucosidase domain appears at the N-terminus of the gene transcript, while other 
domains may or may not be present; e.g. TmGH29 has a C-terminal β-sandwich 
domain
182
 whilst FgGH29 has a C-terminal βγ-crystallin domain188 and BiGH29 
contains a number of C-terminal domains including a carbohydrate binding domain . 
Finally, the substrate specificity of this class of enzymes varies across its members, 
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while some enzymes are able to hydrolyse fucose in linkages to  the 2,3,4 and 6-
hydroxyls of reducing end sugars and work efficiently on the synthetic substrate p-
nitrophenyl-α-ʟ-fucopyranoside, others seem to act specifically on α(1,3/4) -linkages 
and have poor to no activity on p-nitrophenyl-α-ʟ-fucopyranoside. This led to the 
designation of two subfamilies of GH29 α-ʟ-fucosidases by Yamamoto and co-
workers, where GH29-A enzymes have relaxed substrate specificity those from the 
GH29-B sub-family are α(1,3/4)-linkage specific.190,191 The existence of two sub-
families of GH29 is further evidenced by phylogenetic analysis , with two clades 
being comprised GH29 enzymes from animals, archaea and bacteria (GH29-A) and 
those from plants and bacteria (GH29-B).
190
  
The structural basis for the different substrate specificity between the two GH29 
sub-families has been probed by analysis of the crystal structures of two 
representative enzymes from Bacteroides thetaiotaomicron
191
. Sakurama et al. 
noted the absence of two residues involved in hydrogen bonding with the fucoside 
substrate in BtFuc2192 from GH29-B, while BtFuc2970 had a (conserved among the 
GH29-A subfamily) Arg residue that may provide favourable  leaving group 
stabilisation for p-nitrophenyl-α-ʟ-fucopyranoside hydrolysis. BtFuc2192 was 
observed to contain a carbohydrate binding pocket comprised five residues, four of 
which appear conserved in the GH29-B sub-family. The substrate specificity of 
BtFuc2192 further appeared to be limited to saccharides of length greater than 2, 
indicating a requirement for branched Gal moieties in the substrate  for hydrolysis. 
Overall, the results would seem to indicate that GH29-A enzymes tightly bind a 
docking fucose moiety in their -1 sub-site, while enzymes from the GH29-B 
subfamily form weaker interactions with the -1 fucose residue but have enough 
space to accommodate a branched Gal residue
191
. The importance of the branched 
Gal residue in GH29-B enzymes is further evidenced by observation of clear 
electron density for the Fuc and Gal monosaccharides in a complex of  a 
catalytically inactive mutant of BiGH29 with lacto-N-fucopentaose II; electron 
density was poor for the GlcNAc moiety and absent for the redu cing-end lactose 
disaccharide
187
.  
The BiGH29 enzyme was observed crystallographically to undergo a large induced-
fit conformational change of two loop regions on substrate binding.
187
 The catalytic 
acid/base residue Glu
217
, which is separated from the catalytic nucleophile by 
almost 21 Å in the substrate-free complex, displaces during a loop rearrangement 
on substrate binding to an active conformation, closing the active sit e pocket. The 
flexibility of loops around the enzymatic active site, including that containing the 
catalytic acid/base residue may be a conserved feature in GH29 fucosidases; in the 
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crystal structure of TmGH29, no electron density is observed for a loop re gion 
which starts only 3 residues downstream of the catalytic acid/base
182
.  Also, in the 
X-ray crystal structure of BtFuc2970 D229N mutant complexed with synthetic 
substrate p-nitrophenyl-α-ʟ-fucopyranoside (PDB code 2WVU) a conformational 
displacement of the catalytic acid/base E288 is observed compared to the apo 
structure.
184
 It should be noted, however, that this residue lies in an inactive 
conformation as there is a ca. 6.5 Å distance between the glycosidic bond and the 
oxygen atoms of this carboxylate, and the rearrangement may be fortuitous and due 
to the hydrogen bonding interactions formed by the nitro -group of the substrate and 
Arg
262
. Finally, two discrete conformational states have been observed 
crystallographically for the GH29 enzyme from Fusarium graminearum .
188
 The 
conformational dynamics in loop regions may be important for GH29 catalysis, and 
may further provide a structural basis for the difficulty in predicting the catalytic 
acid/base residues of this enzyme class a priori .
189
 
The inhibition of human GH29 enzymes may have clinical potential . H. pylori 
adhesion has been shown to be correlated with expression of FUCA2 in the gut, and 
inhibition of this enzyme has been shown to abolish H. pylori  virulence
4
, thus 
inhibitors of this enzyme class may be useful in clearance of the pathogen . 
Compounds that inhibit α -ʟ-fucosidase may also have utility for chaperone therapy 
of fucosidosis, which, as discussed above,  occurs due to deficiency in α -ʟ-
fucosidase activity. In this approach, compounds that inhibit an enzyme are 
introduced into the cell and at low concentrations seem to activa te these enzymes, 
presumably by promoting their correct folding.  After transport of the chaperoned 
enzyme to their target compartment,  the inhibitor is outcompeted by the enzymatic 
substrate and function is thus restored  (Figure 1.12). This approach has been used 
for a number of different enzymes including both α- and β-galactosidases.192,193 The 
approach has had some success in the treatment of Fabry disease
194
 and is currently 
in phase 3 clinical trials
195
. A multitude of GH29 α-ʟ-fucosidase inhibitors have 
been described in the literature , which will be discussed later in this work .  
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Figure 1.12. The mechanism postulated whereby chemical chaperone therapy may 
restore the function of misfolded lysosomal enzymes.  
 
Unfortunately, despite the wealth of structural information that has been reported 
for α-ʟ-fucosidases from various sources, vide supra, no such information is 
available for the enzymes from man, FUCA1 and FUCA2.   
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1.5 Summary and thesis aims 
Carbohydrates serve myriad critical roles in nature, encompassing  e.g. fertility, 
development, diet, and the immune response. As such, genetic defect in 
carbohydrate processing leads to many diseases, and non -hereditary diseases often 
display altered profiles in constitutively expressed carbohydrate-containing 
structures.  
Fucose, from the rare series of ʟ-sugars, is incorporated into structural extracellular 
matrix carbohydrates, has roles in development due to its involvement in the Notch 
signalling pathway, and is an important monosaccharide in formation of the blood 
group antigens. As the sugar is incorporated into the branch termini  of N- and O-
linked glycans, it is a critical immuno-determinant. Regulation of the critical 
enzymes involved in formation and cleavage of ʟ-fucosylated glycans (GDP ʟ-
fucosyltransferases and α-ʟ-fucosidases) is differentiated as a result of a number of 
disease phenotypes notably including cancer .  
The subject of the following work is the GH29 (CAZy) family α-ʟ-fucosidases, with 
particular aim to characterise the structural  and mechanistic features necessary for 
potent inhibition of the enzyme and, ultimately, gain insight which may helpful for 
treatment of disease phenotypes associated with aberrant regulation of the enzyme  
e.g. H. pylori infection, fucosidosis and cancer. Whilst a number of bacteria have 
many homologous copies of this enzyme class , only two enzymes exist in humans, 
the lysosomal FUCA1 and plasma FUCA2; unfortunately no crystallographic 
structural information is available for these critical enzymes . Due to this lack of 
structural information on human α -ʟ-fucosidases, the GH29 enzyme from 
Bacteroides thetaiotaomicron  (BtFuc2970) will feature heavily in this work as a 
surrogate for the human enzyme. 
In the next chapter, the mechanism whereby five-membered iminocyclitols may 
inhibit GH29 enzymes will be studied by a combination of X -ray crystallography 
and kinetic studies. Subsequently, ferrocene-containing α-ʟ-fucosidase inhibitors 
will be studied; due to the cytotoxic effects of the ferrocenium ion, the se 
compounds may have utility as anti -cancer therapeutics. This third chapter will also 
study the potential for enhancements  in binding affinity towards α -ʟ-fucosidase by 
small molecule α-ʟ-inhibitors possessing multiple fuco-configured moieties. In 
chapter 4, the mechanism of irreversible α -ʟ-fucosidase inhibition by compounds 
containing aziridine moieties as an electrophilic trap will be studied; these 
compounds provide a template for inhibitors with utility as activity -based probes. 
Finally, efforts towards the generation of crystallisation-competent constructs of 
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human fucosidases FUCA1 and FUCA2 will be described before the final chapter 
wherein conclusions will be drawn from the work reported in this study. 
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Chapter 2: Inhibition of bacterial fucosidase 
BtFuc2970 by 5-membered iminocyclitols* 
 
Abstract 
GH29 α-ʟ-fucosidases are of importance due to their roles in maintaining 
homeostasis of N- and O-linked glycan structures and in fertility. Inhibitors of this 
enzyme class may prove clinically useful, for example for treatment of the 
lysosomal storage disorder fucosidosis and clearance of the stomach pathogen 
Helicobacter pylori  from the gastrointestinal tract. Whilst a number of structural 
studies have been reported highlighting the interaction of GH29 enzymes with 6 -
membered inhibitors, this is not so for  5-membered inhibitors, that prove to be 
potent inhibitors of this enzyme class with inhibition constants in the µM -nM 
range. Herein, kinetic and structural parameters for the binding of seven 5 -
membered iminocyclitol inhibitors to a GH29 fucosidase from Bacteroides 
thetaiotaomicron  (BtFuc2970) are reported. The compounds are shown to possess 
K is for BtFuc2970 in the µM range. Crystal structures of the compounds at 
resolutions of 1.59 - 2.10 Å serve to highlight the mode of binding of this class of 
compounds to fucosidase through an E3  conformation, mimicking the 
3
H4  
conformation for the transition state of catalysis. Ring contraction of these 
compounds compared to 6-membered inhibitors is shown to eliminate hydrogen 
bonding interactions. These crystal structures further serve to highlight where the 
aglycon moieties of natural substrates are likely to bind to GH29 -A family 
enzymes. The insights gained in this work may aid in the design of a new series of 
more potent fucosidase inhibitors.  
 
 
 
 
*This work is published in Wright, D. W., Moreno-Vargas, A. J., Carmona, A. T., 
Robina, I. & Davies, G. J. Bioorgan Med Chem  21, 4751-4754 (2013) and Hottin, 
A., Wright, D. W., Davies, G. J. & Behr, J. B. Chembiochem, 277-283 (2014). 
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2.1 Introduction 
GH29 α-ʟ-fucosidases are of critical biological importance, owing in part to their 
maintenance of a number of ʟ-fucosylated glycan structures such as the core fucose 
of Notch protein
196
 and histo-blood group antigens
20
, and also to their roles in 
fertility
109
 (Figure 2.1). Deficiency in α-ʟ-fucosidase activity in mammals leads to 
the lysosomal storage disorder fucosidosis
3
, while the enzyme is differentially 
regulated in a number of cancers
93,197
. Improved understanding of the biological 
activity of human GH29 enzymes would thus be clearly advantageous in the  
diagnostic and therapeutic contexts. Inhibitors of GH29 α -ʟ-fucosidases have 
already been shown to have the ability to modulate adhesion of the stomach 
pathogen Helicobacter pylori
4
, and may have utility in treatment of fucosidosis 
through chaperone therapy
193
. Unfortunately, in spite of the potential benefit it may 
have on human health and disease, no crystal structure is currently available for 
human GH29 enzymes.  
In this light, BtFuc2970 α-ʟ-fucosidase provides a model system for the study of α-
ʟ-fucosidase inhibition. Whilst Thermotoga maritima α-ʟ-fucosidase (TmGH29) has 
a greater primary sequence identity to human α-ʟ-fucosidases (Appendix 1), this 
enzyme contains an extended active sit e loop that is absent in FUCA1 and FUCA2 
and is likely to affect substrate binding and aglycon specificity
182
. BtFuc2970 
shares 27% and 28% sequence identity with human α -ʟ-fucosidases FUCA1 and 
FUCA2, respectively
198
.  
BtFuc2970 is on polysaccharide utilisation locus 44 of the Bacteroides 
thetaiotaomicron  genome (Figure 2.2). The substrate that regulates the expression 
of genes on this locus is currently unknown. The locus contains open reading 
frames for 11 gene products. Five of these genes remain unannotated  whilst the 
others transcribe proteins annotated as a family PL8 chondroitin AC  lyase 
(Bt2964), a GH2 family enzyme (Bt2969), a GH29 α-ʟ-fucosidase (Bt2970), a 
SusC/D pair (Bt2958 and Bt2957 respectively) and a HTCS sensor/regulator 
(Bt2971)
199
.   
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Figure 2.1 Some fucosylated structures that are important in biology. 
Monosaccharides are displayed by the standard proposed by Varki et al. in 2009 
(Yellow circle = galactose, yellow square = GalNAc, blue square = GlcNAc, purple 
diamond = sialic acid, red triangle = fucose).
51
 
 
 
Figure 2.2. Polysaccharide utilisation locus 44 of the genome of Bacteroides 
thetaiotaomicron  VPI-5482. 
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The genome of Bacteroides thetaiotaomicron  contains a total of 9 genes currently 
annotated as encoding GH29 fucosidases; these enzymes are thought to be involved 
in the catabolism of exogenous fucosylated glycans. The organism indeed has a 
complex system for ʟ-fucose metabolism thought to involve two discrete genetic 
loci
136,140
. The large number of GH29 enzymes possessed by Bacteroides 
thetaiotaomicron  likely represents the need for the organism to digest the large 
number of glycosidic linkages and polysaccharides ʟ-fucose is present in.   
Up to the time of writing, two distinct α-ʟ-fucosidases of Bacteroides 
thetaiotaomicron  have been biochemically characterised. These enzymes have 
different substrate specificities
191
. BtFuc2192 belongs to the GH29-B subfamily and 
specifically acts to cleave α -(1→3/4)-fucosidic linkages (EC 3.2.1.111) while 
BtFuc2970 belongs to the GH29-A subfamily, has relaxed substrate specificity, and 
is able to cleave any fucosidic linkage (EC 3.2.1.51)
191
.  
 
2.1.1 Previous structural and mechanistic studies on BtFuc2970 
The crystal structure of BtFuc2970 was solved previously
184
, confirming assignment 
of the catalytic nucleophile (Asp229) and acid/base residues (Glu288)  based on 
sequence predictions from the TmGH29 enzyme.  
Being a member of the GH29 family, BtFuc2970 adopts a (βα)8  TIM barrel fold
182
 
(Figure 2.3). The covalent intermediate for BtFuc2970 hydrolysis was trapped using 
2-deoxy-2-fluoro-β-ʟ-fucopyranose, revealing a 3S1  conformation for the catalytic 
intermediate
184
. This, in addition to observation of the Michaelis complex with 
fucose (in a 
1
C4 conformation) gave evidence to support the 
1
C4↔
3
H4↔
3
S1  
conformational itinerary postulated for GH29 enzyme catalysis based o n previous 
work on TmGH29
182
. Quantum mechanics and molecular dynamics simulations on 
ring distortion in fucose further highlighted that the 
1
C4↔
3
H4↔
3
S1 conformational 
trajectory is energetically viable and indeed favourable
184
.  
The kinetics of BtFuc2970 hydrolysis of p-nitrophenyl-α-ʟ-fucopyranoside and α-ʟ-
fucopyranosyl fluoride were subsequently determined
189
. The kcat value of mutant 
BtFuc2970 E288A was approximately 2000-fold lower than that of the native 
enzyme, whilst no hydrolysis could be measured for the D229A mutant, confirming 
these residues as the catalytic acid/base and nucleophile, respectively
189
.  
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Figure 2.3. 3D fold of α-ʟ-fucosidase 2970 from Bacteroides thetaiotaomicron  
(BtFuc2970), PDB code 2WVV
184
. The main chain of a single protomer is displayed 
in wall-eye stereo as ribbons with colour scheme blended through the model from 
the blue N terminus to the red C terminus.  Figure was drawn using CCP4MG
183
.  
 
The inhibition of BtFuc2970 by fuco-configured 6-membered inhibitors, displaying 
either a pyranose or piperidine ring system
184, 200
 has been probed. The 6-membered 
inhibitors studied displayed dissociation constants in the nM range and displayed 
tightest binding at pH 6.0. The pH optimum for BtFuc2970 catalysis has been 
determined at pH 7.4
200
. 
 
2.1.2 α-ʟ-fucosidase inhibition by 5-membered iminocyclitols  
Interestingly, 5-membered iminosugars have been shown to prove potent inhibitors 
of a number of glycoside hydrolase families.  These compounds appear to be 
exploited in nature, as many compounds with this functionality have been isolated 
as natural products from a variety of sources, including, for example, 2,5 -
dihydroxymethyl-3,4-dihydroxypyrrolidine from Derris elliptica
201
, 1,4-dideoxy-
1,4-imino-ᴅ-arabinitol from Angylocalyx boutiqueanus202, 2-hydroxymethyl-3-
hydroxypyrrolidine from Castanospermum australe
202
 and mannostatins from 
Streptoverticillium verticillus
203
. These compounds have been shown to have 
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inhibitory activities towards a range of glycosidases including α-mannosidase, α-
glucosidase and α-fucosidase203-205.  
Azasugars with appropriate configurations are thought to be potent inhibitors of 
those retaining glycoside hydrolases whose mechanism involves double -
displacement and proceed through a covalent enzyme intermediate, as they mimic 
the positive charge build-up at the enzymatic transition state
169,206
. Further, 5-
membered rings are more conformationally flexible than 6 -membered rings, and the 
low-energy envelope conformation of 5 -membered ring inhibitors mimics the high-
energy boat or half -chair transition state conformations of 6 -membered rings, as in 
both cases four adjacent atoms (the C5, O5, C1 and C2 atoms of natural sub strates) 
have coplanarity. Hence, a great deal of research effort has been directed towards 
the synthesis and screening of 5-membered iminocyclitols as glycosidase inhibitors 
over the past few decades, the key findings of some studies  pertaining to α-ʟ-
fucosidase will be summarised below.  
Pyrrolidine-based α-ʟ-fucosidase inhibitors were first assessed as early as 1993, 
when Wang et al . utilised aldolase enzymes for the chemoenzymatic synthesis of 
compounds I-IV (Table 2.1)
207
. These compounds had K i values of 1.4 – 22 µM for 
bovine kidney α-ʟ-fucosidase; it should be noted that this enzyme, which has 
significant sequence identity with α -ʟ-fucosidases from Homo sapiens  (Appendix 
1), is the enzyme used for most kinetic studies against α -ʟ-fucosidases described in 
the literature.  
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Table 2.1a. Some α-ʟ-fucosidase inhibitors described in the literature.  
Compound number Structural formula K i for bovine kidney 
α-ʟ-fucosidase (µM) 
I 
 
1.4 
II 
 
8 
III 
 
22 
IV 
 
4 
V 
 
3.2 
VI 
 
3.0 
VII 
 
0.008 
VIII 
 
0.010 
IX 
 
0.08 
X 
 
1.6 
XI 
 
0.2 
XII 
 
0.0049 
XIII 
 
0.010 
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Table 2.1b. Some α-ʟ-fucosidase inhibitors described in the literature.  
Compound number Structural formula K i for bovine kidney 
α-ʟ-fucosidase (µM) 
XIV 
 
0.024 
XV 
 
0.0048* 
XVI 
 
0.005 
XVII 
 
0.00105 
* inhibition against bovine epididymis α-ʟ-fucosidase 
 
Research on the fully chemical syntheses of pyrrolidine α-ʟ-fucosidase inhibitors 
started around the turn of the century. In 2001, Robina et al. noted that the 
currently available piperidine-based inhibitors of the enzyme class did not appear to 
be able to tolerate hydrophobic modifications which would be required for 
realisation of the compounds as therapeutic agents in a living system
208
. The 
authors proceeded to synthesise compounds V-VI (Table 2.1) using ᴅ-glucose as a 
starting material. Unfortunately, these compounds had limited utility as inhibitors, 
with mid-range K i values of ca. 3 µM towards bovine kidney α-ʟ-fucosidase. 
Further work on use of this scaffold did not improve inhibitory potency
209
, and it 
was observed that for the realisation of more potent inhibitors such as the 
piperidine deoxyfuconojirimycin (DFJ)
210
, an (S)-configured methyl group must  be 
attached to the C4 carbon of these pyrrolidine inhibitors
209
.  
The chemical synthesis of compounds with an (S)-configured methyl group at the 
C4 carbon of pyrrolidine α-ʟ-fucosidase inhibitors was first reported in 2004 by 
Chevrier et al ., who realised the synthesis of potent (K i = 8-10 nM for bovine 
kidney) pyrrolidine inhibitors VII-VIII using ᴅ-ribose as a starting 
material
211
(Table 2.1). A year later, Moreno-Vargas et al. reported the synthesis of 
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the benzimidazole compound IX, which displays 80 nM inhibition of bovine kidney 
α-ʟ-fucosidase212.   
Attempts towards more potent inhibition  by using transition-state mimicry were 
exploited in α-ʟ-fucosidase inhibition in 2006 by Laroche et al. 213. Here, the 
authors introduced spirocyclopropyl groups to the C4 carbon of a pyrrolidine 
scaffold e.g. compound X, Table 2.1; this functional group was postulated by the 
authors subsequently to flatten the heterocyclic ring causing the inhibitor to more 
closely resemble the half-chair conformation of the enzymatic transition state
214
. 
This approach was, however, a step back in terms of inhibitory potency  compared to 
compounds VII-IX which were produced chronologically earlier , yielding 
compounds with K i values only as high as 1.6 µM
213
. Further, the parent compound 
XI lacking a spirocyclopropyl moiety proved to be a more potent inhibitor ( K i = 0.2 
µM, Table 2.1)
214
.  
Compounds isolated as natural products have also helped to identify and drive the  
synthesis of potent pyrrolidine α-ʟ-fucosidase inhibitors.  Angylocalyx pynaertii , for 
example, has been shown to produce a number of alkaloids including α-ʟ-fucosidase 
inhibitor XII
215
. Subsequent chemoenzymatic synthesis and kinetic evaluation of 
this compound showed it to be a very potent inhibitor of the enzyme, with a K i 
against bovine kidney α-ʟ-fucosidase of 4.9 nM216,217, however the compound was 
also shown to inhibit α- and β-galactosidases. Further, the compound 4-epi-(+)-
codonopsinine XIII (Table 2.1), which was rationally designed based on a natural 
product from Codonopsis clematidae , has potent α-ʟ-fucosidase inhibitory activity 
with K i = 10 nM against bovine kidney α-ʟ-fucosidase 
218
.  
More recently, Elias-Rodruguez et al. used a combinatorial approach to synthesis of 
pyrrolidine α-ʟ-fucosidase inhibitors with triazole-containing aglycon through use 
of the Cu(I) catalysed alkyne-azide cycloaddition reaction
219
. The most potent 
inhibitor synthesised in this way, XIV,  has a K i of 24 nM, showing that this 
technique has utility for the rapid generation of compounds containing diverse 
aglycon moieties. 
A short mention should be given to 6-membered ring piperidine-based inhibitors of 
α-ʟ-fucosidase. DFJ XV is a potent inhibitor of α -ʟ-fucosidases, with a K i of 4.8 nM 
for the bovine epididymis enzyme
210
. In 2003, Wu et al. developed a combinatorial 
library of GH29 α-ʟ-fucosidase inhibitors using 6-membered ring azasugar (1R)-
aminomethyl-1-deoxy-ʟ-fuconojirimycin as a scaffold 220. Interestingly, though the 
compounds thus created have a β -linkage at the anomeric carbon, the approach 
proved to be of great success, the most potent inhibitor XVI had an inhibition 
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potency of K i = 5 nM. Further development of this inhibitor led to XVII, the most 
potent α-ʟ-fucosidase inhibitor known (K i = 1.05 nM) to the author’s 
knowledge
221
(Table 2.1). These studies highlight the importance of extended 
aromatic “aglycon” moieties in improving the activity of α -ʟ-fuosidase inhibitors, 
which has been commented on many times throughout the lit erature. 
Thus, while it is clear that correct chirality of the stereocentres in pyrrolidine 
inhibitors can help to improve inhibition potency, and that the introduction of 
aromatic aglycons can further improve inhibition potency, the structural features 
and minutiae of these interactions are still unclear. While a number of studies 
address the structural features of α-ʟ-fucosidase by piperidines 184,200, 221, structural 
information on inhibition of the enzyme by pyrro lidines is limited to docking 
studies on α-ʟ-fucosidase from Thermotoga maritima216.  
To the author’s knowledge, the first crystal structure of a 5 -membered iminocyclitol 
complexed with a glycosidase enzyme was reported in 2005 against Drosophila 
melanogaster  Golgi α-mannosidase II, whereby the substituents on a pyrrolidine 
inhibitor along with 5-membered rings containing other atoms were observed to 
have conformation dictated by the steric requirements for binding of the ring 
susbstituents in the enzyme rather than the energetic requirements of the 5 -
membered ring.
222
 Subsequently, in 2007, the crystal structure of another 5-
membered iminocyclitol bound to a glycoside hydrol ase enzyme (GH5 
endoglycoceramidase II) was reported
223
. In this structure, the iminocyclitol ring 
was observed to be ‘flipped’ relative to the orientation of 6 -membered ring 
inhibitors, thereby allowing stabilisat ion of its binding through hydrogen bonding 
interactions (Figure 2.4). Additionally, the endocyclic nitrogen superimposed not 
on the endocyclic oxygen of 6-membered ring inhibitors, but on the anomeric 
carbon, presumably allowing its stabilisation by elect rostatic interactions with the 
catalytic nucleophile and acid/base residues.   
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Figure 2.4. Binding mode of a 5-membered iminocyclitol to endoglycoceramidase II 
(PDB entry 2OYM), as contrasts with that of 6 -membered ring azasugars. Adapted 
from Caines et al.
223
.  
 
Reported herein are a number of crystal structures of 5-membered iminosugars 
complexed with bacterial α-ʟ-fucosidase BtFuc2970, which allow the dissection of 
their binding mode. Comparison with other GH29-A family enzymes enables insight 
into some conserved structural features in this subfamily. Further, the inhibition of 
BtFuc2970 by these compounds will be probed . The compounds described in this 
chapter were synthesised and evaluated as inhibitors of bov ine kidney α-ʟ-
fucosidase by collaborators at the Universities of Reims and Seville, and their 
collaboration is acknowledged.  
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2.2 Materials and methods 
2.2.1 Gene expression and protein purification 
A plasmid (pET-YSBLIC3C) containing a gene encoding a truncated BtFuc2970 was 
available from previous work in the Davies group (Figure 2.5, the sequence of the 
truncated BtFuc2970 transcript is available in Appendix 2). An aliquot of this 
plasmid was transformed into chemical ly competent BL21 (DE3) cells, which were 
grown in LB media containing 30 mg L
-1
 kanamycin as a small scale (10 mL) 
culture (cells were incubated at 37 ºC overnight with aeration by shaking at 180 
rpm). This culture was used to inoculate a larger (800 mL) volume of autoclaved 
LB media containing 30 mg L
-1
 kanamycin. Expression of the gene encoding 
BtFuc2970 was initiated by the addition of 1 mg L
-1  
isopropyl-β-D-1-
thiogalactopyranoside (IPTG) when the culture had reached an A 600 in the range 0.6 
- 1.0. Cells were incubated at 30 ºC overnight; subsequently cells were harvested by 
centrifugation and resuspended in 20 mM HEPES buffer, 0.5 M NaCl, 20 mM 
imidazole (pH 7.4). Overexpression of BtFuc2970 was tentatively confirmed by the 
presence of a strong band at ca. 54 kDa molecular weight (the expected molecular 
weight of the BtFuc2970 gene product) on an SDS-PAGE gel. 
BtFuc2970 was purified from cell lysate using a two -step procedure, comprising a 
Ni
2+
 affinity capture of the His 6-tagged protein and subsequent s ize-exclusion 
chromatographic separation. Cells were lysed by sonication, the resulting solution 
was centrifuged at 4416 RCF for 30 m and the supernatant decanted. This 
supernatant was applied to a 5 mL HiTrap column (GE Healthcare) preloaded with 
Ni
2+
 connected to an Äkta FPLC (GE Healthcare). 20 mM HEPES buffer, 0.5 M 
NaCl, 20 mM imidazole (pH 7.4) was passed through the column until the A 280  
response returned to the baseline. After this, an increasing concentration of 
imidazole was applied to the column as a gradient (to 500 mM imidazole over 50 
mL). Fractions with a strong A 280 response were run on a SDS-PAGE gel to 
determine the molecular weight of the protein species , and were concentrated by 
centrifugation at 5000 RCF using an Amicon Ultra -15 10K centrifugal filter. This 
protein was then applied to a Hi -Load 16/60 Superdex 200 prep grade size 
exclusion column (GE Healthcare) connected to an Äkta FPLC. A solution 
comprising 20 mM HEPES buffer, 0.1 M NaCl (pH 7.0) was run through the column 
and two major non-aggregated protein species were observed; both species were 
tentatively confirmed as being due to BtFuc2970 by SDS-PAGE. These species were 
attributed to be BtFuc2970 in monomeric (prevalent form) and dimeric 
oligomerisation states. Protein from the monomeric state was concentrated by 
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centrifugation at 5000 RCF using an Amicon Ultra -15 10K centrifugal filter and 
stored at -80ºC for subsequent experimentation.  
 
 
Figure 2.5. Plasmid map of pET-YSBLIC3C with BtFuc2970 cloned into the YSBL-
LIC3C site. The ORF containing a gene encoding truncated BtFuc2970 is under 
control of the T7 promoter and begins transcription with an N -terminal 3C-
cleavable His6 affinity tag. The plasmid map was generated using SnapGene® 
Viewer. 
 
2.2.2 Inhibitors 
5-membered iminosugar compounds displaying inhibition of fucosidase enzymes 
were received from collaborators (research groups of Profs. Jean-Bernard Behr at 
the University of Reims and Inmaculada Robina at the University of Seville). These 
inhibitors display a 5-membered iminocyclitol core with stereochemical 
configurations matching those of fucose (excepting the lack of a C3 atom), and have 
‘aglycon’ moieties attached to the C1 carbon (numbering scheme shown in Figure 
2.6, as derived from that commonly used for pyranose sugar s). 
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Figure 2.6. General form of 5-membered iminocyclitols described in Chapter 2. 
 
Compounds 1-7 , which will be discussed in this chapter, along with references for 
their syntheses, are displayed in Table 2.2. All of the compounds display inhibitory 
activity towards bovine kidney fucosidase
212,218, 224
. Compound 1 was tested for 
inhibitory activity towards other glycosidases and shown only to inhibit 
fucosidase
212
.  
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Table 2.2. 5-membered iminocyclitols described in Chapter 2.  
Compound 
number 
IUPAC Name Structural formula 
1
212
 (2S,3S,4R,5S)-2-(1H-
benzo[d]imidazol-2-yl)-5-
methylpyrrolidine-3,4-
diol 
 
2
218
 (2S,3S,4R,5S)-2-(4-
methoxyphenyl)-1,5-
dimethylpyrrolidine-3,4-
diol 
 
3
218
 (2S,3S,4R,5S)-2-(4-
methoxyphenyl)-5-
methylpyrrolidine-3,4-
diol 
 
4
218
 (2S,3R,4S,5S)-2-methyl-
5-(4-
methylphenyl)pyrrolidine-
3,4-diol 
 
 
5
224
 (2S,3S,4R,5S)-3,4-
dihydroxy-2-ethynyl-5-
methylpyrrolidine 
 
 
6
224
 (2S,3S,4R,5S)-3,4-
dihydroxy-2-[2'-
phenyl]ethynyl-5-
methylpyrrolidine 
 
7
224
 1-phenyl-4-
[(2S,3S,4R,5S)-3,4-
dihydroxy-5-
methylpyrrolidin-2-
yl]triazole 
 
 
2.2.3 Enzyme kinetics 
The α-ʟ-fucosidase activity of BtFuc2970 and its inhibition by compounds 1-3 and 
5-7 were probed. Enzymatic assays were conducted using synthetic substrate 2 -
chloro,4-nitrophenyl-α-ʟ-fucopyranoside (CNP-fucoside, CarboSynth Ltd.). The 
product of hydrolysis  of this substrate (2-chloro,4-nitrophenol, CNP) absorbs 
visible radiation with a λ max = 405 nm at pH above its pKa  (ca. 5.4). All experiments 
were carried out over a time-course of 5 m during which absorbance was measured 
at 405 nm using a Cintra 10 spect rophotometer (GBC Scientific Equipment Pty 
Ltd.). All solutions used to determine kinetic data were thermally equilibrated (37 
ºC).   
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2.2.3.1 Michaelis-Menten kinetics 
The α-ʟ-fucosidase activity of purified BtFuc2970 was confirmed, and the 
Michaelis-Menten parameters of BtFuc2970 action upon CNP-fucoside determined. 
The rate of enzymatic hydrolysis was determined upon solutions of varying 
concentration of CNP-fucoside. Each solution (1 mL total volume) contained 50 
mM HEPES buffer, 100 mM NaCl (pH 7.4) and a known concentration of substrate; 
50 nM BtFuc2970 was added to this after thermal equilibration to initiate 
hydrolysis. The molar extinction coefficient of CNP (ε 405 = 1.24 × 10
3
 M
-1
) was 
determined by measuring the absorption at 405 nm of a number of solutions of 
CNP-fucoside at known concentration that had been hydrolysed by excess 
BtFuc2970. The Michaelis-Menten parameters for CNP-fucoside hydrolysis (KM = 
0.49 ± 0.04 mM , Vmax = 117 ± 2.6 min
-1
,  Figure 2.7) were calculated through direct 
fit to the Michaelis-Menten equation using the Origin graphing software 
(OriginLab, Northampton, MA). 
 
Figure 2.7. Michaelis-Menten kinetics of CNP-α-ʟ-fucopyranoside hydrolysis by 
BtFuc2970. 
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2.2.3.2 Enzyme inhibition 
The inhibition of BtFuc2970 by compounds 1-3 and 5-7 was studied (Figure 2.8). 
Unfortunately an inadequate amount of compound 4 was available to determine its 
inhibition of BtFuc2970. The inhibition of BtFuc2970 by compounds 1-3 and 5-7 
was studied by in each case determining non-inhibited rate and inhibited rate at 
various concentrations of inhibitor. Each solution contained (1 mL total volume) 50 
mM HEPES buffer, 100 mM NaCl (pH 7.4), 250 nM BtFuc2970 and a known 
concentration of inhibitor; 50 µM CNP-fucoside was added to this to initiate 
hydrolysis.  
Inhibition constants were calculated by determining enzymatic rates in the absence 
and presence of ligand and plotting their ratio against inhibitor concentration over a 
series of inhibitor concentrations. This plot should yield a straight line with 
gradient = 1 / K i and y-intercept of 1 according to Equation 2.1. K is were thus 
determined by linear fit using the Origin (OriginLab, Northampton, MA). Inhibition 
plots used for the determination of K i values are displayed in Figure 2.8.  
Equation 2.1.  
𝑣0
𝑣𝑖
=  
1
𝐾𝑖
[𝐼] + 1 
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Figure 2.8. Plots showing inhibition of BtFuc2970 activity by compounds 1-3 and 5-
7. 
 
2.2.4 Crystallisation and structure determination 
2.2.4.1 Crystallisation 
Crystals of BtFuc2970 were grown in either Greiner Bio One CELLSTAR 24-well 
culture plates (set up manually) using the hanging drop vapour diffusion method or 
MRC MAXI 48-well crystallisation plates (set up by use of a Mosquito liquid 
handling robot, TTP Labtech) using the sitting drop vapour diffusion metho d. 
Crystallisation trials were initiated based on previously successful conditions
184
 and 
further optimised. BtFuc2970 was centrifuged for ca. 5 m before setting up 
crystallisation experiments.  
For the determination of an apo  crystal structure, a crystal of BtFuc2970 was 
transferred to a cryo-protectant solution containing mother liquor supplemented 
with 20% glycerol. Subsequently this crystal was cryo -cooled in liquid N2.  
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Crystals of BtFuc2970 liganded with compounds 1-7 were obtained by either adding 
solid powder of each compound directly to a drop containing one or multiple 
crystals of BtFuc2970 using an acupuncture needle (compounds 1-4), or by adding 1 
µL compound dissolved at 4 mM in 50 mM HEPES 100 mM NaCl (p H 7.4) to the 
crystallisation drop and re-sealing it (compounds 5-7). After incubation for at least 
ca. 30 m, these crystals were transferred to cryo -protectant solutions containing 
mother liquor supplemented with 20% glycerol and cryo -cooled using liquid N2.  
The crystal of apo-BtFuc2970 was sent to the European Synchrotron Research 
Facility for data collection, whilst those of BtFuc2970 complexed with each of 
inhibitors 1-7 were sent to Diamond Light Source.  
 
2.2.4.2 Crystallisation conditions 
Unless otherwise noted, crystallisation drops were set up in a 1:1 ratio of protein to 
mother liquor and BtFuc2970 was added as a 12 mg mL
-1
 solution (final 
concentration after dilution 6 mg mL
-1
). All crystallisation experiments were 
performed at ca. 18 ºC. 
apo-BtFuc2970 
Mother liquor: 17% w/v PEG 6K, 0.124 M ammonium sulfate, 0.1 M imidazole (pH 
8) 2 parts protein: 3 parts mother liquor  
BtFuc2970-1 
Mother liquor: 10.45% w/v PEG 6K, 0.12 M ammonium sulfate, 0.095 M imidazole 
(pH 7)  
BtFuc2970-2 , BtFuc2970-3 
Mother liquor: 12% w/v PEG 6K, 0.13 M ammonium sulfate, 0.1 M imidazole (pH 
7) 
BtFuc2970-4 
Mother liquor: 20% w/vPEG 6K, 0.16 M ammonium sulfate, 0.1 M imidazole (pH 7)  
BtFuc2970-5 
Mother liquor: 16% w/v PEG 6K, 0.16 M ammonium sulfate, 0.1 M imidazole (pH 
7)  
57 
 
BtFuc2970-6 
Mother liquor: 14% w/v PEG 6K, 0.16 M ammonium sulfate, 0.1 M imidazole (pH 
7) 
BtFuc2970-7 
Mother liquor: 20% w/v PEG 3350, 0.2 M ammonium sulfate, 0.1 M imidazole (pH 
7) 
 
2.2.4.3 Structure determination 
Diffraction images for crystals of apo-BtFuc2970 and for each inhibitor complex 
were indexed and integrated using either XDS
225
 or iMOSFLM
226
. POINTLESS
227
 
was used to determine the crystallographic space group in each case, and structure 
factor amplitudes were scaled and merged using SCALA
227
 or AIMLESS
228
.  
The crystals of BtFuc2970 in an apo  form and complexed with each of compounds 
1-4  grew in a novel P21  space group, and these crystals were almost isomorphous to 
each other. The apo-crystal structure was solved by molecular replacement 
(MOLREP
229
) using a truncated version (A-chain of protein only, ligands and 
solvent removed) of the previously determined structure of apo-BtFuc2970 (PDB 
entry 2WVV
184
) as a search model. MOLREP was run using default parameters with 
model data to a maximum resolution of 3.0 Å. The molecular replacement solution 
was used to build a model of apo-BtFuc2970 using iterative cycles of model -
building using COOT
230
 and maximum-likelihood refinement using REFMAC5
231
.  
As the space groups of each inhibitor complex of BtFuc2970 liganded with 
compounds 1-4 were almost isomorphous to the apo-crystal, coordinates from the 
apo-crystal structure were used directly for determination of the inhibitor complex 
structures; R free sets were assigned as they had been for the apo-crystal structure to 
maintain the uniqueness and integrity of the cross-validation Free R set throughout. 
The crystals of BtFuc2970 complexed with each of compounds 5-7 grew in a space 
group almost isomorphous to PDB entry 2WVV
184
), and the same process as 
described above was used for determination of these structures, with 2WVV and its 
identical cross-validation set. 
Coordinate sets and maximum likelihood refinement target values for each of 
compounds 1-7  were generated using CHEMDRAW3D and the PRODRG online 
server
232
. Inhibitor coordinates were initially added at 0.01 occupancies to prevent 
automatic addition of solvent into ligand density when using the COOT ‘find 
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waters’ function whilst minimising model bias. At late stages of refinement th e 
ligand occupancy was increased to 1.0.  
Final models for each of the compounds in this chapter were validated using 
MOLPROBITY
233
 and deposited with the RCSB Protein Data Bank 
(www.rcsb.org
234
, Table 2.3).  
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Table 2.3a. X-ray data collection and refinement statistics for the crystal structures 
discussed in Chapter 2.  
 
 
apo BtFuc2970-1  BtFuc2970-2  BtFuc2970-3  
Data collection     
Beamline/Date  ESRF ID23-2 
21.11.2011 
DLS I03 
12.12.2011 
DLS I04-1 
8.3.2012 
DLS I04-1 
8.3.2012 
Wavelength (Å)  0.8726 0.9763 0.9173 0.9173 
Cell dimensions     
  a ,  b ,  c (Å) 68.2, 96.6, 97.3 68.7, 95.6, 97.0 68.4, 95.8, 97.1 67.5,94.6,96.9 
  α,β,γ (°)  90, 91.3, 90 90, 91.2, 90 90, 90.8, 90 90, 90.9, 90 
Resolution (Å)  30.7-1.59 29.0-1.73 97.1-1.58 29.3-2.10 
Rmer ge  0.11(0.71)* 0.045(0.45) 0.10(0.45) 0.08(0.48) 
I / σI  8.7(2.0) 12.8(1.8) 9.2(2.8) 13.3(2.6) 
Completeness (%)  99.9(99.9) 98.3(94.5) 99.2(99.6) 98.9(99.7) 
Redundancy 3.8 3.2 3.9 4.4 
Wilson B value 15.1 26.4 20.5 32.2 
Refinement     
Resolution (Å)  30.7-1.59 29.0-1.73 97.1-2.00 96.9-2.10 
No. reflections 159881 128119 83899 70362 
Rwor k / R f ree  0.16/0.18 0.17/0.19 0.16/0.19 0.18/0.21 
No. atoms     
  Protein 7172 7083 7102 7045 
  Ligand/ion 69 96 100 112 
  Water 1059 729 852 405 
B-factors (Å
2
)      
  Protein 14.2 33.5 24.9 39.4 
  Ligand/ion 37.3 52.1 40.0 63.5 
  Water 25.1 39.7 32.5 42.4 
R.m.s. deviations      
  Bond lengths (Å)  0.014 0.015 0.016 0.016 
  Bond angles (°)  1.5 1.5 1.6 1.6 
Ramachandran 
Statistics (%) 
    
  Preferred 96.0 95.6 95.8 95.0 
  Allowed 3.3 3.3 3.1 3.9 
  Outliers 0.7 1.1 1.1 1.1 
PDB codes 4J27 4J28 4JFS 4JFT 
*Values in parentheses are for highest -resolution shell.  
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Table 2.3b. X-ray data collection and refinement statistics for the crystal structures 
discussed in Chapter 2.  
 BtFuc2970-4  BtFuc2970-5  BtFuc2970-6  BtFuc2970-7  
Data collection     
Beamline/Date  DLS I03 
12.12.2011 
DLS I04-1 
16.12.2012 
DLS I04-1 
16.12.2012 
DLS I03 
02.02.2014 
Wavelength (Å)  0.9763 0.9200 0.9200 0.9763 
Cell dimensions        
  a ,  b ,  c (Å) 68.0,95.4,96.9 56.6,188.8,97.7 56.4,188.3,97.9 56.0,187.6,97.7 
  α,β,γ (°)  90, 90.8, 90 90,94.3,90 90,94.1,90 90,94.3,90 
Resolution (Å)  55.4-1.66 38.5-2.10 39.3-1.77҂  55.9-1.95 
Rmer ge  0.05(0.16)* 0.12(0.68) 0.11(1.72) 0.07(0.71) 
I / I  10.7(3.5) 7.2(1.8) 6.0(0.7) 8.8(1.7) 
Completeness 
(%) 
99.3(99.1) 93.5(88.8) 95.9(96.7) 98.2(97.4) 
Redundancy 2.9 3.6 4.0 3.9 
Wilson B value  20.5 19.6 22.4 31.9 
 
Refinement 
    
Resolution (Å)  55.4-1.66 38.5-2.10 39.3-1.77 55.9-1.95 
No. reflections 144771 104691 178165 135815 
Rwor k  / R f ree  0.15/0.18 0.21/0.25 0.22/0.26 0.19/0.23 
No. atoms     
  Protein 7183 14052 14183 14304 
  Ligand/ion 100 90 124 136 
  Water  1098 579 588 892 
B-factors     
  Protein 24.3 32.9 35.8 38.3 
  Ligand/ion 41.8 55.5 50.6 55.6 
  Water  37.3 28.7 32.2 39.9 
R.m.s. deviations      
  Bond lengths(Å)  0.015 0.013 0.015 0.016 
  Bond angles()  1.5 1.4 1.5 1.5 
Ramachandran 
Statistics (%) 
    
  Preferred 96.0 95.6 95.6 95.7 
  Allowed 3.3 3.6 3.4 3.4 
  Outliers 0.7 0.8 1.0 0.9 
PDB codes 4JFU 4PCT 4PCS 4PEE 
*Values in parentheses are for highest -resolution shell.  
҂Diffraction data were scaled inappropriately for the 4PCS dataset submitted to the RCSB. 
When scaled with a high resolution cut -off of 2 Å, statistics are as follows: Rmer ge  = 0.705, 
I/I  = 1.6, Completeness = 96.3(87.0), Redundancy = 4.1(3.6), Wilson B value = 26.8, 
half-set correlation = 0.997(0.711).  
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2.3  Results and Discussion 
2.3.1 Inhibition of BtFuc2970 by 5-membered iminocyclitols 
K is determined for inhibition of BtFuc2970 by compounds 1-7 are displayed in 
Table 2.4, along with those previously determined for inhibition of mammalian 
(bovine kidney) α-ʟ-fucosidase218,224,235 by collaborators. 
Table 2.4. Inhibition of BtFuc2970 and mammalian fucosidase by compounds 1-7.  
Compound  K i vs. BtFuc2970 / µM  
(values in parens: fitting error 
from linear fit in Origin) 
K i vs. bovine kidney fucosidase  
/ µM 
1 2.0 (0.1) 0.08 
2 5.4 (0.3) 0.81 
3 3.5 (0.2) 0.01 
4 N/D 0.01 
5 1.0 (0.04) 0.07 
6 0.24 (0.01) 0.014 
7 0.22 (0.003) 0.005 
 
All of the compounds studied display poorer binding affinities towards BtFuc2970 
than towards mammalian enzymes.  In general, the trends observed for inhibition of 
bovine kidney α-ʟ-fucosidase are mirrored in inhibition of BtFuc2970, however the 
magnitude of inhibition is far lower; the potent, nanomolar affinities displayed by 
e.g. compound 7  against bovine kidney fucosidases are not apparent against 
BtFuc2970.  
Kinetic determinations for inhibition of BtFuc2970 were carried out by continuous 
assay of hydrolysis of CNP-α-ʟ-fucopyranoside at pH 7.4 – the previously 
determined pH optimum for enzymatic activity
200
; the tightest binding of 6-
membered iminocyclitol inhibitors to BtFuc2970 was however previously observed 
to be at pH 6.0
200
. Inhibition constants against the bovine kidney α-ʟ-fucosidase 
were determined by stopped assay of hydrolysis of p-nitrophenyl-α-ʟ-
fucopyranoside at pH 5.0 (1) 
235
 or 5.6 (2-8)
218,224
. The discrepancy observed 
between K is against each enzyme may therefore either reflect electrostatic 
differences in the enzymes or inhibitors due to the differing experimental pH, or 
physical differences in the inhibitor binding site s of the two enzymes.  
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2.3.2 Structural analysis of the binding of 5-membered iminocyclitol inhibitors 
to BtFuc2970 
2.3.2.1 X-ray data quality 
Diffraction images for  apo-BtFuc2970 were collected at 1.59 Å resolution, while 
those for BtFuc2970 complexed with compounds 1-7 were collected at 1.66-2.10 Å 
resolution (Table 2.3). X-ray data were scaled at resolution cut-offs based on 
criteria for Rmerge and I/σ(I) considerations. The dataset submitted to the RCSB for 
BtFuc2970-6  (4PCS) was perhaps scaled to an inappropriate resolution, see Table 
2.3. The resolution limit to which these X-ray data were useful would be better 
decided on the basis of half -dataset correlation co-efficients
228
, however this 
technology was not available  at the time of data scaling and merging.  
Compounds 1-7 were unambiguously present in the crystal structures as evidenced 
by clear peaks in Fo-Fc  maps after refinement of protein, solvent and other ions, but 
before the inclusion of compounds 1-7 in refinement (Figure 2.9).  
63 
 
 
 
64 
 
Figure 2.9. Figures of compounds 1-7 , respectively, lying in the active site of 
BtFuc2970.  Atoms of compounds 1-7 are coloured by atom type (carbon in grey).  
The catalytic nucleophile Asp
229
 and acid/base Glu
288
 of BtFuc2970 are displayed 
coloured by atom type (carbon in green, residues are annotated for BtFuc2970:1).  
Carbon atoms displaying an alkyne bond in compounds 5 and 6 displayed as grey 
spheres. The maps displayed are Fo-Fc  maps from before the incorporation of 
phases from compounds 1-7 in refinement, contoured at 5 σ (compounds 1-4), 3 σ 
(5) or 2 σ (6, 7). Figures were drawn using CCP4MG 183.  
 
2.3.2.2 Mode of binding of 5-membered iminocyclitols to BtFuc2970 
In the complex structures determined, the iminocyclitol cores of com pounds 1-7 are 
observed to adopt an E3 conformation (Figure 2.10). In this conformation, the ring 
nitrogen, C1, C2 and C4 atoms lie in a plane, and the C3 atom lies below this plane 
when viewed from the face where atom numbering increases in a clockwise fa shion. 
This conformation mimics and gives evidence to support the postulated 
3
H4 
catalytic transition state for enzyme catalysis by GH29 fucosidases
182,184
 on a 
geometrical basis.  
The iminocyclitol cores of each of the inhibitors studied lie in the BtFuc2970 active 
site such that their C2 and C3 hydroxyls make hydrogen bonding interactions with 
active site residues (Figure 2.11). These hydrogen bonding interactions are the same 
as those made between the C3 and C4 hydroxyls of 6-membered inhibitors with 
BtFuc2970, and also with the TmGH29 enzyme (Figure 2.12). 5-membered 
inhibitors lack the (S)-hydroxyl group that is attached at the C2 position of 6 -
membered inhibitors. This leads to loss of two hydrogen bonding inte ractions 
(between this hydroxyl and both Nε1 of Trp
88
 and Nε2 of His
136
).  
The conformation adopted by five -membered iminocyclitols in the enzymatic active 
site of BtFuc2970 contrasts greatly with that observed previously for this class of 
inhibitor against the GH5 family endoglycoceramidase
223
. Inhibition of this GH5 
enzyme was shown to involve ‘flipping’ of the inhibitor i.e. a 180 ° rotation of the 
inhibitor ring such that the ring substituents pointing towards o ne direction of the 
active site now pointed the other direction (this can be seen graphically in Figure 
2.3). The endocyclic amine of this inhibitor was observed to be positioned where 
the anomeric carbon of a natural substrate would be bound. Here, bindin g of the 
iminocyclitol inhibitor in a flipped conformation appears to be favoured due to 
electrostatic interactions between the endocyclic amine of the inhibitor and the 
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catalytic nucleophile and acid/base residues; further, a suitable hydrogen bonding 
network can still be formed even after ‘flipping’ of the inhibitor ( Figure 2.3). 
 
 
Figure 2.10. Conformation of the iminocyclitol core of five -membered 
iminocyclitol inhibitor 1 as observed in crystal structure bound to BtFuc2970. The 
figure was drawn in wall-eye stereo with aglycon atoms not displayed, using 
CCP4MG
183
.  
 
 
Figure 2.11. Schematic of the interactions between the iminocyclitol core of 
compounds 1-7 and BtFuc2970. Protonation states displayed are arbitrary. 
Hydrogen bonds < 3 Å shown as dashed lines.  
 
 
66 
 
 
Figure 2.12. Superposition of the coordinates of 4J28 (BtFuc2970-1), 2XIB
200
 and 
1ODU
182
 displayed in wall-eye stereo. The iminocyclitol or fucopyranose cores of 
inhibitors and residues that hydrogen bond to 1 are displayed in each case.  Atoms 
are coloured by type; carbon atoms from 4J28 in grey, from 2XIB in coral and from 
1ODU in yellow. Hydrogen bonds (2.6 – 2.8 Å) from 1 displayed as dashed bonds.  
Residues with numbering according to BtFuc2970 are annotated. The figure was 
drawn using CCP4MG
183
.  
 
For the case of fucose-mimetics such as 1-7 however, binding of the inhibitor in a 
flipped conformation would lead to loss of a number of hydrogen bonding 
interactions. The importance of the hydrogen bonds made by the hydroxyls of the 
C2, C3 and C4 carbon atoms of fucose -mimetics has previously been observed by 
Winchester et al. after analysis of structure activity relationships of α -ʟ-fucosidase 
inhibitors
107
. 1-7 have already lost the hydrogen bonding interactions made by their 
missing hydroxyl unit, and ring flipping would lead to loss of the other interactions 
thus leading to a significant energy barrier to inhibitor binding in this 
conformation.  
The crystal structure of compound 3 has been determined
218
. The crystal structures 
of compound 3 in its enzyme free and enzyme bound forms were superposed ( Figure 
2.13). This superposition gives an RMSD of 0.18Å and shows that the conformation 
adopted by the compound as a ligand of BtFuc2970 is almost identical to the one it 
displays in solution. As it is expected that the conformation seen in small molecule 
crystal structure is the ground state conformation, it can be concluded that 5 -
membered iminocyclitols require negligible conformational ch ange in binding to α-
ʟ-fucosidases. This is likely reflected to some degree in the favourable binding of 
5-membered iminocyclitols to BtFuc2970 despite the reduced number of hydrogen 
bonding interactions they make to the enzyme, compared to 6 -membered inhibitors. 
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Figure 2.13. Superposition of the enzyme free and enzyme bound crystal structures 
of compound 3 displayed in wall-eye stereo. Atoms are coloured by type; carbon 
atoms from BtFuc2970-3 in grey, from the small molecule crystal structure
218
 in 
green.  
 
2.3.2.3 Positioning of the aglycon moieties of iminocyclitol inhibitors  
5-membered iminocyclitols lie in the BtFuc2970 active site in a way that satisfies 
the maximum number of hydrogen bonding interactions possible ( Figure 2.12). The 
aglycon moieties of 5-membered inhibitors bound to BtFuc2970 are observed to 
occupy a different section of the hydrophobic landscape when compared to that 
occupied by the aglycons of 6-membered inhibitors bound to both BtFuc2970 and 
TmGH29 (Figure 2.14). In this binding mode, the aglycon moieties of inhibitors 1-7 
lay atop a hydrophobic ridge formed by residues Trp
88
 and Trp
232
. Upon 
superposition of the available crystal structures of GH29 -A family enzymes, this 
hydrophobic ridge appears to be conserved through 3D fold (Figure 2.1 5). Residue 
Trp
88
 in BtFuc2970 is structurally conserved throughout GH29 -A family enzymes 
whilst the residue corresponding to Trp
232
 of BtFuc2970 invariantly presents a 
similarly sized van der Waal’s radius (Figure 2.15). A hydrophobic region of GH29 
family enzymes has previously been alluded to based on structure activity 
relationships e.g.
220, but has not to the author’s knowledge been described 
structurally.  
Initially, it was thought that ring contraction of 5 -membered ring inhibitors 
compared to 6-membered ring inhibitors caused ring rotation to maintai n the 
hydrogen bonding network of these compounds and thus oriented the aglycon 
moiety in a non-physiological direction e.g. 
236
. However, after close inspection of 
the available crystal structures of GH29 enzymes it appears unlikely that this is the 
case.  
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Figure 2.14. Superposition of the coordinates of 4J28 (BtFuc2970-1), 2WVU
184
 and 
2ZXA
221
, shown in wall-eye stereo. Inhibitors are coloured by atom type; carbon 
atoms from 1 in grey, from para-nitrophenyl-α-ʟ-fucopyranoside (2WVU) in coral 
and from acetyl-fuconojirimycin (2ZXA) in yellow. Protein atoms of BtFuc2970 
(4J28) displayed as a white surface. The figure was drawn using CCP4MG
183
.  
 
 
Figure 2.15. The hydrophobic ridge formed in GH29-A family fucosidase crystal 
structures. GH29-A fucosidase crystal structures from BtFuc2970 (liganded with 7,  
side-chains of residues Trp
88
 and Trp
232
, and 7 displayed in cyan with cyan 
surfaces), Thermotoga maritima  (PDB code 1HL8
182
, side-chains of Trp
67
 and 
Met
225
 in pink with pink surfaces) and Fusarium graminearum  (PDB code 4PSR
188
, 
side-chains of Trp
47
 and Phe
227
 in coral with coral surfaces) were superposed. 
Orthogonal figures of the hydrophobic ridge were prepared using CCP4MG
183
.  
 
In the available crystal structures of α-ʟ-fucosidases (BtFuc2970 and TmGH29) 
complexed with 6-membered ring compounds, the ligands display ‘non -natural’ 
features. Inhibitors complexed with TmGH29 all display a β-linkage at C1, while in 
the crystal structure of a D229N mutant of BtFuc2970 complexed with 2,4-
dinitophenylfucopyranoside the catalytic acid/base E288 is flipped out of an active 
conformation. Comparison of the aglycon trace between 5 -membered inhibitors of 
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BtFuc2970 and lacto-N-fucopentaose II complexed with Bifidobacterium longuum  
GH29-B fucosidase (PDB entry 3UET)
187
, however, shows that the aglycons of 
compounds 1-7 lay in a similar position to that of lacto-N-fucopentaose II (Figure 
2.16). As such, it is likely that the orientation observed  for the aglycons of 
compounds 1-7 liganded with BtFuc2970 is physiologically relevant.  
 
Figure 2.16. Superposition of the coordinates of 4J28 (BtFuc2970-1) and 3UET
187
.  
Inhibitors are coloured by atom type; carbon atoms from 1 in grey, from lacto-N-
fucopentaose II in coral. Positions of residues Trp88 and Trp232 are indicated in 
the figure. Protein atoms of BtFuc2970 (4J28) displayed as a white surface. The 
figure was drawn using CCP4MG
183
.  
 
In all of the structures obtained throughout this chapter, sulfate ions were observed 
proximal to the enzymatic active site, in what appears to be an electrostatically 
positive binding site, binding of the sulfate is stabilised by a nu mber of hydrogen 
bonds from residues Arg
262
, Arg
271
 and His
272
 (Figure 2.17). Whilst sulfate ions 
were always present in crystallisation solutions, this is due to the preferential 
crystallisation of this enzyme in conditions containing sulfate.  
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Figure 2.17. Position of sulfate ions proximal to the active site of BtFuc2970. The 
protein main chain of BtFuc2970-1 (PDB entry 4J28) displayed as ribbons coloured 
in cyan. Atoms of 1 , the sidechains of residues Arg
262
, Arg
271
 and His
272
 and sulfate 
moiety are displayed coloured by atom type (carbon atoms of 1 displayed in grey). 
Hydrogen bonds made between the sulfate moiety and the protein side -chains of 
BtFuc2970 are displayed as dashed lines. The figure was drawn using CCP4MG
183
.  
 
BtFuc2970 belongs to polysaccharide utilisation locus 44 of the genome of 
Bacteroides thetaiotaomicron  VPI-5482; this locus also contains genes encoding a 
chondroitin AC lyase and a β-galactosidase. It is thus tempting to speculate that the 
substrate for this PUL is some form of fucosylated chondroitin sulfate. The 
glycosaminoglycan with this name, however, comprises main chain β1→4 -linked 
glucuronic acid and β1→3 -linked N-acetyl galactosamine, with sulfated Fucα1→3 
branches appended to the main chain glucuronic acid
22,25
. The other currently 
annotated transcripts of this locus do not appear to have the necessary functionality 
to degrade this substrate, however they have not been biochemically characte rised. 
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2.4  Conclusions 
Kinetic and X-ray crystallographic studies were used to probe the interactions of a 
series of fuco-configured 5-membered iminocyclitols with GH29 α-ʟ-fucosidase 
BtFuc2970 from Bacteroides thetaiotaomicron . X-ray crystal structures of these 
compounds complexed with BtFuc2970 elucidated their mode of binding; through 
an E3  conformation that mimics the postulated 
3
H4  transition state for catalysis
184
. 
This binding conformation was also observed to be the conformational ground state 
of these inhibitors based on analysis with the previously published small molecule 
crystal structure of a representative inhibitor. The loss of a single hydroxyl 
compared to 6-membered ring inhibitors was shown to cause disruption of the 
hydrogen bonding network which has previously been shown to be important for 
GH29 inhibition
220
. The crystal structures further served to highlight the likely 
orientation adopted by the aglycons of natural substrates in the GH29-A family and 
allowed the observation of a conserved hydrophobic ridge that is present in all 
GH29-A family members for which crystal structures are known. Kinetic studies of 
the inhibitory activity of these inhibitors on BtFuc2970, when compared with 
previous values against bovine kidney α-ʟ-fucosidase, showed a discrepancy 
whereby inhibition was more potent against the mammalian enzyme than 
BtFuc2970; this may be due to differences in either the pH that inhibition 
experiments were carried out or the inhibitor binding sites in each enzyme.  
BtFuc2970 belongs to polysaccharide utilisation locus 44 of the genome of 
Bacteroides thetaiotaomicron  VPI-5482, which also contains a gene encoding a 
chondroitin AC lyase. It was observed that crystals of this enzyme preferentially 
form in sulfate-containing crystallisation solutions, and that sulfate is invariably 
located proximal to the enzymatic active site, in an area of the enzyme with a 
positive electrostatic potential. It is thus tempting to speculate that the natural 
substrate for this locus may be a form of fucosylated chondroitin sulfate.  More 
detailed biochemical characterisation of the remaining gene products on this locus 
could prove helpful for determination of its biologi cal substrate and function.  
The results presented herein may aid in the design of more potent inhibitors to 
target GH29 α-ʟ-fucosidases, which may have therapeutic relevance due to the 
myriad biological functions the enzyme is involved in . As no X-ray crystal structure 
is yet available for a human GH29 enzyme, i t is uncertain to what extent structural 
insight made on this surrogate system is applicable to the aforementioned, however.   
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Chapter 3: Multivalency in fucosidase inhibition and 
targeting of neoplastic cells by ferrocenyl-
iminocylitols* 
 
Abstract 
As GH29 α-ʟ-fucosidase is implicated, or differentially regul ated in a number of 
disease phenotypes, there is a need for the generation of more potent inhibitors of 
this enzyme class which may be able to probe the biology of these diseases or treat 
them. In nature, multivalency effects often dramatically increase th e affinity of 
interactions between carbohydrates and lectins, and it may be possible to harness 
this multivalency effect in the inhibition of carbohydrate processing enzymes. Since 
upregulation of human GH29 α -ʟ-fucosidase is a known determinant of oral, b reast 
and liver neoplasias, the use of pharmacophore -containing α-ʟ-fucosidase inhibitors 
may provide a route for chemotherapy of these cancers. We report herein 
crystallographic structure determination of complexes of GH29 enzyme BtFuc2970 
liganded with a monovalent α-ʟ-fucosidase inhibitor and its trivalent counterpart at 
1.7 and 1.68 Å respectively, coupled with kinetic data for their inhibition of 
BtFuc2970. These data are used to conclude that multivalency affinity 
enhancements by chelation are geometr ically impossible and those by stastistical 
rebinding are unlikely to be seen in this case due to the low valency of the 
compounds. Further, the 1.88 - 2.30 Å crystal structures of α -ʟ-fucosidase 
configured iminosugars coupled to ferrocene pharmacophores a re reported. While 
these compounds are shown to bind in the GH29 active site and others have shown 
they have anti-proliferative action on the MDA-MB-231 breast cancer cell line, 
further experiments would be needed to assess their clinical usefulness.  
 
 
 
 
*This work is published in Moreno-Clavijo, E.  et al. Eur J Org Chem 2013, 7328-
7336 (2013) and Hottin, A. et al. Chem-Eur J 19, 9526-9533 (2013).  
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3.1 Introduction  
As GH29 α-ʟ-fucosidase is implicated or differentially regulated in a number of 
disease phenotypes, there is a need for the generation of more potent inhibitors of 
this enzyme class. In nature, multivalency effects are often found in the interactions 
of carbohydrates with their lectin receptors. These effects can dramatically ( ca. 6 
orders of magnitude) increase the affinity of a carbohydrate -lectin interaction,
237
 
and it may be possible to harness this multivalency in the inhibition of carbohydrat e 
processing enzymes.
238
 
  
3.1.1 Multivalency effects in carbohydrate recognition  
Carbohydrates typically bind only weakly with their receptors, rarely with 
dissociation constants lower than 10
-6
 M
239
;  this property can be of biological 
importance e.g.  in the binding of selectins to their ligands in the inflamm atory 
cascade
45
. Nevertheless, carbohydrate-receptor interactions are widespread and 
critical throughout biology, and some of the roles of carbohydrate interactions 
require tight binding between carbohydrates and their receptors.  
It has been known for many years  that mutlivalency or avidity effects are often 
exploited by nature in the interaction of carbohydrates with their receptors, ranging 
from species with low valency values to the high -order multivalency achieved by 
species such as viruses
239
. The availability of multivalent binding mechanisms for 
carbohydrates may lead to enhancement of the affinity of a particular interaction 
over what would be expected were the affinity to be corrected on a per subunit 
basis, hence providing access to the large affinities required for many biological 
processes. This effect is termed the ‘cluster glycoside effect’. 240 Enhancements in 
binding affinity gained through this mechanism require a receptor lectin with 
multiple carbohydrate binding sites, and ligands containing multiple carbohydrates, 
such as the glycans expressed in the glycocalyx; expansion of oligosaccharides 
resembling N-acetyllactosamine glycans from monoantennary to triantennary has 
been shown to increase their affinity for mammalian hepatic lectins by 6 orders of 
magnitude
241
.  
During multivalent binding, rotational and translational entropic costs only need to 
be paid during the first binding event, thereby enhancing the affinity of the second 
sub-ligand binding event
239,242
; multivalency affinity enhancements achieved in this 
way can be as high as 10
3
-10
6
 fold
237
. A number of mechanisms exist whereby 
multivalency can effect the tighter overall binding of a ligand to its receptor 
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(Figure 3.1).
237
 Chelation effects may occur when a multivalent ligand is able to 
bind simultaneously to multiple receptor sites on a single receptor, in this case a 
long enough linker region is required to allow individual subunits to span the 
distance between adjacent receptor binding sites. When linkers separating ligand 
subunits are too short for this, affinity enhancements may occur due to “statistical 
rebinding” or “proximity effects”. These are caused by the slower dissociation of a 
ligand when multiple (sub)ligands are available for interaction with a receptor due 
to the higher local concentration of sub -ligands.
237
 Clustering of receptors on cell 
surfaces is also common in nature, providing a high concentration of receptor 
moieties in a limited volume, to which multivalent inhibitors may bind. This 
clustering is a particularly prominent feature of lectins involved in cellular 
adhesion and signal transduction roles. 
 
 
Figure 3.1. Mechanisms by which a ligand may interact through multivalency.  
 
While multivalent ligands capable of chelating lead to very high multivalency 
affinity enhancements, which are optimal with relatively low valencies of under ca. 
10, this is not the case for those ligands that may only garner “statistical rebinding” 
affinity enhancements; these ligands are able to achieve only weaker affinity 
enhancements of up to 2000-fold, and achieve these only with very high valency of 
the carbohydrate moiety.
237
 
As mentioned previously, the adhesion and colonisation of a number of bacteria to 
their host is mediated by interactions between carbohydrates and their receptors. In 
some cases, multivalency effects are taken advantage of during t he colonisation or 
pathogenicity of a prospective resident of the host.  For example, the pathogenic 
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bacterium Pseudomonas aueruginosa , which was discussed briefly in Chapter 1, 
harbours tetrameric lectins, LecA and LecB, which bind to galactose and fucose,  
respectively
243,244
. The synthesis and evaluation of multivalent ligands for both of 
these lectins has been reported in the literature. For multivalent inhibition of LecB, 
Johansson et al  produced two 15,625 member combinatorial libraries of amino-acid 
based dendrimer scaffolds appended with four fucose units by solid -phase peptide 
synthesis.
245
 The compounds thus generated displayed a range of affinities towards 
LecB, with the best compounds showing a 100-fold affinity enhancement over 
fucose alone. Further, these compounds were able to inhibit P. aeuruginosa  biofilm 
formation, with the most potent inhibitor showing complete inhibition at 50 µM, 
and disperse existing colonies of P. aeuruginosa .
245
     
Interestingly, Brissonnet et al. recently reported the synthesis of iminosugar coated 
dextran polymers and their evaluation as multivalent ligands of carbohydrate 
processing enzymes, rather than lectins.
238
 The authors generated dextran polymers 
of varying size functionalised with the iminosugar glycosidase hydrolase inhibitors 
deoxynojirimycin (DNJ) and deoxymannonojirimycin (DMJ). These compounds 
were then tested as inhibitors of a panel of glycoside hydrolases including the α-ʟ-
fucosidase from Thermotoga maritima  and a mannoside phosphorylase from an 
uncultured Bacteroides strain. Surprisingly, while multivalency effects of up to 70 -
fold were reported, some of the enzymes tested even had their catalytic activities 
increased in the presence of DNJ or DMJ -coated dextrans, where it would be 
expected that the iminosugar inhibitors DNJ and DMJ bind in the active site and 
inhibit the enzymes. It is unclear what the basis is for the activation of these 
enzymes, but it may be due to non-specific allosteric factors or the compounds 
promoting alternative reaction pathways such as transglycosylation which compete 
for availability of active substrate.  
 
3.1.2 Searching for determinants of neoplasia  
Cancer remains one of the leading causes of death throughout the world,
72
 and thus 
it is not at all surprising that the research field is both voluminous and rapidly 
growing (a search of PubMed for articles published in 2014 with title including 
‘cancer’ had more than 55,000 hits, while the same search of previous years have 
successively fewer hits in a linear trend).  
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One of the most difficult hurdles to overcome in treatment of cancer is overcoming 
the remarkable phenotypic and functional heterogeneity possessed by neoplastic 
cells. It is believed that this heterogene ity is due to the differentiation of ‘cancer 
stem cells’ into mature cells with diverse phenotypes. 246, 247 In the ‘cancer stem cell’ 
model, not all tumour cells are thought to be equal, with tumour growth being 
driven by relatively few tumourigenic stem cells that are capable of self -renewal 
and are incredibly resistant to stress, i.e. have features typical of normal stem cells. 
This model is popular as it helps to explain a number of the features associated with 
cancer in the clinical setting, e.g. that while therapy may be effective in the short -
term, rarely does recurrence of the tumour not occur in the long term.  
Due to the phenotypic diversity exhibited by neoplastic cells, common determinants 
(biomarkers) shared by many tumour cells from cancers of the same organ, or even 
multiple organs, are pivotal to the diagnosis, prognosis, and the decision of an 
appropriate therapeutic course for cancer.
248
 One effective methodology for cancer 
chemotherapy is to find means to target cell disruption preferentially to neoplastic 
cells over healthy cells by utilising differences that  exist between these two cell 
types.
249
 
GH29 α-ʟ-fucosidase is known to be systematically upregulated in some cancers, 
including oral
197
, breast
84
 and liver
83
 neoplasias. It may thus be envisaged that the 
use of compounds containing selectivity elements towards α-ʟ-fucosidase along 
with a pharmacophore warhead may allow the targeted disruption of tumour cells in 
patients with these cancers (Figure 3.2). This hypothesis does, however, hinge on 
the existence of a partitioning effect whereby the concentrati on of compounds of 
general form displayed in Figure 3.2 is higher around cells expressing higher levels 
of α-ʟ-fucosidase. 
Ferrocenium salts are potent cytotoxic agents that are thought to act as such by 
their generation of reactive oxygen species (ROS) in  cells
250
. Administration of 
ferrocenyl compounds into the body may lead to deleterious effects as ROS would 
have cytotoxic activities on all cells in a dose -dependent fashion, however 
neoplastic cells have an increased basal level of ROS and are particularly 
vulnerable to ROS-induced DNA damage mechanisms
251, 252
, making compounds 
containing this functionality particularly good pharmacophores for cancer cell 
disruption. Further, if directed by means of a selectivity moiety towards the 
biomarker α-ʟ-fucosidase (Figure 3.2), these species may provide a particularly 
efficient means for the disruption of oral, liver and breast cancers.  
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Figure 3.2. Schema of a targeted chemotherapeutic. The selectivity element allows 
targeting towards a particular neoplasia determinant while the pharmacophore 
effects cell disruption and the linker element joins these two functional elements 
together. 
 
Herein, we aim to address the potential for a multivalent ligand configured for α-ʟ-
fucosidase inhibitory activity to provide  an affinity enhancement over its 
monovalent counterpart, by structural and kinetic means. Further, the crystal 
structures of three compounds designed as potential chemotherapeutics comprising 
an α-ʟ-fucosidase inhibitory scaffold and ferrocenyl aglycons are reported and the 
potential for the use of these compounds in chemotherapy is discussed. The 
syntheses of compounds described in this chapter, and their K i values against 
bovine kidney α-ʟ-fucosidase were realised by collaborators at the Universities of 
Reims and Seville, and their collaboration is acknowledged.  
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3.2 Materials and methods 
3.2.1 Gene expression and protein purification 
Expression and purification of BtFuc2970 was effected as described previously in 
2.2.1. 
 
3.2.2 Inhibitors 
Further 5-membered iminosugar compounds configured as inhibitors of α-ʟ-
fucosidase enzymes (see Chapter 2) were received from collaborators (research 
groups of Profs. Jean-Bernard Behr at the University of Reims and Inmaculada 
Robina at the University of Seville). The compounds discussed in this chapter are 
displayed in Table 3.1. The syntheses of compounds 8-9, 11-12, along with their 
inhibition data towards bovine kidney α-ʟ-fucosidase are documented (publications 
given in Table 3.1). Compounds 10 and 13 currently lie outside the scope of the 
scientific literature and thus do not have published syntheses. Compounds 8-9, 11-
12 have been reported to display inhibition of bovine kidney fucosidases. 
Compounds 8 and 9 were further tested for inhibitory activity towards other 
glycosidases and shown only to inhibit α-ʟ-fucosidase212.  
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Table 3.1. 5-membered iminocyclitols described in chapter  3. 
Compound 
number 
IUPAC name Structural formula 
8
253
 (2S,3S,4R,5S)-2-Benzylcarbamoyl-5-
methylpyrrolidine-3,4-diol 
 
9
253
 N,N',N’’-(1,3,5-
phenylenetris(methylene))tris-
[(2S,3S,4R,5S)-3,4-dihydroxy-5-
methylpyrrolidine-2-carboxamide] 
 
10 1,4-
bis[(2S,2’S,3S,3’S,4R,4’R,5S,5’S)-5-
methyl-3,4-dihydroxypyrrolidin-2,2’-
yl]-butane 
 
11
254
 (2S,3S,4R,5S)-2-[N-
(methylferrocene)]aminoethyl-5-
methylpyrrolidine-3,4-diol 
 
12
254
 (2S,3S,4R,5S)-2-[N-
(propylferrocene)]aminoethyl-5-
methylpyrrolidine-3,4-diol  
 
13 1-(3-ferrocenylprop-2-enyl)-4-
[(2S,3S,4R,5S)-5-methyl-3,4-
dihydroxypyrrolidin-2-yl]-triazole 
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3.2.3 Enzyme kinetics 
The α-ʟ-fucosidase activity of BtFuc2970 and its inhibition by compounds 8-13  
were probed; enzymatic assays were conducted as described in 2.2.3.  
3.2.3.1 Enzyme inhibition 
The inhibition of BtFuc2970 by compounds 8-13 was studied by in each case 
determining non-inhibited rate and inhibited rate at various concentrations of 
inhibitor. Each solution contained (1 mL total volume) 50 mM HEPES buffer, 100 
mM NaCl (pH 7.4), 250 nM BtFuc2970 and a known concentration of inhibitor; 50 
µM CNP-fucoside was added to this to initiate hydrolysis. Data analysis was carried 
out as described in 2.2.3.2. Inhibition plots used for the determination of K i values 
of 8-13 are displayed in Figure 3.3. 
 
Figure 3.3. Plots showing inhibition of BtFuc2970 activity by compounds 8-13.    
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3.2.4 Crystallisation and structure determination 
3.2.4.1 Crystallisation 
Crystallisation experiments were conducted as described previously in 2.2.4.1.  
Crystals of BtFuc2970 liganded with compounds 8-9 were obtained by adding solid 
powder of each compound directly to a drop containing one or multiple crystals of 
BtFuc2970 using an acupuncture needle.  
Soaking crystals of BtFuc2970 with compounds 11 or 12 led to visible crystal 
cracking and poor diffraction quality. As such, co -crystallisation of BtFuc2970 with 
these compounds was effected. To this end, BtFuc2970 (24 mg mL
-1
) was incubated 
with 11 or 12 (solutions of 11 and 12 dissolved at 4 mM in 20 mM HEPES, 100 mM 
NaCl, pH 7.0) in 1:1 stoichiometry for ca. 1 hour prior to setting up crystallisation 
experiments. Crystals obtained in this way were cryo -protected by transfer into 
solutions containing mother liquor supplemented with 20% glycerol and 
subsequently cryo-cooled in liquid N2.  
For compounds 10  and 13, crystals were transferred to a new crystallisation drop (1 
µL, 30% w/v PEG 3350, 0.2 M ammonium sulphate, 0.1 M HEPES, pH 7.0). To this 
solution, 1 µL of 10 or 13 (dissolved at 10 mM in 10 mM HEPES, 100 mM NaCl, 
pH 7.0) was added. After incubation for at least ca. 30 m, these crystals were 
transferred to cryo-protectant solutions containing mother liquor supplemented with 
20% glycerol and cryo-cooled using liquid N2.  
Diffracting crystals of BtFuc2970 complexed with each of inhibitors 8-13 were sent 
to Diamond Light Source (9-13) or the European Synchrotron Research Facility (8) 
for data collection.  
 
3.2.4.2 Crystallisation conditions 
Unless otherwise noted, crystallisation drops were set up in a 1:1 ratio of protein to 
mother liquor and BtFuc2970 was added as a 12 mg mL
-1
 solution (final 
concentration after dilution 6 mg mL
-1
). All crystallisation experiments were 
performed at ca. 18 ºC. 
BtFuc2970-8 
Mother liquor: 13.5% w/v PEG 6K, 0.099 M ammonium sulfate, 0.09 M imidazole 
pH 7   
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BtFuc2970-9 
Mother Liquor: 12.75% w/v PEG 6K, 0.1105 M ammonium sulfate, 0.085 M 
imidazole pH 7 
BtFuc2970-10 
Mother liquor: 20% w/v PEG 3350, 0.1 M ammonium sulphate, 0.1 M imidazole pH 
7.0 
BtFuc2970-11  
Mother liquor: 14% w/v PEG 6K, 0.12 M ammonium sulfate, 0.1 M imidazole (pH 
7) 
Equal volumes of BtFuc2970 at 24 mg mL
-1
 and 10 (4 mM in 50 mM HEPES 100 
mM NaCl (pH 7)) were incubated at room temperature for ca. 1 h prior to setting up 
the crystallisation experiment.  
BtFuc2970-12 
Mother liquor: 16% w/v PEG 6K, 0.13 M ammonium sulfate, 0.1 M imidazole (pH 
7)  
Equal volumes of BtFuc2970 at 24 mg mL
-1
 and 11 (4 mM in 50 mM HEPES 100 
mM NaCl (pH 7)) were incubated at room temperature for ca. 1 h prior to setting up 
the crystallisation experiment.  
BtFuc2970-13 
Mother liquor: 20% w/v PEG 3350, 0.1 M ammonium sulphate, 0.1 M imidazole pH 
7.0 
 
3.2.4.3 Structure determination 
Diffraction images for crystals of each inhibitor complex were indexed and 
integrated using either XDS
225
 or iMOSFLM
226
. POINTLESS
227
 was used to 
determine the crystallographic space group in each case, and structure factor 
amplitudes were scaled and merged using SCALA
227
 or AIMLESS
228
.  
The crystals of BtFuc2970 complexed with compounds 8-9 grew in space groups 
similar to those described herein in 2.2.4.3 for apo-BtFuc2970 and BtFuc2970 
complexed with compounds 1-4. As the space group of each inhibitor complex of 
BtFuc2970 liganded with complexes 8-9 was almost isomorphous to the apo-crystal, 
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coordinates from the apo-crystal structure were used directly for determination of 
the inhibitor complex structures; R free sets were assigned as they had been for the 
apo-crystal structure to maintain the uniqueness and integrity of the cross -
validation Free R set . Coordinate sets and maximum likelihood refinement target 
values for each of compounds 8-9 were generated using CHEMDRAW3D and the 
PRODRG online server
232
. Inhibitor coordinates were initially added at 0.01 
occupancy to prevent automatic addition of solvent into ligand density when using 
the COOT ‘find waters’ function whilst minimising model bias. At late stages of 
refinement the ligand occupancy was increased to 1.0.   
The crystals for compounds 10-13 grew in a crystal form almost isomorphous with 
that previously reported on apo-BtFuc2970 (PDB code 2WVV
184
). In this case 
coordinates from the apo-crystal structure of PDB code 2WVV (non-protein atoms 
removed) were used directly for determination of the inhibitor complex structures; 
R free sets were assigned as they had been for the apo-crystal structure to maintain 
the uniqueness and integrity of the cross -validation Free R set. Compounds 10-13 
contain ferrocenylamine aglycon moieties that preclude dictionary creation and use 
in refinement using current versions of PRODRG and REFMAC. Maximum 
likelihood refinement target values and a coordinate set for each of these ligands 
were thus kindly generated manually by Garib Murshudov (Medical Research 
Council Laboratory of Molecular Biology, Cambridge).  
Final models for compounds 8-13 were validated using MOLPROBITY.
233
 X-ray 
data for compounds 8-9, 11-13 were deposited with the RCSB Protein Data Bank 
(www.rcsb.org
234
, Table 3.2).  
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Table 3.2a. X-ray data collection and refinement statistics for the crystal structures 
discussed in Chapter 3.  
 BtFuc2970-8  BtFuc2970-9  BtFuc2970-10  
Data collection    
Beamline/Date  ESRF ID23-2 
21.11.2011 
DLS I03 
12.12.2011 
DLS I03 
02.02.2014 
Wavelength (Å) 0.8726 0.9763 0.97625 
Cell dimensions       
  a ,  b ,  c (Å) 67.5, 95.4, 97.2 68.4, 96.0, 97.2 56.1,187.7,97.6 
   ()  90, 90.1, 90 90, 91.3, 90 90,94.2,90 
Resolution (Å)  97.1-1.57 48.7-1.68 67.6-1.83 
Rmer ge  0.095(0.50) 0.096(0.54) 0.09(0.79) 
I / I  6.6(1.7) 9.7(2.5) 6.8(1.5) 
Completeness (%) 99.0(99.6) 100(100) 99.8(99.8) 
Redundancy 3.8 3.2 3.8(3.9) 
Wilson B value  15.1 21.4 34.7 
 
Refinement 
   
Resolution (Å)  97.1-1.7 48.7-1.68 67.6-2.10 
No. reflections 135052 141053 110778 
Rwor k  / R f ree  0.125/0.167 0.166/0.192 0.19/0.23 
No. atoms    
  Protein 7225 7187 14332 
  Ligand/ion 96 136 140 
  Water  1130 1055 773 
B-factors (Å
2
)     
  Protein 16.0 23.7 44.0 
  Ligand/ion 31.7 44.3 60.7 
  Water  30.4 34.6 42.9 
R.m.s. deviations     
  Bond lengths (Å)  0.018 0.011 0.014 
  Bond angles ()  1.7 1.3 1.5 
Ramachandran 
Statistics (%) 
   
  Preferred 96.3 96.5 96.1 
  Allowed 2.9 2.8 2.9 
  Outliers 0.8 0.7 1 
PDB codes 4JL2 4JL1 Not yet deposited  
*Values in parentheses are for highest -resolution shell.  
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Table 3.2b. X-ray data collection and refinement statistics for the crystal structures 
discussed in Chapter 3.  
 BtFuc2970-11  BtFuc2970-12  BtFuc2970-13  
Data collection    
Beamline/Date  DLS I04-1 
8.3.2012 
DLS I03 
16.9.2012 
DLS I03 
02.02.2014 
Wavelength (Å)  0.9173 1.200 0.97625 
Cell dimensions      
  a ,  b ,  c (Å) 55.5,187.0,97.7 56.5,189.0,97.5 56.5,188.8,98.1 
   ()  90, 94.2, 90 90, 94.1, 90 90,93.9,90 
Resolution (Å)  97.4-1.71 97.3-1.72 68.0-2.01 
Rmer ge  0.07(0.43) 0.07(0.98)* 0.11(0.90) 
I / I  10.9(2.8) 14.4(1.8) 5.9(1.2) 
Completeness (%) 96.7(95.0) 99.9(99.9) 99.7(99.7) 
Redundancy 4.0 6.3 3.7(3.7) 
Wilson B value 23.2 42.1 36.8 
 
Refinement 
   
Resolution (Å)  97.4-1.88 97.3-2.10 68.0-2.30 
No. reflections 155246 112918 85655 
Rwor k / R f ree  0.192/0.222 0.21/0.24 0.20/0.24 
No. atoms    
  Protein 14138 13859 14259 
  Ligand/ion 172 155 153 
  Water 732 215 445 
B-factors    
  Protein 30.7 54.0 52.2 
  Ligand/ion 68.7 90.8 102.7 
  Water 30.2 45.5 44.1 
R.m.s. deviations     
  Bond lengths (Å)  0.017 0.013 0.013 
  Bond angles ()  1.7 1.4 2.4 
Ramachandran 
Statistics (%) 
   
  Preferred 96.7 95.7 94.6 
  Allowed 2.4 3.4 4.0 
  Outliers 0.9 0.9 1.4 
PDB codes 4JFV 4JFW Not yet deposited  
*Values in parentheses are for highest -resolution shell.  
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3.3 Results and Discussion 
3.3.1 Multivalency effects in fucosidase inhibition 
Inhibitory constant K i values determined for inhibition of BtFuc2970 by compounds 
8-10 in this work are displayed in Table 3.3, along with those reported for 
inhibition of bovine kidney fucosidase
253,255
.   
Table 3.3. Inhibition of BtFuc2970 and bovine kidney α-ʟ-fucosidases by 
compounds 8-10.  
Compound  Ki vs. BtFuc2970 / µM (values in 
parens: fitting error from linear fit in 
Origin) 
Ki vs. bovine kidney fucosidase / µM 
8 4.7 (0.3) 2.1 
9 0.75 (0.02) 0.3 
10 1.1 (0.03) 0.023
255
 
 
The inhibitory potencies of iminocyclitols 8  and 9  as calculated against both 
BtFuc2970 and bovine kidney α-ʟ-fucosidases are in good agreement, with K is being 
slightly weaker against BtFuc2970 by a factor of ca. 2.5. 10, however, appears to be 
a far more potent inhibitor of bovine kidney α-ʟ-fucosidase (23 nM) than BtFuc2970 
(1.1 µM); it is uncertain what the cause of this discrepancy is.  
 
3.3.1.1 X-ray crystallography and structural analysis  
In the datasets where compounds 8-10 were soaked into crystals of BtFuc2970, the 
compounds were unambiguously present in the crystal structures as evidenced by 
clear peaks in their likelihood-weighted Fo-Fc maps after refinement of protein, 
solvent and other ions but before the inclusion of compounds 8-10  in refinement 
(Figure 3.4) 
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Figure 3.4. Figures of compounds 8-10, respectively, lying in the active site of 
BtFuc2970. Atoms of compounds 8-10 are coloured by atom type (carbon in grey). 
The catalytic nucleophile Asp
229
 and acid/base Glu
288
 of BtFuc2970 are displayed 
coloured by atom type (carbon in green, residues are annotated for BtFuc2970:8). 
Electron density from likelihood-weighted Fo-Fc maps calculated before the 
incorporation of phases from compounds 8-10 in refinement is displayed, contoured 
at 5 σ (8), 3 σ (9), or 2 σ (10). Figures were drawn using CCP4MG183.  
 
The interactions made between the iminocyclitol cores of compounds 8-10 and the 
enzyme are identical to those observed for compounds 1-7, and these inhibitors bind 
in an E3 conformation as seen previously (see section 2.4.2.2). The aglycons of 8  
and 9 observed crystallographically are however poorly ordered. 9 displays two 
separate binding modes, in one of which the exocyclic amide carbonyl group forms 
hydrogen bonding interactions with Nε2 of His
166
 and Nε1 of Trp
88
. The binding 
modes of 8 and 9 are displayed in Figure 3.5, highlighting the conformational 
flexibility displayed by the inhibitor aglycons.  Each crystal structure comprises two 
independent observations of the ligand occupancy, and in each crystal structure, one 
of the independent observations is better resolved than the other. The aryl groups of 
8 and 9 occupy different positions as observed in crystal structure ( Figure 3.5). 
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This is thought to be a crystallographic artefact, however, as the ‘better’ 
observation of 8  is in close crystal contact with another protomer. The aryl moiety 
of 9 is observed to stack atop the hydrophobic ridge formed by BtFuc2970 residues 
Trp
88
 and Trp
232
 (this ridge is discussed in more detail in 2.4.2.3). This strong 
hydrophobic interaction also helps to explain the more potent α-ʟ-fucosidase 
inhibition of 10 over 8 and 9 (K i = 0.023 vs.  2.1 and 0.3 µM respectively, Table 
3.3). 
 
 
Figure 3.5. Monovalent 8 and trivalent 9 show disorder and alternate binding 
modes. The independent crystallographic observations of 8 and 9  were superposed, 
and are displayed as cylinders coloured by atom type (carbon atoms from 8 in grey, 
from 9  in green). The figure was drawn in wall -eye stereo using CCP4MG.
183
 
 
Structural and kinetic data were analysed to determine the existence of a 
multivalency effect in the binding potency of α-ʟ-fucosidase inhibitors. The closest 
distance between adjacent BtFuc2970 active sites in the crystal packing 
arrangement is ca. 45 Å. This is similar to the closest distance observed in the 
crystal structure of the GH29 enzyme from Thermotoga Maritima , which is slightly 
lower at ca. 40 Å. This large distance would preclude the binding of multiple fuco-
configured moieties decorated around a single scaffold (as in 9) through a chelation 
mechanism due to the short linker not allowing chelate binding .  
Compound 9 is a ca . 7 times more potent fucosidase inhibitor than its monovalent 
counterpart 8, against both bovine kidney fucosidase and BtFuc2970 (0.3 vs. 2.1 µM 
and 0.7 vs. 4.7 µM respectively, Table 2.). From these data it could be concluded 
that affininity enhancement due to a statistical rebinding effects was possible, 
however, a divalent analogue of 8 and 9 is a weaker inhibitor of bovine kidney α-ʟ-
fucosidase than its monovalent and trivalent counterparts ( K i = 4 µM vs. 0.3 µM 
and 2.1 µM, respectively
253
). Other sets of mono/multivalent compounds tested also 
seemed to show no significant improvement in binding affinity for multivalent 
89 
 
inhibitors over monovalent ones, or even poorer activity for the multivalent 
species.
253
 It is thus perhaps more likely that the affinity enhancement seen in the 
case of compounds 8  and 9  is due to entropic effects rather than statistical 
rebinding effects. This is in agreement with the observation that affinity 
enhancements for multivalent ligands interacting through a statistical rebinding 
mechanism require there to be a large number of subunits to attain a multivalency 
affinity enhancement.
237
 The expansion of this framework from a small molecule 
synthesis with low valency of α-ʟ-fucosidase inhibitory moieties  to that of larger 
compounds with much higher valency may however prove to be effective; this 
approach has been applied before with ligands not configured specifically towards 
α-ʟ-fucosidase, which were intriguingly shown to activate Thermotoga maritima  α-
ʟ-fucosidase rather than inhibit it 238. 
Compound 10 is a divalent α-ʟ-fucosidase inhibitor comprising two 5-membered 
iminocyclitols configured for α-ʟ-fucosidase inhibitory activity and a short C 4 
alkane linker. Interestingly, the entirety of the second iminocyclitol moiety i.e. that 
which is not binding to the enzymatic active site, is observed crystallographically, 
cf. the disorder seen for the aglycon of compound 9. The crystallographic space 
groups for BtFuc2970 complexes with 8 and 9 are different to that for the complex 
with 10 (Table 3.3a), although as ample solvent channels are observed close to the 
active site in both structures, this should have no bearing on aglycon 
conformational flexibility. The second iminocyclitol moiety of 10 is however 
observed to lie atop Trp
232
, one of the two tryptophan residues that form the 
conserved GH29 hydrophobic ridge (Figure 3.6). Non-specific interactions between 
carbohydrate moieties and aromatic amino acid side -chains are a common feature of 
carbohydrate binding, e.g. in the binding of sugars other than those flanking the 
scissile bond in endo-acting glycoside hydrolases with broad substrate 
specificity.
256
 Further, the iminocyclitol ring, which should have partial positive 
charge at the pH of crystallogenesis and data collection, may make electrostatic 
interactions with the electron-rich Trp π-system. The binding of the second subunit 
of 9 to Trp
232
 of BtFuc2970 thus potentially explains the observation of clear 
electron density for this moiety cf. that of the additional subunits of 9, which may 
not bind in this position due to sterics.  
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Figure 3.6. The second subunit of 10 binds above residue Trp
232
. Compound 10 and 
the side-chains of BtFuc2970 active site residues Asp
229
 and Glu
288
, and that of 
residue Trp
232
 are displayed as cylinders coloured by atom type (carbon atoms from 
10 in grey). Surfaces of Trp
232
 and the atoms forming the second subunit of 10 are 
drawn, coloured in coral (Trp
232
) and cyan (10). Orthogonal images were drawn 
using CCP4MG.
183
  
 
3.3.2 Pharmacophore targeting towards α-ʟ-fucosidase 
K is determined for inhibition of BtFuc2970 by compounds 11-13 are displayed in 
Table 3.4, along with those determined for inhibition of bovine kidney 
fucosidase
255,257
.   
 
Table 3.4. Inhibition of BtFuc2970 and bovine kidney α-ʟ-fucosidases by 
compounds 11-13.   
Compound  Ki vs. BtFuc2970 / µM (values in 
parens: fitting error from linear fit in 
Origin) 
Ki vs. mammalian fucosidase / µM 
11 0.52 (0.01) 0.29 
12 0.46 (0.02) 0.29 
13 0.15 (0.005) 0.023
255
 
 
The K i values determined for inhibition of BtFuc2970 and bovine kidney α-ʟ-
fucosidase by compounds 11-13 are in agreement; it has previously been noted that 
this class of compound are more potent inhibitors of bovine kidney fucosidases than 
BtFuc2970 (2.3.1, 3.3.1).  
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3.3.2.1 X-ray crystallography and structural analysis  
In the datasets where compounds 11-13 were either co-crystallised with BtFuc2970 
(11-12) or soaked into crystals of BtFuc2970 (13), the compounds were 
unambiguously present in the crystal structures as evidenced by clear peaks in their 
likelihood-weighted Fo-Fc maps after refinement of protein, solvent and other ions 
but before the inclusion of compounds  10-12 in refinement (Figure 3.7).
 
 
Figure 3.7. Compounds 11-13, respectively, lying in the active site of BtFuc2970. 
Atoms of compounds 11-13 are coloured by atom type (carbon in grey). Fe atoms of 
compounds 11-13 are displayed as grey spheres. The catalytic nucleophile Asp
229
 
and acid/base Glu
288
 of BtFuc2970 are displayed coloured by atom type (carbon in 
green, residues are shown for BtFuc2970:11). Electron density from likelihood-
weighted Fo-Fc maps calculated before the incorporation of phases  from compounds 
11-13 in refinement is displayed, contoured at 3 σ (11), 4 σ (12) or 2 σ (compound 
13). Figures were drawn using CCP4MG
183
.  
 
The aglycons of compounds 11-13 are highly disordered. X-ray data for BtFuc2970 
complexed with 12 were collected at 1.2 Å. At this wavelength, a significant 
anomalous scattering component is observed that is attributed to the ferrocenyl iron 
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atom, confirming its presence in the crystal structure ( Figure 3.8). The high 
temperature factors observed for the aglycons of 11-13  represent their disorder, 
which is likely due to exposure to solvent. Only a small number of protein 
complexes containing ferrocenyl moieties are available in the PDB, in these 
structures the ferrocenyl moieties are all bound in buried hydrophobic regions of 
the protein
258,259
 and it is thus no surprise that the ferrocenyl moieties are observed 
to be conformationally rigid. For the case of 11-13 however, it is reasonable to 
assume that the ligand aglycons are disordered as they are located far from the 
enzyme surface and thus solvent -exposed. 
The only additional electrostatic interaction observed between compounds 11-13  
and BtFuc2970 compared to compounds 1-10 is a hydrogen bond between the 
secondary amine moieties of 11-13 and a sulfate group likely abstracted from the 
crystallisation mother liquor  (this can be seen in Figure 3.8). 
 
 
Figure 3.8. The position of the aglycon of compound 11 in the BtFuc2970 active 
site is supported using anomalous scattering. BtFuc2970 atoms are displayed as a 
white surface. 11 is displayed as cylinders coloured by atom type, with carbon 
atoms in grey. The electron density map shown is an anomalous difference map 
contoured at 5 σ (0.019 e Å -3) and is averaged over the four molecules in the 
asymmetric unit. The figure was drawn in wall -eye stereo using CCP4MG
183
.  
 
Compounds 11-13 each display a ferrocenyl pharmacophore appended to the 
iminocyclitol core by an amine linkage. Ferrocenium salts are potent cytotoxic 
agents that are thought to act as such by their generation of reactive oxygen species 
(ROS) in cells, which are thought to induce apoptosis in the affected cell.
250,260
 
Compounds such as 11-13 were designed to test the hypothesis that the α-ʟ-
fucosidase inhibitory moieties they possess may impart selective targeting of the 
ferrocenyl pharmacophores in these compounds towards cells upregulating α -ʟ-
fucosidase (such as neoplastic cells from liver
83
, breast
84
 and oral cancers
197
). 
Neoplastic cells are more vulnerable to ROS-induced cell disruption than healthy 
93 
 
cells
251,252
, however the selective targeting of a pharmacophore warhead towards 
cells overexpressing a biomarker such as  α-ʟ-fucosidase may further reduce the 
systemic toxicity imparted by chemotherapeutic agents . 
Compounds 11 and 12 have been reported to show anti -proliferative activity 
towards the MDA-MB-231 breast cancer cell line
254,257
, so clearly the ferrocenyl 
moieties in these compounds have their expected cytotoxic effect. This activity 
does not appear to be correlated to α-ʟ-fucosidase inhibition, as an isomer of 12,  
differing only in its stereochemistry at the anomeric carbon, displays more potent 
inhibition of MDA-MB-231 cells than 12, though it exhibits a 25-fold decrease  in 
inhibition of bovine kidney α-ʟ-fucosidase  (100% vs. 77% inhibition of MDA-MB-
231 cell growth at 50 µM).
254,257
 
It is, however, currently unknown whether compounds 11-13, or any homologous 
ferrocene-containing α-ʟ-fucosidase inhibitors show selectivity in their cytotoxic 
activity towards neoplastic cells over healthy cells. Needless to say, the potential 
for therapeutic use of compounds such as 11-13 would require there to be a 
significantly greater uptake of these compounds by neoplastic cells over healthy 
cells, as otherwise the application of many other ferrocene-containing compounds 
may provide a similar clinical outcome.  
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3.4 Conclusions 
The crystal structures of a mono, di and trivalent compound complexed with the 
bacterial α-ʟ-fucosidase BtFuc2970 are reported. These compounds each contain a 
number of 5-membered iminocyclitol moieties configured towards inhibition of α-ʟ-
fucosidase. Further, their inhibition of BtFuc2970 was evaluated by kinetic studies.  
Analyses utilising the crystal structures and kinetic data of these enzymes further 
indicate that a multivalency affinity enhancement is not possible with a chelation 
effect due to the distance between adjacent GH29 active sites, and that a ‘statistical 
rebinding’ multivalency affinity enhancement does not exist with low subunit (≤ 3) 
valencies, in agreement with the established literature. It may be possible that the 
multivalency effects often seen in carbohydrate binding interactions e.g. in lectins 
are also applicable to glycoside hydrolases however as, recently, a multivalent 
iminocyclitol functionalised dextran was shown to possess multivalent affinity 
enhancements to a number of carbohydrate processing enzymes including the α -ʟ-
fucosidase from Thermotoga maritima .
238
 It is unsure how these multivalent 
compounds interact, as surprisingly they proved to be activators rather tha n 
inhibitors of some of the enzymes tested.  
α-ʟ-fucosidase inhibitors linked to ferrocene pharmacophores were complexed with 
BtFuc2970 and the structure of the resulting complexes were solved using X -ray 
crystallography. As α-ʟ-fucosidase is systematically upregulated in a number of 
cancers including liver, breast and oral cancer, α -ʟ-fucose configured 
iminocyclitols may provide a delivery method for cytotoxic pharmacophores. 
Compounds containing ferrocenyl groups are known cytotoxic agents, potentially 
through their induction of reactive oxygen spec ies-mediated apoptosis. The 
ferrocene groups of the di -functional compounds were observed to point towards 
solvent and make no interactions with the protein itself, as such the aglycon 
moieties were observed to possess significant conformational flexibilit y; 
nonetheless, the position of the ferrocenyl Fe atom was in one case experimentally 
observed by its anomalous scattering component, providing evidence for the correct 
assignment of ligand position. These compounds have been shown to display anti-
proliferative activity against a MDA-MB-231 breast cancer cell line. It is currently 
unknown, however, whether the iminocyclitol component effectively causes 
partitioning of these reagents in vivo towards neoplastic cells rather than healthy 
cells. Without the undertaking of this crucial experiment, it will not be known 
whether this approach has any utility for chemotherapy.  
  
95 
 
Chapter 4: Covalent trapping of α-ʟ-fucosidase by 
activity-based probes* 
 
Abstract 
Activity-based probes (ABPs) are a class of irreversible enzyme inhibitors which 
allow the specific trapping of active enzyme from a milieu of species both in vitro 
and in vivo. Incorporating, or being der ivatised with reporter moieties, they allow 
the quantification, visualisation and tracking of enzyme activity in a variety of 
contexts. We report herein the 1.64-1.92 Å X-ray crystal structures of the bacterial 
α-ʟ-fucosidase BtFuc2970 covalently trapped with two ABP scaffolds at the 
enzymatic nucleophile, unequivocally showing that these ABPs react with only 
active α-ʟ-fucosidase at the enzymatic active site. This is the first time that a  fuco-
configured small molecule containing an electrophilic trap has been 
crystallographically observed bound to an α-ʟ-fucosidase enzyme and provides 
evidence for the postulated mechanism of these ABPs. Fuco-configured ABPs may 
have potential uses in tracking fertility events in vivo and for discovering novel 
enzymes with α-ʟ-fucosidase activity.  
 
 
 
 
 
 
 
 
 
 
*This work is published in Jiang, J. et al. Chem Sci  6, 2782-2789 (2015). 
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4.1  Introduction 
4.1.1  Activity-based probing  
The genomic revolution opened up a wealth of opportunities towards a more 
detailed understanding of human physiology and disease. In the past, classical 
techniques such as proteomics and transcriptomics have been useful in elucidating 
the biological roles of proteins and nucleic acids. To further our understanding of 
the roles of these species in physiology and disease, however, requires more 
information than is available by using these techniques, which are often applied to 
the understanding of global transcription or translation levels. This is due to the 
fact that the biological function of a given species of interest is correlated more 
firmly with activity than mere quantity. Many proteins, for example, require post-
translational events to occur in order for them to carry out their intended function, 
such as their complexation with other proteins or  nucleic acids, glycosylation
109
 or 
phosphorylation
261
, correct localisation in a target compartment, or the proteolytic 
cleavage of a pro-peptide into a mature form
262
. These events rely not entirely on 
the genome-level transcription of a protein, but rather on a complex array of factors 
which may be difficult to disentangle and prove intractable to mimic in vitro. Thus, 
there is a need for tools which can specifically track active enzyme activity in vivo 
and on a biological timescale, and with minimal perturbation of the system under 
study.  
Molecular imaging has proven a powerful tool towards this aim, as the non -invasive 
technique allows the detailed spatiotemporal characterisation of specific targets in 
vivo, or of living cells ex vivo
263,264
. This technique often involves the use of 
molecular probes as reporter groups which have an output visible to microsc opy 
techniques, and can be used to view biological processes in real time in intact cells. 
Molecular probes are used to effect detection of the biological target, and thus 
should have high specificity towards this target.  
A number of strategies exist for the design of probes with specificity towards their 
biological target such as the inclusion of, inter alia, radiolabelled small molecules 
and monoclonal antibodies
264
. For the case of enzymes, known catalytic activ ity can 
be exploited in order to achieve this specificity; compounds that are designed in 
such a way are termed activity-based probes (ABPs) and act by covalently trapping 
an enzyme on the basis of its catalytic mechanism
265-267
.  
Activity-based probes contain a number of features allowing their effective use  
(Figure 4.1)
265
. Chemically reactive warheads allow the covalent and irreversible 
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trapping of an enzyme target. Speci ficity towards a particular enzyme class, and 
potentially to a particular subset of enzymes within a given class, is governed by 
specificity elements; the design of a specificity element allows tuning of reactivity 
to be either very specific, or broad, depending on intended function. Finally, the 
incorporation of a probe or reporter moiety in an ABP allows an output dependent 
on covalent binding of the ABP to its target, and may include the use of fluorogenic 
substrates for quantification or visualisation o f active enzyme in the molecular 
imaging context and/or affinity tags for the isolation of active enzymes of a given 
class from a milieu of species.  
 
 
Figure 4.1. Structural features of activity-based probes (A). Warheads are designed 
to covalently and irreversibly trap an enzyme based on its mechanism. The 
specificity element of an ABP targets its reactivity towards active enzymes on the 
basis of reaction mechanism. ABP probes may be quantitative reporter elements or 
affinity tags, and may be introduced by derivatisation in vivo. Activity-based 
protein profiling shema (B). ABPs are introduced to a milieu of enzymes in vitro or 
in vivo but specifically label a target enzyme class based on activity.  
 
The emergence of bio-orthogonal chemistry as a powerful tool available to the 
enterprising chemical biologist has had many implications on the field of activity -
based protein profiling (ABPP)
267
. This technique can be used for the generation of 
two-step ABPs, that is ABPs that do not contain an intact probe, but contain a 
linker for functionalisation in situ after covalent binding towards their biological 
target (Figure 4.2). This strategy offers a number of advantages over the direct 
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inclusion of probe moieties in an ABP
267
. Perturbation to the biological system is 
likely to be weaker using a two-step approach, and binding of the ABP to its target 
may be more favourable as it more closely resembles a natural substrate. Binding of  
the ABP to off-targets may also be minimised by use of a two-step labelling regime, 
as the lipophilicity of a compound is thought to be linked to its non -specific 
binding
264
. Further, transport of an ABP across the cell membrane for in vivo 
experiments will likely be more favourable without the addition of hydrophobic 
reporter moieties. Examples of bio -orthogonal reactions that have been used in the 
ABPP field include the Staudinger ligation between azide and phosp hine 
moieties
268,269
, and both Cu(I) catalysed and Cu(I) -free azide-alkyne cycloaddition 
reactions
270,271
.  
 
Figure 4.2. The mechanism of activity-based probing by a two-step process. Bio-
orthogonal ligation using the azide -alkyne cycloaddition reaction is a representative 
example of methods which may be used.  
 
The potential scope of ABPP was highlighted by a seminal paper shortly before the 
completion of the human genome project. Liu and co-workers reported the synthesis 
of XVIII (Table 4.1), a compound designed from the fusion of the known serine 
protease inhibitor moiety fluorophosphonate with biotin, allowing the capture of 
trapped proteins through the use of streptavidin affinity chromatography. The 
authors further showed that this compound was able to label a number of serine 
proteases from rat testis. This selective labelling of a protein family in a complex 
medium containing many other species was concluded to be a po werful tool, 
allowing the interrogation of activity (rather than transcription) levels and 
dynamics thereof, of this enzyme class, which has a number of roles in physiology 
and disease. 
Shortly after this, Greenbaum et al. reported the synthesis of two cys teine protease 
ABPs XIX-XX (Table 4.1), containing epoxide moieties as an electrophilic trap. 
These compounds, based on a natural product known to irreversibly inhibit the 
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enzyme class, contained both biotin moieties and an iodinatable phenol moiety. 
While XIX was shown to have activity against a broad panel of cysteine proteases, 
compound XX proved to be specific against the cathepsin family of proteases. 
Further, by using compound XIX, they were able to visualise the changes in 
cysteine protease activity as a function of disease progression in multiple tumour 
cell lines, illuminating the role of these enzymes in cancer development.  
A two-step approach to ABPP was first exploited by Cravatt and co -workers in 
2003, allowing, for the first time, application o f the ABPP platform to the study of 
intact proteomes in vivo
270
. The authors demonstrated that azide -containing 
sulfonate XXI (Table 4.1) could be functionalised in vivo by Cu(I) catalysed 
Huisgen cycloaddition
272
 with rhodamine alkyne. This two-step approach allowed 
the visualisation by fluorescence SDS-PAGE of glutathione S-transferases in vitro, 
in cultured COS cells and in heart tissue homogenates of mice treated with XXI and 
subsequently reacted with rhodamine alkyne. This coupling of  the powerful tool of 
bio-orthogonal reactions with ABPP heralded its application across a variety of 
enzymatic and cellular contexts.  
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Table 4.1. Some activity-based probes described in the literature.  
Compound number Structural formula 
XVIII 
 
XIX 
 
XX 
 
XXI 
 
 
Activity-based protein profiling was first brought into the glycoside hydrolase field 
a year later in 2004, when Vocadlo & Bertozzi demonstrated labelling of a number 
of β-galactosidases by a di -fluorosugar269. Their ABP, 6-azido-2,6-dideoxy-2-
fluoro-β-ᴅ-galactosyl fluoride XXII (Table 4.2), was capable of irreversibly 
trapping  β-galactosidase by stabilisation of the covalent enzyme intermediate via 
the 2-fluoro substituent (vide supra), and derivatisation of its pendant azide moiety 
in situ by the bio-orthogonal Staudinger ligation
268
 resulted in a FLAG-tagged 
biochemical probe capable of labelling a number of β -galactosidase enzymes tested. 
The attachment of the sterically undemanding azide tag to the C6 po sition and 
subsequent derivatisation ( i.e. use of a two-step approach) was posited by the 
authors to be critical for efficient labelling of the enzyme, due to the limited 
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hydrophobic cavities present in exo-acting glycoside hydrolases.  Since this first-in-
class, a number of studies reporting ABPP of glycosidases have been reported.  
ABPP may be used to detect novel enzymes with a given activity, as was shown 
elegantly by Vocadlo and co-workers in 2008
273
. After the deposition of an 
inhibitor-bound crystal structure of a Vibrio cholerae GH3 family exo-
glucosaminidase, the authors noted the presence of a large cavity around the 
inhibitor 2-acetamido group. Postulating that this cavity may allow attachment of a 
bio-orthogonal tag for two-step ABPP, the group synthesised compound XXIII 
(Table 4.2), which was indeed able to irreversibly inhibit the Vibrio cholerae  GH3 
enzyme. Functionalisation of this ABP was effected with both FLAG -peptide and 
biotin moieties. Further, application of XXIII to cultures of the opportunistic 
pathogen Pseudomonas aeruginosa  and subsequent bio-orthogonal ligation with a 
biotin-alkyne allowed identification of a potentially clinically important novel GH3 
family enzyme from this organism.  
The use of epoxide containing, sugar configured probes by a number of research 
groups in the Netherlands
274
 exemplifies the potential to use ABPP to track active 
enzyme dynamics in vivo. ABPs XXIV-XXVI  (Table 4.2) reported by these groups 
are selective and incredibly potent irreversible inhibitors of glucocerebrosidase  I, 
the major lysosomal enzyme that catalyses the hydrolysis of glucosylceramide ; 
deficiency in activity of this enzyme causes the lysosomal storage disorder  Gaucher 
disease
275
. Interestingly, use of a two-step ABPP experiment was shown to not be 
needed against this enzyme as, serendipitously, ABPs XXV and XXVI  display more 
potent binding to the enzyme than their azido -counterpart XXIV (K i = 44 nM for 
XXIV v. 7 and 8 nM for XXV and XXVI  respectively), and the BODIPY ABPs were 
still able to enter the cellular compartment in vivo. By utilising the two BODIPY 
ABPs XXV-XXVI, which have different fluorescence emission spectr a, the authors 
were able to conduct pulse-chase experiments on cultured fibroblasts. Incubation 
overnight with red-fluorescent XXVI, followed by the addition of green-fluorescent 
XXV at set time points allowed the authors to approximate the half -life of 
glucocerebrosidase I residency in the lysosome at 30 h, agreeing with literature 
values determined using conventional pulse -chase labelling
276
. Further, the authors 
were able to visualise the differences in glucocerebrosidase I activity in the 
fibroblasts of Gaucher patients with various mutant genes. This result in particular 
showed promise for XXV-XXVI as tools for the diagnosis of Gaucher disease.  
One potential shortcoming of compounds XXV-XXVII as ABPs is that they are 
specific to glucocerebrosidase I, and have no activity against other retaining exo-β-
glucosidases, glucocerebrosidases II and III and lactase/phlorizin hydrolase; these 
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enzymes may also have clinical relevance as glucocerebrosidase III is thought to be 
involved in the detoxification of plant glycosides
277
 and lactase/phlorizin hydrolase 
deficiency is the cause of lactose intolerance
278
. Noting that all exo-β-glucosidases 
are able to hydrolyse 4-methylumbelliferyl-β-ᴅ-glucopyranoside, Overkleeft and co-
workers developed aziridine ABPs such as XXVII (Table 4.2), which contain an 
electrophilic trap between the positions that would equate to the endocyclic oxygen 
and the anomeric carbon of a natural substrate
279
. Upon formation of the covalent 
enzyme intermediate, they expected that the pendant amide moiety would occupy 
approximately the position of the aglycon in natural substrates. Thus, the authors 
posited that this approach should have the ability to label not just 
glucocerebrosidase I, but also the other exo-β-glucosidases, which indeed proved to 
be the case. Further, as this approach exploits the presence of an enzymic cavity at 
the non-reducing end of the -1 sugar, which is a feature in common to all exo-
glycosidases, this approach should have broad utility against this enzyme class
279
.  
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Table 4.2. Some activity-based probes active against glycoside hydrolases described 
in the literature.  
Compound number Structural formula 
XXII 
 
XXIII 
 
XXIV 
 
XXV 
 
XXVI 
 
XXVII 
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4.1.2 Glycosidase inhibition by ring-strained compounds 
Ring-strained heterocycles are potent electrophiles and have use for the study of 
retaining glycoside hydrolases. Epoxyalkyl glycosides such as XXVIII (Table 4.3) 
have been used historically to elucidate the catalytic mechanism of glycoside 
hydrolases including, inter alia , lysozyme
280
 and cellulase
281
. Enzymatic catalysis 
occurs preferentially to the epoxyalkane moiety, labe lling either catalytic 
carboxylate. The covalently trapped glycosidase can further be observed 
crystallographically
282, 283
. Unfortunately, labelling may be on either of the catalytic 
carboxylates so their assignment requires further experimental validation
282
.   
 
Table 4.3. Some ring-strained heterocycles displaying inhibition of  glycoside 
hydrolases described in the literature .  
Compound number Structural formula 
XXVIII 
 
XXIX 
 
XXX 
 
XXXI 
 
XXXII 
 
 
Prior to the availability of bioinformatics approaches to identify the catalytic 
nucleophile of glycoside hydrolases
170
, conduritol B-epoxide XXIX (Table 4.3) was 
used for this purpose against a number of glucosidases such as the human enzymes 
sucrose-isomaltase
284
 and α-glucosidase285. As a stable covalent intermediate is 
formed by nucleophilic attack of a glycoside hydrolase upon XXIX, peptic 
digestion and mass spectrometry allowed the identification of candidate enzymatic 
nucleophile residues. 
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Aziridines such as XXX (Table 4.3) offer advantages over epoxides in the study of 
glycoside hydrolases, as aziridine moieties are protonated at physiological pH and 
may form favourable electrostatic interactions with the negatively charged ca talytic 
active site. The first use of an aziridine -based glycoside hydrolase inhibitor was 
reported in 1988 by Tong et al. 
286
, where the authors showed irreversible inhibition 
of coffee bean α-galactosidase by compound XXX. A year later, Caron and Withers 
rationalised that glycosidase inhibition potency should be increased by merging the 
reactivity of epoxy-glycosides with the benefits of a protonated nitrogen atom 
discussed above and reported the synthesis and evaluation of conduritol aziridine 
XXXI (Table 4.3)
287
. This compound did indeed prove to be a potent irreversible 
inhibitor of both α- and β-glucosidases. 
A number of glycosidases complexed with ring-strained heterocyclic inhibitors have 
been observed by X-ray crystallography. In 2005, Sussman and co-workers 
determined the crystal structure of conduritol B -epoxide XXIX (Table 4.3) 
complexed with human glucocerebrosidase I
288
. The observation of a covalent 
adduct between residue Glu
340
 and the anomeric carbon of XXIX in the 2.4 Å 
crystal structure confirmed assignment of the catalytic nucleophile and informed 
identification of two conformationally flexible loop regions. These regions, which 
were conformationally locked in the complex structure but showed flexibility in the 
apo structure of glucocerebrosidase I
289
, were postulated to act as a lid controlling 
active site access; this finding is supported by Gaucher mutations in one of these 
loops. 
The 1.9 Å X-ray crystal structure of cyclophellitol  XXXII (Table 4.3) complexed 
with a GH1 family β-glucosidase from Thermotoga maritima was reported in 
2007
290
. Cyclophellitol, a natural product first derived from the mushroom 
Phellinus  sp.,
291
 was observed covalently bound to the enzyme in a 
4
C1  
conformation.  
ABP glycosides configured with ring substituents mimicking those of ʟ-fucose may 
have utility e.g. as biomarkers for cancer
93,197
 or for cell biology research, 
particularly in fertility, due to the known importance of α-ʟ-fucosidase in this 
field
109
. Herein, the X-ray crystal structures of the bacterial α-ʟ-fucosidase 
BtFuc2970 complexed with two such glycosides  that have specificity towards GH29 
retaining α-ʟ-fucosidases are reported. In the enzyme-ligand complex structures 
(1.64 – 1.92 Å), covalent bonding is observed between the ligands and the 
enzymatic nucleophile, unequivocally showing that these ABPs react with only 
active α-ʟ-fucosidase at the enzymatic active site. Surprisingly, one of the 
compounds appears to bind not in a low energy 
3
S1 conformation, but in the 
3
H4  
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conformation expected for the catalytic transition state. We would like to thank 
collaborators in the research group of Prof. Hermen Overkleeft, without whom this 
work would not have been possible.  
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4.2 Materials and methods 
4.2.1 Gene expression and protein purification 
Expression and purification of BtFuc2970 was effected as described previously in 
2.2.1.  
 
4.2.2 Activity-based probes and scaffolds 
Compounds 14-19 (Table 4.4) were received from collaborators, namely the 
research group of Prof. Herman Overkleeft at the Leiden Institute of Chemistry, 
Leiden University. These compounds either display the characteristics of ABPs ( 17-
19), or have a structure which represents the same reactivity of ABPs against an α-
ʟ-fucosidase target whilst not possessing a reporter moiety (14-16, 16  may however 
be derivatised by bio-orthogonal chemistry to yield 17-19 or other compounds 
bearing a reporter moiety). Syntheses of these compounds are detailed in 
292
.  
Compounds 14-19 have aziridine moieties, located between the positions of a sugar 
substrate that would correspond to the endocyclic oxygen and C1. The 
stereochemistry of the positions which would equate to C2-C5 of a sugar substrate 
are the same as ʟ-fucose. Thus, these compounds were designed to be specifically 
active towards α-ʟ-fucosidase as a target.  
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Table 4.4 Activity-based probes and similar compounds described in chapter 4.  
Compound 
number 
IUPAC name Structural formula 
14 Phenyl((1R,2R,3R,4R,5R,6R)-2,3,4-
trihydroxy-5-methyl-7-
azabicyclo[4.1.0]heptan-7-
yl)methanone 
 
15 1-((1R,2R,3R,4R,5R,6R)-2,3,4-
trihydroxy-5-methyl-7-
azabicyclo[4.1.0]heptan-7-yl)ethan-1-
one 
 
16 8-Azido-1-((1R,2R,3R,4R,5R,6R)-
2,3,4-trihydroxy-5-methyl-7-
azabicyclo[4.1.0]heptan-7-yl)-octan-
1-one 
 
17 8-(4-(4-(5,5-Difluoro-1,3,7,9-
tetramethyl-5H-4l4,5l4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-10-
yl)butyl)-1H-1,2,3-triazol-1-yl)-1-
((1R,2R,3R,4R,5R,6R)-2,3,4-
trihydroxy-5-methyl-7-
azabicyclo[4.1.0]heptan-7-yl)octan-1-
one 
 
18 8-(4-(4-(5,5-Difluoro-3,7-bis(4-
methoxyphenyl)-5H-4l4,5l4-
dipyrrolo[1,2-c:2',1'-f]-
[1,3,2]diazaborinin-10-yl)butyl)-1H-
1,2,3-triazol-1-yl)-1-
((1R,2R,3R,4R,5R,6R)- 
2,3,4-trihydroxy-5-methyl-7-
azabicyclo[4.1.0]heptan-7-yl)octan-1-
one 
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19 N-((1-(8-oxo-8-
((1R,2R,3R,4R,5R,6R)-2,3,4-
trihydroxy-5-methyl-7- 
azabicyclo[4.1.0]heptan-7-yl)octyl)-
1H-1,2,3-triazol-4-yl)methyl)-6-(5- 
((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-
yl)pentanamido)hexanamide 
 
 
4.2.3 Crystallisation and structure determination 
4.2.3.1 Crystallisation 
General practice for crystallisation experiments was as described previously in 
2.2.4.1.  
Crystals of BtFuc2970 liganded with compounds 14 and 15 were obtained by adding 
1 µL compound dissolved at 5 mM in 10 mM HEPES, 100 mM NaCl, pH 7.0 ( 14) or 
20 mM in 0.1 M HEPES, 0.2 M ammonium sulfate, 25% w/v PEG 3350, pH 7.5 (15) 
to drops containing crystals of BtFuc2970. After incubation for at least ca. 30 m, 
these crystals were transferred to cryo-protectant solutions containing mother liquor 
supplemented with 20% glycerol and cryo -cooled using liquid N 2.  
Diffracting crystals of BtFuc2970 complexed with compounds 14 and 15 were sent 
to Diamond Light Source for data collection.  
 
4.2.3.2 Crystallisation conditions 
Unless otherwise noted, crystallisation drops were set up in a 1:1 ratio of protein to 
mother liquor and BtFuc2970 was added as a 12 mg mL
-1
 solution (final 
concentration after dilution 6 mg mL
-1
). All crystallisation experiments were 
performed at ca. 18 ºC. 
BtFuc2970-14 
Mother liquor: 25% w/v PEG 3350, 0.2 M ammonium sulfate, 0.1 M HEPES (pH 
7.5) 
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BtFuc2970-15 
Crystals were obtained through using the micro -seeding technique
293
. A seed stock 
was created by transferring micro-crystals of BtFuc2970 grown in 15% w/v PEG 
3350, 0. M ammonium sulfate, 0.1 M HEPES (pH 7.5) to a microcentrifuge tube 
containing a seed bead (Hampton Research) and supplementing with 50 µL mother 
liquor. Microcrystals were then crushed by the use of a vortex mixer and diluted to 
concentrations of 10
-1
 –  10 -3  in mother liquor.  
Final crystals were obtained through seeding at a dilution of 10
-3
 into a solution 
containing mother liquor: 21% w/v PEG 3350, 0.2 M ammonium sulfate, 0.1 M 
HEPES (pH 7.5). The final solution in the crystallisation drop comprised a ratio of 
0.5 protein: 0.4 mother liquor: 0.1 seed stock.    
 
4.2.3.3 Structure determination 
Diffraction images for crystals of each inhibitor complex were indexed a nd 
integrated using either IMOSFLM
226
 (BtFuc2970-14) or XIA2
294
 (BtFuc2970-15). 
AIMLESS
228
 was used for data reduction in each case; for BtFuc2970-15, unmerged 
XIA2 data were merged and an R free flag set using AIMLESS.  
The crystals of BtFuc2970 complexed with compounds 14 and 15 grew in an almost 
isomorphous space group to PDB entry 4JFV; and protein atom co-ordinates from 
this entry were used directly to obtain starting phases for refinement. R free sets were 
assigned as they had been for 4JFV to maintain the uniqueness and integrity of the 
cross-validation R free set.  
Coordinate sets and maximum likelihood refinement target values for compounds 14 
and 15 were generated using CHEMDRAW3D and the PRODRG online server
232
. 
Inhibitor coordinates were initially added at 0.01 occupancy to prevent automatic 
addition of solvent into ligand density when using the COOT ‘find waters’ function 
whilst minimising model bias. At late stages of refinement the ligand occupancy 
was increased to 1.0. Dictionaries defining the link between the catalytic 
nucleophile of BtFuc2970 (Asp229) and compounds 14 and 15 were generated using 
JLIGAND
295
.  
Final models for BtFuc2970-14 and BtFuc2970-15 were validated using 
MOLPROBITY
233
 and deposited with the RCSB Protein Data Bank 
(www.rcsb.org
234
).   
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4.2.3.4 Conformations adopted by ABPs in crystal structures 
The conformations adopted by 14 and 15  in their crystal structures bound to 
BtFuc2970 were kindly determined and plotted by Dr. Carme Rovira at the 
University of Barcelona. Cremer-Pople parameters
296
 were determined from PDB 
entries 4WSK and 4WSJ, averaged over the 3 or 4 ligands present in the PDB entry 
(for 14 and 15, respectively). These parameters were then plotted on the 
conformational free energy landscape of BtFuc2970, which was previously 
calculated
184
; further methodological detail is available in the supporting 
information of this reference.   
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4.3  Results and Discussion 
4.3.1 Crystal structure of BtFuc2970 covalently trapped by ABPs 
Initially, a number of attempts were made to determine crystal structures of 
BtFuc2970 complexed with compounds 14, 16-19, by adding both solid powder of 
these compounds, and solubilised compounds to crystallisation drops cont aining 
crystals of BtFuc2970. Ligand binding was, however, only evident in one case, for 
compound 14 .  
Diffraction images for this complex were collected at 1.73 Å resolution, however 
the data quality was anisotropic according to AIMLESS, and data were ref ined to 
1.92 Å, as this was the recommended limit of data usefulness on the basis of half -
dataset correlation
228
(Table 4.5). 14 was observed to be bound to BtFuc2970 clearly 
in 3 of the 4 monomers in the asymmetric unit, before the introduction of phases 
from the ligand in refinement (Figure 4.3). The phenyl moiety of the aglycon of 14  
was however poorly ordered and could only be modelled in 1 monomer of the 4 
present in the asymmetric unit. The final refined Rwork and R free values for this 
complex structure are 0.18 and 0.23 respectively.  
 
Figure 4.3. Compound 14 lying in the active site of BtFuc2970, displayed in wall -
eye stereo. Atoms of compound 14 are coloured by atom type (carbon in grey). The 
catalytic nucleophile Asp
229
 and acid/base Glu
288
 of BtFuc2970 are displayed 
coloured by atom type (carbon in green). The map displayed is a likelihood -
weighted Fo-Fc map from before the incorporation of phases from compound 14 in 
refinement, contoured at 2 σ (14). The figure was created using CCP4MG 183 .  
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Table 4.5. X-ray data collection and refinement statistics for the crystal structures 
discussed in chapter 4.  
 BtFuc2970-14  BtFuc2970-15  
Data collection   
Beamline/Date  DLS i03 02/02/14  DLS i03 18/10/14 
Wavelength (Å)  0.97625 0.97625 
Cell dimensions      
  a ,  b ,  c (Å) 55.6, 186.5, 98.2 55.5, 187.0, 98.2  
   ()  90, 94.2, 90 90, 94.2, 90 
Resolution (Å)  62.17-1.73 93.5-1.64 
Rmer ge  0.095(0.86)* 0.058(0.62) 
I / I  7.0(1.8) 11.2(2.0) 
Completeness (%)  96.9(96.7) 98.1(98.5) 
Redundancy 4.0(3.7) 4.1(4.3) 
Wilson B value 26.1 20.4 
 
Refinement 
  
Resolution (Å)  97.9-1.92 97.9-1.64 
No. reflections 292076 328440 
Rwor k / R f ree  0.18/0.23 0.16/0.19 
No. atoms   
  Protein 14267 14073 
  Ligand/ion 107 81 
  Water 1204 1618 
B-factors (Å
2
)    
  Protein 31.8 25.1 
  Ligand/ion 41.9 24.3 
  Water 36.8 35.3 
R.m.s. deviations    
    Bond lengths (Å)  0.019 0.019 
    Bond angles ()  1.81 1.78 
Ramachandran 
Statistics (%) 
  
  Preferred 95.8 96.7 
  Allowed 3.1 2.4 
  Outliers 1.1 0.9 
PDB codes 4WSK 4WSJ 
*Values in parentheses are for highest -resolution shell.  
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The postulated mechanism by which sugar -configured aziridine-containing 
compounds act to inhibit glycoside hydrolases is by trapping of the enzyme as a 
covalent intermediate, as has been shown previously for the epoxide -containing 
natural product cyclophellitol complexed with β-glucosidase297.  SN2-like 
nucleophilic attack of the catalytic nucleophile towards the anomeric position of a 
compound such as 14 would be expected to lead to trans-diaxial ring-opening of the 
aziridine and the formation of a stable covalent intermediate (Figure 4.4). The 
crystal structure of BtFuc2970-14  clearly supports this mechanism, as clear electron 
density is observed for a covalent in teraction between the catalytic nucleophile of 
BtFuc2970 and 14 (Figure 4.5), and since the covalent bond distances refine well to 
between 1.43 and 1.47 Å, as would be expected of an ester C-O bond.  
 
 
Figure 4.4. Proposed reaction schematic for ABP compo unds towards α-ʟ-
fucosidase enzymes. 
 
The interactions made between BtFuc2970 and 14 are displayed in Figure 4.6. The 
cyclohexane core of 14 is held tightly in place by hydrogen bonding interactions, 
and further stabilised by a hydrophobic interaction between Trp
316
 and the C4, O4, 
C5, C6 atoms of 14 (numbering scheme as for ʟ-fucose).   
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Figure 4.5. The covalent interaction between BtFuc2970 and 14, displayed in wall-
eye stereo. Atoms of compound 14 are coloured by atom type (carbon in grey). The 
catalytic nucleophile Asp
229
 of BtFuc2970 is displayed coloured by atom type 
(carbon in green). Electron density displayed is calculated from likelihood -
weighted 2Fo-Fc from final models, contoured at 1 σ. The figure was created using 
CCP4MG
183
.  
 
The crystal structure of a covalent intermediate bound to BtFuc2970 was previously 
determined
184
. This result, PDB entry 2WVS, represents the irreversible binding of 
the difluoro fuco-configured inhibitor 2-fluoro-fucosylfluoride to the enzyme, and 
as such a direct comparison of the interactions formed by these two inhibitors is 
informative. In general, the active sites of these two structures have high homology, 
however there are a few differences which will be discussed.   
 
116 
 
 
 
Figure 4.6. Interactions made between 14 and BtFuc2970. A: 3D representation 
drawn using CCP4MG
183
. Hydrogen bonds < 3.2 Å shown as dashed lines. Residue 
Trp
316
 forms a ca. 3.7 Å hydrophobic interaction with 14. B: Schematic 
representation drawn using CHEMDRAW. Protonation states displayed are 
arbitrary. Hydrogen bonds < 3.2 Å shown as dashed lines. Residue Trp
316
 forms a 
ca. 3.7 Å hydrophobic interaction with 14. 
 
A minor shift in atomic coordinates of residue Trp
88 
is observed between the two 
structures, likely causing weakening or loss of a hydrogen bonding interaction 
formed between this residue and the hydroxyl at the C2 position of the inhibitors 
(3.32 Å in 4WSK vs. 3.08 Å in 2WVS). A larger (1.3 Å) displacement is seen for 
residue Trp
232
. Residue Arg
262
, which hydrogen bonds with both the catalytic 
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nucleophile and acid/base residue in 2WVS, is displaced in 4WSK, appearing in a 
conformation whereby hydrogen bonding occurs between this residue and the 
catalytic acid/base Glu
288
 rather than the nucleophile residue Asp
229  
(Figure 4.7). 
Residue 288 has the most striking conformational difference; in 4WSK, the 
enzymatic acid/base residue Glu
288 
is positioned in an inactive conformation, 
located 6.8 Å away from the anomeric carbon of 14, which is too far for Glu
288
 to 
act as a proton donor to a pendant O at this position, Figure 4.7. In 2WVS, 
however, Gln
288
 resides in what would be an active conformation were the residue 
not mutated (the shortest C1-Gln
288
 distance is 5.5 Å). 
As both BtFuc2970-14 (4WSK) and 2WVS are covalent enzyme intermediates of the 
same enzyme, the inactive conformation for the catalytic acid/base observed in 
BtFuc2970-14 is likely to be caused by the extra moieties present in 14 compared to 
2-fluoro-fucosylfluoride. Upon ring-opening of the aziridine of 14, its ‘aglycon’ 
moiety is attached to the position which would equate to that of the endocyclic 
oxygen of a natural substrate.  It is thus postulated that BtFuc2970 does not tolerate 
appendages to this position well due to sterics. Indeed, the aglycon amide oxygen 
forms a close contact (ca. 3.4 Å) with the carbonyl in the enzymatic nucleophile 
A
229
.  
Based on the observations that the aglycon of 14 appears poorly ordered in its 
crystal structure (Figure 4.5) and the inactive conformation observed for the 
catalytic acid/base of BtFuc2970 when complexed with 14, discussion was initiated 
with Prof. Overkleeft about the possibility of synthesising an ABP scaffold with a 
less sterically-demanding aglycon, which may have a higher on -rate and thus 
provide a clearer structure solution. Subsequent to this discussion, compound 15,  
lacking the aryl group of 14, was synthesised and soaked into crystals of 
BtFuc2970, yielding a crystal s tructure of the covalent adduct formed.  
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Figure 4.7. The active site of BtFuc2970 in PDB entries 4WSK (this work, 
BtFuc2970-14) and 2WVS (BtFuc2970 E288Q mutant covalently bound to 2 -fluoro-
fucosylfluoride
184
). Sidechain atoms of residues Asp
229
, Arg
262
, 288 (Glu for 4WSK, 
Gln for 2WVS) and ligand atoms are coloured by atom type (carbon atoms from 
4WSK in green and from 2WVS in coral, fluorine from 2WVS in grey). Hydrogen 
bonds between Arg
262
 and the nucleophile and residues 229 and 288 displayed as 
dashed bonds. The figure was drawn using CCP4MG
183
.  
    
Diffraction images for this dataset were collected and refined to 1.64 Å resolution, 
which was the extent of the data usefulness according to a half-dataset 
correlation
228
. This structure, with a less sterically-demanding aglycon, indeed more 
clearly showed interaction of the ligand aglycon with BtFuc2970, and all 4 copies 
of 15 in the asymmetric unit were observed to have clear electron density  for the 
entirety of the ligand (Figure 4.8), including the covalent bond formed between the 
enzymatic nucleophile and 15. The final refined Rwork and R free values for this 
complex structure are 0.16 and 0.19 respectively, again an improvement over 
BtFuc2970-14. As with BtFuc2970-14, the enzymatic acid/base residue Glu
288
 is 
observed in an inactive conformation;  this supports the hypothesis that this 
displacement is due to the presence of a pendant group to the carbon atom at which 
a natural substrate would have an endocyclic oxygen.  
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Figure 4.8. Compound 15 lying in the active site of BtFuc2970, displayed in wall -
eye stereo. Atoms of compound 15 are coloured by atom type (carbon in grey). The 
catalytic nucleophile Asp
229
 and acid/base Glu
288
 of BtFuc2970 are displayed 
coloured by atom type (carbon in green). The map displayed is a likelihood -
weighted Fo-Fc map from before the incorporation of phases from compound 15 in 
refinement, contoured at 3 σ (15). The figure was created using CCP4MG 183 .  
 
The conformations adopted by 14 and 15 in their crystal structures (4WSK and 
4WSJ) were kindly determined by Dr. Carme Rovira at the University of Barcelona 
and plotted on the conformational free energy landscape of BtFuc2970 (Figure 4.9). 
14 adopts a 
3
S1 conformation, while 15  adopts a 
3
H4  conformation; this is, 
interestingly, the conformation postulated for the catalytic transition state based 
upon the conformational trajectory previously shown for this enzyme
184
. The X-ray 
data quality used to generate 4WSJ (BtFuc2970-15) are better than that for 4WSK 
(BtFuc2970-14). In particular, the atomic coordinates of the C1 atom of 14 are 
uncertain due to poor electron density in this region; the conformation adopted by 
14 is 4WSK is thus more influenced by mathematical refinement and geometric 
restraints than experimental observations. The electron density for 15, however, is 
much clearer and thus it is concluded that both of these ABPs bind to this enzyme 
in a conformation more resembling that of the enzymatic transition state, however it 
is uncertain what the reason for this is.  
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Figure 4.9. Conformations adopted by ligands in 4WSK and 4WSJ. Conformations 
are plotted as filled stars (Yellow: 15 from 4WSJ, White:  14 from 4WSK) on the 
calculated free energy landscape of BtFuc2970. Figure prepared by Carme Rovira at 
the University of Barcelona.  
 
Catalytic nucleophile (D229N) and acid/base mutants (E288A) of BtFuc2970 were 
prepared in order to determine the crystal structures of these mutants complexed 
with ABPs. Catalytic nucleophile mutants are often used to observe a ligand 
complex after docking with the enzyme but before reactivity o ccurs i.e. the 
Michaelis complex. Acid/base mutants, on the other hand, reduce the rates of both 
the glycosylation and deglycosylation steps of the prototypical retaining glycoside 
hydrolase mechanism, hence allowing observation of a covalent intermediate when 
used in conjunction with reactive compounds with a good leaving group (these 
approaches were previously applied to BtFuc2970
184
).  
Unfortunately, after soaking of both BtFuc2970 nucleophile and acid/base mutants 
with 15, diffraction data representing complex formation could not be obtained; a  
high-resolution apo structure of D229N BtFuc2970 was however obtained after 
soaking of the enzyme with 15 for ca. 24 h. 
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4.4  Conclusions 
We have crystallographically observed a covalent adduct between the catalytic 
nucleophile of a GH29 α-ʟ-fucosidase and ʟ-fucose-configured aziridine containing 
compounds, which were designed to have utility as activity -based probes. This 
crystallographic observation is the first documented between a glycoside hydrolase 
and sugar-configured aziridine containing compound, and serves to prove the 
postulated mechanism by which these compounds act to selectively target active 
enzyme.  
ABPs able to covalently inhibit and label α-ʟ-fucosidase such as 17-19 have great 
potential in a variety of therapeutic, diagnostic and proteomics technologies. 
Compounds 17-18, incorporating fluorescent probes for visualisation and 
quanitification of α-ʟ-fucosidase activity, may be useful as, inter alia , biomarkers 
of cancer progression, and for elucidating the field of cell biol ogy, e.g. in the field 
of fertility. These compounds have already been demonstrated to have the ability to 
label GH29 enzymes both in vitro and in vivo
292
. Application of 19 to spleen lysates 
from a healthy individual and a sufferer of Gaucher disease allowed labelling of 
FUCA1/2 present in the sample (Figure 4.10), with a greater GH29 activity being 
evident for the Gaucher spleen; the upregulation of degradative enzymes i s a known 
feature of Gaucher spleens
298
. Further, 19 was shown to bind to GH29 from mouse 
spleen, liver and kidney in vivo (Figure 4.10).  
 
Figure 4.10. Labelling of GH29 α-ʟ-fucosidases by 19. Adapted from 292.  
 
If fertility events in humans are similar to those in mice, i.e. they require the 
presence of semen membrane-bound GH29 for its sialyl-Lewis
x
 moieties to interact 
with oocyte zona pellucida and membranes, but not activity of the enzyme
102,108
,  
compounds 17-18 may have use as biological probes for the in vivo tracking of 
fertility events.  
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As a number of cancer strains have upregulated α-ʟ-fucosidase activity, there exists 
potential for chemotherapy using pharmacophores appended to covalent inactivators 
such as the ABPs discussed in this chapter; this approach may be more effective 
than that using covalent enzyme inhibitors such as 10-12 in the previous chapter. 
The biotinylated ABP 19 may be used for the screening of GH29 activity from 
culture supernatant allowing discovery of new enzymes in this family; irreversible 
binding of the ABP warhead to GH29 enzymes may be achieved through the 
application of supernatant over a streptavidin affinity column pre -incubated with 
19, for example. Elution with free biotin would allow the characterisation of novel 
GH29 enzymes e.g. as in the example of Vocadlo and co-workers
273
.  
As many of the potential purposes of fuco-configured ABPs are therapeutic in 
nature, understanding of the active site features of human GH29 enzymes is perhaps 
more pertinent than that of bacterial ones. Since, in the absence of a GH29 crystal 
structure, it is uncertain to what extent the active site of human GH29 enzymes is 
similar to that of BtFuc2970, elucidation of the crystal structure of human GH29 
enzymes would be beneficial in allowing further, directed synthetic efforts to 
improve upon the existing ABP scaffold.  
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Chapter 5: Expression and purification of human 
fucosidases FUCA1 and FUCA2  
 
Abstract 
Human GH29 family α-ʟ-fucosidases I and II (FUCA1 and FUCA2) are critical to 
many biological events such as bacterial colonisation of the gastrointestinal tract, 
the immune response, and fertility. A multitude of inhibitors against this enzyme 
class has been reported in the literature; the inhibition of these proteins has clinical 
relevance e.g. for treatment of the lysosomal storage disorder fucosidosis and 
clearance of the stomach pathogen Helicobacter pylori  from its host. The 3D crystal 
structures of these enzymes may aid in inhibitor design and potentially further 
illuminate their biological roles, however no such crystal structures are yet 
available. Described herein are attempts made towards the expression, purification 
and crystallisation of FUCA1 and FUCA2. The expression of these proteins in 
heterologous systems had only limited success as FUCA1 could be expressed and 
purified to a yield of 3.5 mg enzyme per litre culture volume while FUCA2 
purification was unsuccessful. Pure FUCA1 and FUCA2 could however be obtained 
by expression of genes encoding the enzymes in both cultured HEK-293T and CHO-
K1 cells; expression levels of FUCA1 were higher than that of FUCA2, and 
transient transfection of HEK-293T cells yielded more expressed protein than from 
CHO-K1 cells. Preliminary crystallisation experiments using a purified FUCA1 
construct described herein are reported, along with Michaelis Menten kinetics for 
the enzyme (KM = 0.099 ± 0.01 mM, Vmax = 1305 ± 47 min
-1
). This work may be 
built upon for the realisation of the crystal structures of FUCA1 and FUCA2.  
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5.1 Introduction 
The physiological roles of mammalian α-ʟ-fucosidase have been discussed 
elsewhere (see Chapter 1 and section 1.4.1.2 in particular) and will not be repeated. 
Briefly, the enzyme has important roles in maintaining homeostasis of a number of 
biologically critical fucosylated glycans
20, 196
 which are often differentially 
regulated in neoplasia
93,197
, and its deficiency causes the neurovisceral storage 
disorder fucosidosis
3
. Further, the enzyme plays an important role in fertility
109
.  
What follows is a review of the literature  which stemmed particularly from the 
potential to learn more about and treat fucosidosis, namely the discovery, 
characterisation, and purification of α-ʟ-fucosidase in humans. Both the lysosomal 
enzyme FUCA1 and the less well -studied secreted α-ʟ-fucosidase FUCA2 will be 
discussed. 
The existence of the α-ʟ-fucosidase enzyme was first documented in 1961 by Levvy 
and McAllan
299
. Due to the known presence of ʟ-fucose in mucins, blood group 
antigens
300
 and milk oligosaccharides
301
 at the time, the authors postulated the 
existence of ʟ-fucosidase enzyme/s with unknown anomeric specificity. To assess 
this, the authors first synthesised both  p-nitrophenyl-α-ʟ-fucopyranoside and p-
nitrophenyl-β-ʟ-fucopyranoside302. Tissue homogenates were collected from a range 
of mammalian species, gender and tissue types, and their action upon each substra te 
was probed.
299
 While no tissue type released p-nitrophenolate from the β -linked 
substrate, a wide range of tissues released the product from p-nitrophenyl-α-ʟ-
fucopyranoside thus proving the existence of an α -ʟ-fucosidase enzyme. Further, 
the authors examined the kinetic profile of the enzymes from ra t epididymis and ox 
liver, and determined their pH optima at pH 6.1 and 5.6, respectively and Michaelis 
constants of 2.1 mM and 2.2 mM, respectively. A further observation made was the 
apparent abundance of α -ʟ-fucosidase in epididymal homogenates, hinting at a role 
for the enzyme in insemination which would be elucidated many years later.  
The existence of two ‘forms’ of α -ʟ-fucosidase (α-ʟ-fucosidases I and II) in 
mammals was first demonstrated in pig kidney.
303
 These forms could be 
distinguished by their elution profiles on size -exclusion chromatography, 
thermostability, pH dependence for catalytic activity and their abilit y to hydrolyse a 
variety of different fucosylated substrates. Subsequently, two groups 
contemporaneously showed the existence of these two distinct forms in human 
liver
304
 and a variety of tissue types including the same
305
. Here, both groups 
demonstrated that the two forms isolated from a single organ could be separated by 
size-exclusion chromatography, while one group also achieved their separation 
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using ion-exchange chromatography
304
. The two forms were further characterised by 
their differing pH stability, thermostability, and substrate specificities. In each 
case, one form was observed not to bind to Sephadex G-200 and appeared in the 
void volume of the elution profile. While  Robinson and Thorpe concluded that this 
enzyme was a higher molecular weight species than the other, and may be an 
aggregated form of it
304
, the other authors postulated that the two forms are of 
similar molecular weights, and are only separated on Sephadex G-200 due to non-
specific adsorption of one form onto Sephadex
305 . Numerous isoforms of human α -
ʟ-fucosidase have since been observed by isoelectric focusing of the enzyme from a 
variety of human tissue types e.g.
306-308
.  
Alhadeff et al . investigated the comparative α-ʟ-fucosidase activities between 
normal and fucosidotic livers .
306
 Activity assays were carried out using novel 
substrate 4-methylumbelliferyl-fuco-ʟ-pyranoside. While the pH optima determined 
for healthy and fucosidotic liver were essentially identical (5.4 and 5.3 
respectively), Michaelis constants were marginally different (85 µM and 58 µM 
respectively) and the fucosidotic liver was observed to have only 4% α-ʟ-fucosidase 
activity compared to the enzyme from healthy liver. The authors further observed 6 
isoforms of the enzyme from healthy liver using isoelectric focusing, with 
isoelectric points between 5.5 and 6.9. Sialic acid residues in the enzym e were 
cleaved by neuraminidase treatment and the α -ʟ-fucosidase activity of the two most 
acidic isoforms of the enzyme was observed to be reduced, suggesting sialic acid 
residues are present in at least some isoforms of the enzyme and are important for 
its activity. The loss of activity at acidic pH after neuraminidase treatment of the 
enzyme was also observed by other, independent researchers.
309,310
  A subsequent 
study showed that treatment of the more neutral isoforms of human liver α-ʟ-
fucosidase with sialyltransferase could regenerate the acidic isoforms of the 
enzyme, confirming the role of sialic acid residues in its activity at acidic pH.
311
  
The effect of deglycosylation of the enzyme has been further studied. By treating 
human liver α-ʟ-fucosidase with N-glycanase, Piesecki and Alhadeff showed that 
deglycosylation of the enzyme caused negligible difference in its recognition or 
activity against p-nitrophenyl-α-ʟ-fucopyranoside, 2’ -fucosyllactose, Lacto-N-
fucopentaose II or the blood group A trisaccharide.
312
 The activity profile of the 
enzyme with respect to pH was altered upon deglycosylation, however , with a shift 
towards a more neutral pH optimum and loss of enzymatic activity in the acidic 
regions. Further, deglycosylation of the enzyme did not appear to affect the gross 
conformation of the enzyme as observed by circular dichroism. Thus, glycosylation 
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of the enzyme may be critical in allowing its function in the acidic environment of 
the lysosome but appears to have limited, if any, other effects.  
 
5.1.1 Purification of α-ʟ-fucosidase 
α-ʟ-fucosidase was first purified to apparent homogeneity in 1975313;  previous 
attempts to purify α-ʟ-fucosidase from various sources had not removed the activity 
of other glycosidases
305,314. α-ʟ-fucosidase was purified from homogenates of five 
human livers using a two-step chromatography procedure utilising agarose-ε-
aminocaproyl-fucosamine. By capturing the enzyme by affinity with a moiety 
resembling its substrate, purification was effected with high yield (66% by activity) 
and the purified protein was free from contaminating glycoside hydrolase activity. 
Electrophoresis of the purified enzyme using SDS -PAGE revealed a single protein 
band with molecular weight ca. 50 kDa. Analytical size exclusion chromatography 
and sedimentation equilibrium ultracentrifugation were also carried out on t he 
enzyme and yielded molecular weights of ca. 175 kDa and ca. 230 kDa, 
respectively. Kinetic parameters of the purified enzyme’s hydrolysis of 4 -
methylumbelliferyl-α-ʟ-fucopyranoside  and p-nitrophenyl-α-ʟ-fucopyranoside 
substrates yielded KM and Vmax values of 0.22 mM, 14.1 µmol mg
-1
 and 0.43 mM, 
19.6 µmol mg
-1
 respectively. 
In 1978, the same author reported the purification of the enzyme from human serum 
using a similar method.
315
 Isoelectric focusing of the enzyme revealed seven 
isoforms for the enzyme, but the predominant band was the most acidic with an 
isoelectric point around 5. Interestingly, treatment of the enzyme with 
neuraminidase (a glycoside hydrolase acting in an exo-fashion on sialic acid) 
drastically altered this pattern, resulting in isoforms with isoelectric points around 
pH 6-7. The oligomeric state of the enzyme was also greatly influenced by 
neuraminidase treatment; size exclusion chromatography revealed what was likely  
an oligomer of molecular weight 296 kDa, which reduced significantly to ca . 37 
kDa on treatment of the enzyme with neuraminidase. Thus, sialic acid was 
concluded to be incorporated into the enzyme and to alter its oligomeric state. In 
this study, the authors ran SDS-PAGE gels of both serum and liver enzymes; two 
bands were observed for each enzyme, however these were of different molecular 
weights (56 and 54 kDa for the serum enzyme and 53 and 49 kDa for the liver 
enzyme). The authors concluded that post-translational modifications of serum α-ʟ-
fucosidase, such as sialylation, may be responsible for its properties, which are 
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different to those of fucosidases from liver and brain characterised by the same 
group.
316
 
The complete FUCA1 open reading frame was sequenced from chromosomal DNA 
from human liver, placenta and colon in 1989
317
. The mature protein comprises 439 
residues after cleavage of a 22 residue long hydrophobic signal peptide. The gene 
transcript contains three potential glycosylation sites based on the presence of three 
Asn-X-(Ser/Thr) consensus sequences.  
Sequencing of the FUCA1 gene and isolation of cDNA clones was first carried out 
in 2003, allowing recombinant expression of the enzyme.
318
 The enzyme was 
inserted from cDNA
317
 into the BamH1 restriction endonuclease site of expression 
vector pGEX-2T to yield a gene encoding FUCA1 as a glutathione S-transferase 
fusion protein
318
. The resulting gene was expressed in Escherichia coli  BL21 cells. 
Most of the protein produced was located in the pellet fraction of the cells after 
lysis by sonication, indicating that it was sequestered in cellular inclusion bodies. 
The insoluble protein was, however, purified with high yield (65 mg purified 
protein from 1 L culture media), and showed a broad activity profile against 
substrate 4-methylumbelliferyl-α-ʟ-fucopyranoside. The pH profile of the enzyme 
was however dissimilar to FUCA1 in the neutral region, lacking an activity 
maximum between pH 6.0 and 7.0 that is seen for human fucosidases from many 
sources
313,315,316
.  The authors explained this observation by the inability of 
Escherichia coli  to glycosylate the protein.  
In 2009, Liu and co-workers successfully expressed soluble FUCA1 using the 
Escherichia coli  BL21(DE3) cell strain.
319
 The authors inserted the fuca1 sequence, 
less the first 22 amino acids which form a signal peptide, into the pET22b(+) 
vector. Cells bearing the plasmid were incubated in LB media and gene expression 
was effected by the addition of 1 mM IPTG; expression was carried out for 8 hours 
at 37 °C before harvesting and resuspension in 20 mM sodium acetate buffer pH 
5.5. Purification of the enzyme was carr ied out by ammonium sulfate precipitation, 
followed by cation exchange chromatography, anion exchange chromatography, and 
finally size exclusion chromatography. It was observed that growth in LB media 
with pH 6.0-6.5 was essential for activity, as when pH was above 7.0 the protein 
expressed showed no activity but maintained solubility.  
This study further investigated the catalytic nucleophile and acid/base residues of 
FUCA1. At this time, the only α -ʟ-fucosidase with a reported X-ray crystal 
structure was that from Thermotoga maritima (TmGH29)
182
. The authors used 
multiple sequence alignment with FUCA1, TmGH29 and a number of GH29 
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enzymes from other organisms to identify a conserved carboxylate corresponding to 
the catalytic nucleophile of TmGH29. No such conservation was observed for the 
catalytic acid/base of TmGH29, however. Liu et al . created mutant enzymes for 
each Asp or Glu residue of FUCA1 that appears to be conserved between GH29 
enzymes and performed activity assays on the mutant enzymes using a range of 
synthetic substrates with varying pKa  values in order to generate Brønsted plots
319
. 
Only mutations to residues D225 and E289 of FUCA1 had any noticeable effect on 
kcat or Km values. The relative reaction rates of hydrolysis for the E289G mutant on 
substrates with a range of pKa values revealed a change in mechanistic rate 
determining step when the pKa of the substrate approached the solvent pH, from 
defucosylation to fucosylation, consistent with the absence of acid/base assistance.    
Chemical rescue with sodium azide was further used in order to investigate the 
roles of D225 and E289 in catalysis. When enough space is available in a mutant 
glycoside hydrolase active site, e.g. after mutation of enzymatic nucleophile or 
acid/base residue to glycine, azide is able to ‘rescue’ the activity of these enzymes 
as it can act as a nucleophile or general base (Figure 5.1).
180,320
 The addition of 
sodium azide to E289G and D225G was observed to increase the rate of p-
nitrophenyl-α-ʟ-fucopyranoside hydrolysis by these enzymes 30 and 6 -fold, 
respectively. Further, the authors observed α -fucosyl azide and β-fucosyl azide as 
reaction products on rescue of E289G and D225G respectively by nuclear magnetic 
resonance spectroscopy, providing more evidence for the assignment of D225 as the 
catalytic nucleophile and E289 as the catalytic acid/base residue.    
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Figure 5.1. Chemical rescue of retaining α -ʟ-fucosidase activity by azide. Rescue of 
deficient acid/base activity leads to formation of an α-fucosyl product (A) while 
rescue of deficient nucleophile activity leads to formation of a β -fucosyl product 
(B). 
 
While the assignment of D225 as the catalytic nucleophile of this enzyme is agreed 
within the field, there is contention over the assignment of E289 as the catalytic 
acid/base. In 2010, Bueren et al. noted that “on the basis of sequence alone, neither 
the catalytic acid observed structurally nor the human residue proposed through 
kinetic analysis of variants is conserved within  the family”.184  From the structural 
point of view, residue D275 of FUCA1 appears more likely to be the catalytic 
acid/base as it lays more close to the active site observed in the crystal structure of 
every other GH29 enzyme currently available (Figure 5.2), although when this 
residue was mutated to glycine by Liu et al. , no difference in enzyme activity was 
observed
319
. Further, the position corresponding to that of residue E289 in a 
homology model of FUCA1 lies buried in the protein, not at all proximal to the 
enzymatic active site observed in other GH29 structures. While conformational 
flexibility has now been observed for many enzymes in the GH29 family including 
those from Thermotoga maritima
221
 and the eukaryote Fusarium graminearum
188
,  
such a large conformational change as that which would be envisioned to be 
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required for displacement of residue E289 into a catalytically active position is 
unprecedented in protein science.     
 
 
Figure 5.2. The assignment of the catalytic acid/base residue of human α-ʟ-
fucosidase is still under contention. The protein chains of crystallographically 
observed α-ʟ-fucosidases from Bacteroides thetaiotaomicron  (BtFuc2970, from 
PDB entry 4JL2), Thermotoga maritima  (TmGH29, from PDB entry 1OUD) and 
Fusarium graminearum  (FgGH29, from PDB entry 4NI3) along with that from a 
homology model of FUCA1 prepared using the Phyre2 server
321
 are displayed as 
transparent ribbons coloured through the chain in ice blue ( BtFuc2970), gold 
(FgGH29), coral (TmGH29) and light green (FUCA1). Further, the side -chains of 
the catalytic residues of BtFuc2970 (Asp
229
 and Glu
288
), TmGH29 (Asp
224
 and 
Glu
266
) and FgGH29 (Asp
226
 and Glu
288
) are displayed as cylinders in the same 
colours at their respective protein chains, and the sidechains of the residues Asp
225
 
and Asp
275
 from a homology model of FUCA1 are displayed in light green; these 
residues are further annotated on the figure in the order described above. The f igure 
was drawn in wall-eye stereo using CCP4MG
183
.  
 
Contrary to FUCA1, there is a dearth of research dedicated to the secreted α -ʟ-
fucosidase FUCA2.
322
 The enzyme was first discovered in 1984
323
, and its gene was 
subsequently assigned to chromosome 6
324
.  In 2009, a role for the enzyme in 
cleavage of fucosylated glycan structures as a response to the invasion of stomach 
pathogen Helicobacter pylori  was reported.
4
 Expression of the enzyme in the 
neoplastic Capan 1 cell line was shown to be effected by the presence of 
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Helicobacter pylori . Further, knockdown studies showed that FUCA2 expression 
allowed the pathogen to incorporate exogenous fucose into its cell surface glycans, 
forming host-type Le
x
 antigens. During this study, the authors successfully 
expressed and purified FUCA2 inserted into expression vector pCMV -Tag2B 
(containing a C-terminal FLAG tag) in 293T cells; purification of the enzyme was 
achieved through application of lysed cell supernatant over anti -FLAG antibody 
affinity beads. The colonisation of many pathogenic bacteria involves the 
interaction between fucosylated host endothelial glycans such as Le
x
 and lectins 
expressed on the cell surface of the colonist.
5,6
 This enzyme may thus be evolved to 
provide an innate defence mechanism against the invasion of pathogens which 
produce these host-like glycans, as host release of ʟ-fucose may allow clearance of 
pathogens by out-competing their interaction with endothelial fucosylated glycans.  
 
5.1.2 Managing the glycosylation status of glycoproteins  
The decoration of proteins with N-linked glycans poses a significant hurdle in 
structural biological studies.
325
 This is because, while the glycosylation of native 
glycoproteins is often crucial to their correct folding, the heterogenous 
glycosylation trees present in mammals make crystallisation difficult; a s such, 
simplification of glycan trees in a protein sample is often necessary for the 
successful crystallogenesis of glycoproteins. This may be effected in three ways; 
through protein expression in cell lines that do not express critical carbohydrate 
processing enzymes involved in the N-glycosylation pathway, by inhibiting the 
activity of these enzymes during transient expression, or by enzymatic 
deglycosylation of the enzyme post -expression.
325
  
Glycosylation deficient strains of both CHO
326,327
 and HEK
328, 329
 cell lines have 
been discovered.
327
 Many of these cell lines seem to have evolved by mutation 
offering an evolutionary advantage against plant lectin induced stress. While the 
currently available glycosylation deficient CHO cell lines are known to have 
mutations in a wide range of carbohydrate processing enzymes
327
, the two 
glycosylation deficient HEK cell lines known to the author have deficiency in the 
N-acetylglucosaminyl transferase I
328
 and α-mannosidase II329 genes. The 
carbohydrate processing enzyme inhibitors kifunensine
330
  and swainsonine
331
 may 
also be used for simplification of N-linked glycosylation in proteins grown in tissue 
culture, when added to culture media these inhibitors inhibit cellular α-
mannosidases I and II respectively and thereby prematurely halt N -glycosylation 
before the generation of complex glycans.
325
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Complex glycans pose a particular problem in the expression of glycoproteins 
destined for downstream crystallographic studies.
325
 Complex glycans do not act as 
substrates for the endoglycosidase EndoH, and glycosylation trees cleaved by the 
enzyme retain their most interior GlcNAc moiety. This resid ue is known to be more 
important in mediating interactions with the hydrophobic region of the protein to 
which it is bound than the more exterior monosaccharides
332
, and while proteins 
cleaved by EndoH to yield glycan trees containing just this sugar tend to have 
similar polydispersities to those containing the full length tree, loss of this residue 
has been shown to promote protein aggregation
325, 333
. The premature termination of 
the N-glycosylation pathway before formation of complex glycans is thus extremely 
useful for the production of glycoproteins for crystallisation studies; these 
glycoproteins can be deglycosylated with EndoH rather than PNGase, increasing 
their propensity to crystallise.      
A plethora of studies, including ones presented in this thesis, investigate the 
inhibition of GH29 fucosidases in order to harness the potential medical benefits 
that potent inhibitors of fucosidase may have, particularly for tre atment of 
fucosidosis
3
 and Helicobacter  pylori infection
4
. Structural insights may play a large 
role in the design of potent fucosidase inhibitors however the crystal structures of 
both human fucosidases are currently unresolved.   
Herein, efforts made towards the gene expression and purification of FUCA1 and 
FUCA2 are described, to finally shed light on the structural features of these 
important enzymes. Initially, expression tests using the heterologous Escherichia 
coli and Pichia pastoris  expression systems will be described, followed by those 
using cultured mammalian cells as an expression system.  
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5.2 Materials and methods 
5.2.1 Heterologous expression of FUCA1 and FUCA2 
The genes encoding fucosidases FUCA1 and FUCA2 were codon optimised for 
expression in Escherichia coli , and were synthesised and inserted into pET-30a
+
 
vectors between NcoI and XhoI restriction endonuclease sites by GenScript 
(Appendix 3); these samples were available in the lab from previous work 
conducted by Dr. Alicia Lammerts van Bueren. These plasmids encode FUCA1 and 
FUCA2 with an N-terminal His6 affinity tag and S-tag. Aliquots of these plasmids 
were transformed into chemically competent BL21(DE3), pLEMO and C41 cells, 
which were grown in LB media containing 30 mg L
-1
 kanamycin as small scale (10 
mL) cultures (cells were incubated at 37 ºC overnight with aeration by shaking at 
180 rpm).  
FUCA1 and FUCA2 constructs were also sub-cloned into both the pETite® NHis 
SUMO (EXPRESSO T7 SUMO cloning and Expression System, Lucigen) and pET -
22b
+
 vectors. Oligonucleotide primers were designed, and were  synthesised by 
Eurofins MWG Operon.  
For sub-cloning into the pETite® NHis SUMO vector, Phusion® polymerase (New 
England Biolabs) was used to amplify gene products from FUCA1 and FUCA2 
templates in the pET-30a
+
 vector by polymerase chain reaction. After t reatment 
with DpnI to remove template DNA (ca. 1 hour at room temperature), the amplified 
reaction product was used to transform Hi -Control 10G chemically competent cells 
(EXPRESSO T7 SUMO cloning and Expression System, Lucigen) according to 
manufacturer’s  instructions. Diluted transformed cells were plated on LB Agar 
plates containing 30 mg L
-1
 Kanamycin. A number of colonies that grew were 
sequenced (GATC Biotech) and a colony containing the non -mutated insert was 
used to grow a 10 mL LB overnight culture  containing 30 mg L
-1
 Kanamycin. 
Plasmid DNA was extracted and purified using a QIAprep Spin Miniprep Kit 
(Qiagen) and used to transform chemically competent BL21 (DE3) cells. These cells 
were plated on LB Agar plates containing 30 mg L
-1
 Kanamycin and a single colony 
was used for all subsequent experiments.    
For sub-cloning into the pET-22b
+
 vector, Phusion® polymerase (New England 
Biolabs) was used to amplify gene products from FUCA1 and FUCA2 templates in 
the pET-30a
+
 vector by polymerase chain reaction. The amplified DNA obtained 
and pET-22b
+
 vector were treated with the NcoI and XhoI restriction endonucleases 
separately to yield DNA segments with complementary sticky ends. Cleaved pET -
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22b
+
 vector was then treated with Antarctic phosphatase (37 °C, 2 hours) in order to 
prevent re-ligation of the vector with itself . The enzyme mix in the solution 
containing the treated vector was then heat inactivated at 80 °C for 20 minutes. 
Reaction products for both the insert and vector were purified using a PCR 
Purification kit (Qiagen) and were ligated using T4 ligase; a  ratio of 1 part vector 
to 3 parts insert (by molarity) was used for the ligation reactions  which were 
incubated at 16 ºC overnight. The product of this reaction was then used to 
transform electrocompetent XL1 Blue cells (Agilent) and diluted transformed cells 
were plated on LB Agar plates containing 50 mg L
-1
 Ampicillin. A number of 
colonies that grew were sequenced (GATC Biotech) and a colony containing the 
non-mutated insert was used to grow a 10 mL LB overnight culture containing 50 
mg L
-1
 Ampicillin. Plasmid DNA was extracted and purified using a QIAprep Spin 
Miniprep Kit (Qiagen) and used to transform chemically competent BL21 (DE3) 
cells. These cells were plated on LB Agar plates containing 50 m g L
-1
 Ampicillin 
and a single colony was used for all subsequent experiments.     
 
5.2.1.1 Gene expression and protein purification  
For small scale expression tests, 1 mL samples of 10 mL overnight cultures in LB 
media taken before induction with isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
and after expression (at 37 ºC for ca. 4 hours or at 16 ºC overnight) were lysed to 
determine expression profiles. Samples were centrifuged and the media supernatant 
was removed. Subsequently lysis was performed chemica lly by the addition of 200 
µL BugBuster® Protein Extraction Reagent (Novagen) over 10 minutes. Soluble 
fractions were obtained by centrifuging and removing the supernatant from thus 
treated samples, whilst insoluble fractions were obtained by the treatment  of the 
resulting cell pellet with 50 µL 4% SDS over 10 minutes. Expression test samples 
were run on SDS-PAGE gels to determine recombinant gene expression and 
solubility profiles. 
For large scale expression runs, 10 mL overnight cultures in autoclaved LB media 
containing either 30 mg L
-1
 Kanamycin or 50 mg L
-1
 Ampicillin, depending on the 
resistance gene present in the plasmid, were used to innoculate a larger (1 L) 
volume of autoclaved LB media containing the same concentration of antibiotic. 
Expression was initiated by the addition of 1 mg L
-1  
IPTG when the culture had 
reached an A600 in the range 0.6 - 1.0. Cells were incubated at 16 ºC overnight  
before harvesting by centrifugation. The buffers these samples were re -suspended in 
were comprised HEPES buffer (10-50 mM), 150-500 mM NaCl and 20 mM 
135 
 
imidazole (pH 7-8). Resuspended cell pellets were stored at -20 °C until 
purification was attempted.  
For protein purification, cell pellets were thawed at room temperature and lysed by 
sonication. The resulting solutions were centrifuged at 4416 RCF for 30 m and the 
supernatant decanted. This supernatant was applied to a 5 mL HiTrap column (GE 
Healthcare) preloaded with Ni
2+
 connected to an Äkta FPLC (GE Healthcare). Low 
imidazole buffers (as above) were passed through the column until the A280 
response returned to the baseline. After this, an increasing concentration of 
imidazole was applied to the column as a gradient (to 500 mM imidazole over 50 
mL). Fractions with a strong A 280 response were run on a SDS-PAGE gel to 
determine the molecular weight  and purity of the protein species present in the 
eluate. For expression of FUCA1 in the pET -30a+ vector, the fractions deemed to 
have the highest purity were concentrated by centrifugation at 5000 RCF using an 
Amicon Ultra-15 10K centrifugal filter. This protein was then applied to a Hi -Load 
16/60 Superdex 200 prep grade size exclusion column (GE Healthcare) connected to 
an Äkta FPLC. A solution comprising 50 mM HEPES buffer,  150 mM NaCl (pH 
8.0) was run through the column and samples were collected from the eluate.  
FUCA1 expression was also attempted using Pichia pastoris  as an expression 
vector, by Dr. Jared Cartwright (Bioscience Technology Facility, University of 
York). FUCA1 template in pET-30a
+
 vector was handed over to Dr. Jared 
Cartwright, who designed constructs containing a Saccharomyces cerevisiae  prepro-
alpha-factor signal peptide for secretion into the media and N -terminal His6 tag for 
easy screening of expression by Western blotting, cloned the constructs and t ested 
their expression levels on a small and large scale.   
 
5.2.2  Expression of FUCA1 and FUCA2 in mammalian tissue culture  
5.2.2.1 General Considerations 
Tissue culture consumables were purchased as sterile packaged goods; Serological 
pipettes from Sarstedt, flasks from Corning, roller bottles from Greiner and culture 
media from Gibco.  
All tissue culture experiments were conducted in a laminar flow hood with an 
airflow of ca. 0.75 m s
-1
. At least 10 minutes UV irradiation was applied both prior 
to and after tissue culture experiments. The flow hood was wiped with 70% ethanol 
both prior to and after tissue culture experiments, and additionally with anti -
bacterial spray after experiments. All items entering the hood were sprayed and 
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wiped with 70% ethanol before entering the hood. Tissue culture flasks were 
incubated at 37 ºC in a 5% CO2 atmosphere. Roller bottles were rolled at ca. 0.5 
RPM.  
Adherent HEK-293T and CHO-K1 cell lines originally purchased from Sigma 
Aldrich and subsequently maintained in-house were used for all mammalian cell 
culture experiments. Stock T75 flasks containing HEK -293T and CHO-K1 cells 
were maintained throughout the course of tissue culture experiments and were 
passaged regularly every 3 or 4 days. HEK-293T cells were cultured in DMEM 
media supplemented with 10% FBS while CHO-K1 cells were cultured in 1:1 
DMEM/Ham’s F10 media supplemented with 10% foetal bovine serum (FBS). 
Passaging was conducted in the following manner. Media was aspirated and the 
flask washed with 10 mL phosphate-buffered saline (PBS) which was then 
aspirated. Cells were released from the flask surface by the addition of 2 mL 
Trypsin/EDTA solution (Gibco)  and administration of slight percussive force. Cells 
were diluted with 8 mL media containing 10% FBS and cent rifuged at 200 RCF for 
5 minutes. Subsequently, supernatant was decanted and cells were re -suspended in 
10 mL media containing 10% FBS. Typically a 1 in 10 dilution of cells was effected 
into a fresh T75 flask into which 9 mL media supplemented with 10% FB S and 1 
mL re-suspended cells was added. The remaining 9 mL of re -suspended cells were 
discarded. 
 
5.2.2.2   Cell expansion into larger culture volume 
Expansion of cells into larger culture volume was performed at the same time points 
as cell passage. The remaining 9 mL of re-suspended cells were transferred to T175 
flasks containing 30 mL of media supplemented with 10% FBS, typically at a 1 in 
10 or 20 dilution. 
 
5.2.2.3 FUCA1 and FUCA2 genes and plasmid amplification  
Constructs for the expression of FUCA1 and FUCA2 in mammalian cell culture 
were obtained through the Glyco-Enzyme Repository 
(http://glycoenzymes.ccrc.uga.edu/ ).  Five constructs for FUCA1 and four 
constructs for FUCA2 were received (Figure 5.3). Constructs were received as 
glycerol stocks of live cultures of Escherichia coli DH5 Alpha cell lines containing 
the constructs in Figure 5.3 cloned into a modified mammalian Gateway DEST 
vector (for vector maps and sequences see the web -server at 
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http://glycoenzymes.ccrc.uga.edu/). While all constructs were available for FUCA1, 
the pGEC2 construct was not available for FUCA2.  
 
Figure 5.3. FUCA1 and FUCA2 constructs obtained from the Glyco -Enzyme 
Repository. 
 
Glycerol stocks of FUCA1 and FUCA2  constructs in the E. coli DH5 Alpha cell 
strain were used to inoculate 10 mL LB media containing 50 mg µL
-1
 Ampicillin 
and incubated at 37 ºC with aeration at 180 rpm overnight. These cultures were 
subsequently used to inoculate 200 mL LB media containing 50 mg µL
-1
 Ampicillin 
which was incubated at 37 ºC with aeration at 180 rpm overnight. Plasmid DNA was 
purified using a Macherey-Nagel NucleoBond® Xtra Midi EF Midiprep kit as per 
manufacturer’s instructions.  
FUCA1 and FUCA2 constructs containing minimal His 8 tags upstream of the gene 
encoding the α-ʟ-fucosidase were designed. Three constructs were prepared , 
containing minimal, non-cleavable His-Tags either directly upstream of the FUCA1 
coding sequence (8His_FUCA1), or containing one (8HisSG_FUCA1) or two 
(8HisSGSG_FUCA1) SG dipeptides before start  of the FUCA1 coding sequence . 
Oligonucleotide primers were used to remove the existing N -terminal sequence, 
introduce the new sequence and amplify the FUCA1 gene from FUCA1 pGEN1 by 
polymerase chain reaction to yield linear plasmid (Appendix 4); polymerase chain 
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reaction was effected by using Q5 polymerase (New England Biolabs) as per the 
manufacturer’s instructions, using the thermocycling conditions below ( Table 5.1). 
Table 5.1. Thermocycling conditions for generation of linear plasmid for FUCA1 
constructs with minimal octahidstidine affinity tags.  
Temperature / °C Duration Number of cycles 
98 °C 30 s 1 
98 °C 10 s 
25 67 °C 30 s 
72 °C 3 m 
72 °C  2 m 1 
4 °C HOLD 1 
 
Amplified products were treated with the KLD enzyme mix from a Q5 site directed 
mutagenesis kit (New England Biolabs) as per the manufacturer’s instructions. The 
product of this reaction was used to transform NEB 5 -Alpha cells (New England 
Biolabs). Transformed cells were applied neat and at 1 in 10 dilution with LB to LB 
Agar Ampicillin plates which were grown overnight at 37 °C. Colonies were picked 
from the plates after incubation overnight and grown in LB media containing 50  mg 
L
-1
 ampicillin as a small scale (10 mL) culture  (cells were incubated at 37 ºC 
overnight with aeration by shaking at 180 rpm).  
DNA sequences of the products were checked using the CMV forward promoter 
primer (CGCAAATGGGCGGTAGGCGTG) and a reverse promoter specific to the 
C-terminus of the pGEN and pGEC vectors (TGACAACGGGCCACAACTCCTC). 
Glycerol stocks derived from media inoculated by a single colony of each of the 
three constructs were used for all subsequent experiments; DNA used for 
transfection testing was isolated using an identical method to FUCA1 pGEN1, vide 
supra. 
 
5.2.2.4 Transfection of adherent mammalian cell lines 
Transfections were performed using either linear polyethylenimine or 
polyethylenimine “Max” as transfection reagents. The quantity of plasmid DNA 
used for transfection was standardised to flask surface area with 0.28 µg DNA used 
per cm
2
 flask surface area. Ratios of transfection reagent to plasmid DNA quoted , 
vide infra , are described by the relationship x mL of a 1 mg mL
-1
 stock of 
transfection reagent per µg plasmid DNA required for transfection where the ratio 
is x:1.  
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For transfections, the relevant volume of transfection reagent was added to a 
quantity of serum free DMEM and incubated for ca. 10-15 minutes. Plasmid DNA 
was then added and incubated for another ca. 10-15 minutes before administering to 
cells. Transfections were typically carr ied out between 50-70% confluency of 
cultured cells as is commonly quoted in transfection protocols.  
 
5.2.3 Purification of cell culture derived FUCA1 and FUCA2 and assays  
Conditioned media harvested from mammalian cell culture flasks was centrifuged 
for ca. 30 mins at 4416 RCF and the supernatant containing secreted proteins was 
retained. Supernatant was subsequently filtered through glass wool to remove 
further cell debris.  
When tangential flow filtration was used for purification, a hollow fibre mPES 
MiniKros® Sampler Filter Module (Spectrum Labs) with a 10  kDa molecular weight 
cut-off was connected to a KrosFlo® Research Tangential Flow Filtration System 
(Spectrum Labs). A protease inhibitor tablet (cOmplete, EDTA free (Roche)) was 
added to clarified conditioned media and media was concentrated by tangential 
flow. Concentrated media was further clarified by centrifugation for ca. 10 mins at 
4416 RCF and decanting the supernatant.  
 
5.2.3.1 Immobilised metal affinity chromatography  
Clarified media concentrated using tangential flow filtration was applied to a 1 mL 
HisTrap excel column (GE Healthcare) using a peristaltic pump. Conditioned media 
was applied once through the column fully, and subsequently recirculated through 
the column with both inlet and outlet tubing running to the same solution of 
conditioned media. In some experiments, tangential flow filtration was not used and 
instead clarified conditioned media was directly loaded onto the column using the 
procedure outlined above.  
The lines on an ÄKTA HPLC (GE Healthcare) were equilibrated with buffer 
containing a low concentration of imidazole (50 mM Tris, 500 mM NaCl, 20 mM 
imidazole, pH 8.0. Subsequently, the pre-loaded 1 mL HisTrap excel column was 
introduced to the system. Low imidazole buffer was run through the system for 5-10 
mL before application of a linear gradient (over 20 mL) to buffer containing 500 
mM imidazole but otherwise identical to the low imidazole buffer. Eluate fractions 
were collected using a 96-well plate.   
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Fractions with an A280 response were tested on SDS-PAGE gels and those 
containing bands at ca. 55 kDa which appeared to be suitably pure were 
concentrated using a 3 kDa molecular weight cut -off Microcon concentrator 
(Millipore).   
 
5.2.3.2 Size exclusion chromatography 
Concentrated protein fractions were applied to an S200 16 -60 or 16-600 Superdex 
size exclusion column (GE Healthcare) pre -equilibrated with 10 mM Tris 150 mM 
NaCl (pH 8.0), connected to an ÄKTA HPLC (GE Healthcare). The same buffer 
used for column equilibration was passed through the column and fractions were 
collected using a 96-well plate. Fractions with an A280  response were tested on 
SDS-PAGE gels and those containing bands at ca. 55 kDa which appeared to be 
suitably pure were concentrated using a 3 kDa molecular weight cut-off Microcon 
concentrator (Millipore).   
 
5.2.3.3 Enzymatic assays on purified FUCA1 
A number of enzymatic assays were conducted on purified samples of the FUCA1 
pGEN1 construct. Deglycosylation of the enzyme was tested using both the E ndoH 
and PNGase enzymes. Further, TEV protease -mediated cleavage of the FUCA1 
pGEN1 construct was tested.  
Deglycosylation of FUCA1 pGEN1 was tested by use of EndoH f (New England 
Biolabs) using the manufacturer’s recommended protocol; both native and 
denaturing conditions were tested.  Deglycosylation assays using PNGase F (New 
England Biolabs) was also conducted according to the manufacturer’s recommended 
protocol in both native and denaturing conditions. Proteolysis assays of FUCA1 
pGEN1 were also conducted using AcTEV protease (Life Technologies), as per the 
manufacturer’s recommended protocol.  
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5.2.3.4  Enzyme Kinetics 
The α-ʟ-fucosidase activity of a FUCA1 construct (8His_FUCA1, vide infra) was 
determined. Enzymatic assays were conducted using synthetic substrate 2-chloro,4-
nitrophenyl-α-ʟ-fucopyranoside (CNP-fucoside, CarboSynth Ltd.). The product of 
hydrolysis of this substrate  (2-chloro,4-nitrophenol, CNP) absorbs visible radiation 
with a λmax = 405 nm at pH above its pKa (ca. 5.4). Experiments to determine the 
Michaelis-Menten parameters for catalysis by this construct were carried out over a 
time-course of 2 m during which absorbance was measured at 405 nm using a  Cary 
100 UV-Vis Spectrophotometer (Agilent Technologies) . All solutions used to 
determine kinetic data were thermally equilibrated (37  ºC).  
The rate of hydrolysis of CNP-fucoside by purified 8His_FUCA1 was determined 
upon solutions of varying concentration of CNP -fucoside. Each solution (1 mL total 
volume) contained 50 mM HEPES buffer, 100 mM NaCl (pH 7.4) and a known 
concentration of substrate; 250 nM FUCA1 was added to this after thermal 
equilibration to initiate hydrolysis.  The molar extinction coefficient of CNP (ε 405 = 
1.24 × 10
3
 M
-1
) was determined by measuring the absorption at 405 nm of a number 
of solutions of CNP-fucoside at known concentration that had been hydrolysed by 
excess BtFuc2970 (See section 2.2.3.1). The Michaelis-Menten parameters for CNP-
fucoside hydrolysis were calculated through direct fit to the Michaelis -Menten 
equation using the Origin graphing software (OriginLab, Northampton, MA) . 
 
5.2.3.5  Crystallisation of 8His_FUCA1 
Purified 8His_FUCA1 (7.7 mg mL
-1
) was incubated with 10 mM compound 2 (see 
2.2 and Table 2.2) in a 1:1 ratio on ice for ca. 1 hour and centrifuged for ca. 5 min 
before setting up crystallisation experiments. All crystallisation experiments were 
performed at ca . 18 ºC. INDEX (Hampton Research) and PACT (Molecular 
Dimensions) crystallisation screens were set up; 120 nL aliquots of 8His_FUCA1: 2 
were dispensed along with 120 nL aliquots of mother liquor from these screens in 
MRC 96-well crystallisation plates. Liquid handling was carried out using a 
Mosquito liquid handling robot, TTP Labtech. An optimisation tray (MRC MAXI 
48-well crystallisation plate) was designed and dispensed by Wendy Offen from the 
most successful crystal ‘hit’.  
Crystals were transferred to cryo-protectant solutions containing mother liquor 
supplemented with 20% glycerol and cryo -cooled using liquid N 2. Diffraction was  
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tested in-house using a Rigaku micromax-007HF X-ray generator, used in 
conjunction with an Actor robotic sample changer .  
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5.3  Results and Discussion 
A number of means towards the expression of active human fucosidases were 
carried out. Initially, heterologous  expression of FUCA1 and FUCA2 was attempted 
in Escherichia coli, following the reported expression and purification of these 
enzymes by Liu & Li in 2009
334
. These will be discussed briefly. 
 
5.3.1  Expression of FUCA1 and FUCA2 in heterologous organisms  
Initially, FUCA1 and FUCA2 genes in pET-30a
+
 vectors which were codon 
optimised for expression in E. coli , lacked their native signal sequences and 
contained an N-terminal hexa-histidine affinity tag were tested for expression in 
BL21 (DE3), pLEMO and C41 cells on a small scale; expression in C41 cells 
seemed to yield a larger protein band in the soluble phase on SDS gel 
electrophoresis at the ca. 55 kDa range (not shown) so this cell line was used for 
200 mL expression and purification tests. Most of the protein obtained was present 
in inclusion bodies in the insoluble fraction of the cells (Figures 5.4 and 5.5, A). 
Cells were lysed by sonication and soluble protein was purified by Ni
2+
-affinity 
chromatography (Figures 5.4 and 5.5). For FUCA1, the protein band observed at ca .  
55 kDa (Figure 5.4, C) was observed to be active against p-nitrophenyl-α-ʟ-
fucopyranoside on bench tests, causing a colour change in the reaction solution due 
to formation of a yellow p-nitrophenolate product , while this was not the case for 
FUCA2 (Figure 5.5, C). FUCA1 was further purified by size exclusion 
chromatography (Figure 5.4, D-E) with a total yield of ca. 3.5 mg L
-1
 culture 
volume. A second, higher (ca. 60 kDa) molecular weight species was observed to 
co-purify with the ca. 55 kDa band assigned as the FUCA1/2 gene transcript in 
eluates from the Ni
2+
 affinity chromatography steps (Figures 5.4 and 5.5, B-C). The 
size exclusion chromatography purification procedure  for FUCA1 however allowed 
removal of this contaminant (Figure 5.4, E). While 3.5 mg L
-1
 is potentially a 
tractable yield of protein for subsequent X-ray crystallographic studies, further 
methods were explored to improve protein yield  before starting crystallisation 
trials. 
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Figure 5.4. Expression and purification of FUCA1 in pET -30a
+
 vector from 
transformed C41 cells. The sample run on the first lane of each gel figure ( A,  C, E) 
is a Biorad broad range molecular weight marker  (M), with molecular weights of 
protein standards displayed. The black arrow on expression gels indicates the 
position of the band attributed to FUCA1.  A:  expression of FUCA1 in C41 cells; 
lanes 1-2 post-induction samples from  expression at 16 °C (1: soluble fraction, 2: 
insoluble fraction) lanes 3-4 post-induction samples from expression at 37 °C (3: 
soluble fraction, 4: insoluble fraction). B: Immobilised metal affinity purification 
of recombinant FUCA1 in C41 cells; A 280 response is shown in blue while the 
percentage of high imidazole in the mixed buffer sample is shown in orange. C: 
Immobilised metal affinity purification of FUCA1 expressed in C41 cells; lane 1 
shows a sample of the protein loaded onto the affinity column, the samples run on 
lanes 2-9 are from successively higher run volumes (samples 2-4 are from peak 1, 
while samples 5-9 are from peak 2, see B). D: Size exclusion chromatography of 
FUCA1 expressed in C41 cells; A280 response is shown in blue. E: Size exclusion 
chromatography of FUCA1 expressed in C41 cells; lane 1 is a sample taken from 
the protein loaded onto the column, lanes 3-8 are eluate fractions from successively 
higher run volumes (samples 3-4 are from peak 3, while samples 5-8 are from peak 
4, see D) while lane 2  is concentrated protein pooled from eluate fr actions from 
peak 4.   
145 
 
 
Figure 5.5. Expression and purification of FUCA2 in pET-30a
+
 vector from 
transformed C41 cells. The sample run on the first lane of each gel figure ( A,  C) is 
a Biorad broad range molecular weight marker  (M), with molecular weights of 
protein standards displayed. The black arrow on expression gels indicates the 
position of the band attributed to FUCA1.  A:  expression of FUCA2 in C41 cells; 
lanes 1-2  pre-induction samples (1: soluble fraction, 2: insoluble fraction) lanes 3-
4 post-induction samples from expression at 16 °C (3: soluble fraction, 4: insoluble 
fraction). B: Immobilised metal affinity purification of recombinant FUCA2 in C41 
cells; A280 response is shown in blue while the percentage of high imidazole in the 
mixed buffer sample is shown in orange. C:  Immobilised metal affinity purification 
of FUCA2 expressed in C41 cells; the samples run on lanes 1-7 are from 
successively higher run volumes (between fractions 1 to 7 as shown on the trace, 
see B). 
 
It was assumed that the co-purified protein which runs on SDS-PAGE at ca. 60 kDa 
may be the chaperonin GroEL, however no experimentation either confirmed or 
denied this. Chaperonins such as GroEL act to aid in the correct folding of unfolded 
proteins, so it was expected that improving the folding capacity of the proteins may 
improve protein purity and yield. Attachment of the yeast small ubiquitin -like 
modifier (SUMO) peptide gene to proteins has been shown to improve protein 
solubility and folding, even for protein targets which are difficult to express in a 
soluble form.
335-337
 This method was attempted for expression of FUCA1 and 
FUCA2; the genes encoding these proteins were sub -cloned into the pETite® N-His 
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SUMO Kan vector and used to transform BL21 (DE3) cells. Unfortunately, no 
significant difference in the yield of soluble protein was observed from SDS -PAGE 
(Figure 5.6) compared to expression in the pET-30a
+
 vector (Figures 5.4 and 5.5, A) 
so other methods were explored for the expression  of these enzymes.  
 
 
Figure 5.6. Expression of FUCA1/2 genes cloned in pETite® N-His SUMO Kan 
vector from transformed Hi-Control BL21 (DE3) cells. The sample run on the first 
lane of each figure is  a Biorad low range molecular weight marker  (M), with 
molecular weights of protein standards displayed . The black arrow on expression 
gels indicates the position of the band attributed to FUCA1/2.  A: expression of 
FUCA1 in Hi-Control BL21 (DE3) cells. B: expression of FUCA2 in Hi-Control 
BL21 (DE3) cells. Lanes in each gel (A,  B): lane 1 pre-induction sample from the 
soluble phase,  lanes 2-3 post-induction samples from expression at 18 °C (2:  
soluble fraction, 3: insoluble fraction), lanes 4-5 post-induction samples from 
expression at 37 °C (4: soluble fraction, 5: insoluble fraction).  
 
The FUCA1 and FUCA2 protein transcripts were analysed more closely. Use of the 
DIANNA disulfide bond prediction web-server
338
 predicted two (FUCA1) or three 
(FUCA2) disulfide bonding pairs for the enzymes, and in homology models of the 
human α-ʟ-fucosidases prepared using iTASSER 339 the cysteine residues predicted 
by DIANNA appear to be close enough in space for disulfide bonding to occur. The 
formation of disulfide bonds in eukaryotes is achieved through the protein disulfide 
isomerase enzyme, which is localised in the endoplasmic reticulum and thus 
encountered during protein folding
340,341
; in bacterial cells however it is achieved 
by a number of enzymes in the perisplasmic space, which are not encountered 
during protein folding or encountered at all by proteins which do not enter this 
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compartment
342
. The pelB leader sequence of Erwinia carotovora
343
 can be 
introduced into bacterial cells to stimulate compartmental isation of a nascent 
protein towards the periplasmic space, thereby allowing for the formation of 
disulfide bonds
344
.  
FUCA1 and FUCA2 were thus sub-cloned into the pET-22b
+
 plasmid, which 
contains a pelB leader sequence for protein trafficking to the periplasmic 
compartment. BL21 (DE3) cells were then transformed by these plasmids and 
expression levels determined (Figure 5.7), however again the solubility of 
expressed FUCA1 did not appear to be greater than that from the pET -30a
+
 vector 
(Figure 5.4 and 5.5, A).    
 
Figure 5.7. Expression of FUCA1/2 genes cloned in pET22b
+
 from transformed 
BL21 (DE3) cells. The sample run on the first lane of each figure is  a Biorad broad 
range molecular weight marker  (M), with molecular weights of protein standards 
displayed. The black arrow on expression gels indicates the position of the band 
attributed to FUCA1/2. A: expression of FUCA1 in BL21 (DE3) cells. B: expression 
of FUCA2 in BL21 (DE3) cells. Lanes in each gel (A, B): lane 1 pre-induction 
sample from the soluble phase, lanes 2-3 post-induction samples from the soluble 
phase (2: expression at 16 °C, 3: expression at 37 °C), lane 4 pre-induction sample 
from the insoluble phase, lanes 5-6 post-induction samples from the insoluble phase 
(2: expression at 16 °C, 3: expression at 37 °C). 
 
Pichia pastoris  was further used as an alternative vector for expression of FUCA1. 
These experiments were conducted by Dr. Jared Cartwright of the Bi osciences 
Technology Facility, University of York. While expression of FUCA1 in Pichia 
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pastoris  did lead to production of some soluble prote in, it was deemed that the low 
yield obtained was not worth following up.  
At around this time, facilities for protein expression in both baculovirus -infected 
insect cells and mammalian cells were being developed at the York Structural 
Biology Laboratory. Since limited progress had been made with the recombinant 
expression of FUCA1 and even less with FUCA2, and in order to learn further 
skills, it was decided to pursue the expression of these enzymes in a more native 
environment through mammalian tissue cul ture (see 5.3.2). FUCA1 and FUCA2 are 
known glycoproteins
306 ,309,310,312
 and have predicted disulfide bonds (vide supra). 
As such, expression of the enzymes in a tissue culture environment should improve 
the solubility of the protein produced as the cellular environment and enzymatic 
machinery of cultured mammalian cells more closely resembles that in heterologous 
expression. This expression system is particularly suited to the expression of 
glycoproteins, proteins comprising disulfide bonds and secreted proteins, and 
typical yields of purified proteins produced from the HEK -293T cell line, for 
example, range between 1-80 mg L
-1
.
345
   
 
5.3.2  Expression of FUCA1 and FUCA2 in mammalian tissue culture 
5.3.2.1 Constructs from the CCRC 
9 constructs obtained from the complex carbohydrate research centre , five 
harbouring the gene for human α-ʟ-fucosidase FUCA1 and four harbouring that for 
FUCA2, were tested for expression levels in  cultured HEK-293T and CHO-K1 
adherent cells. Small scale expression tests were run of both secreted protein and 
protein harvested from cells (Figure 5.8). 
Cells transfected with constructs containing green fluorescent protein were visibly 
green and the conditioned media from these samples also appeared green. While 
caution should be taken in interpreting differences in expression level between 
different membranes using Western blots, expression in CHO-K1 cells seemed to be 
uniformly lower than that in HEK-293T cells. The secretion of all of the constructs 
also seemed to be efficient, as most of the protein observed was from the soluble 
phase. The FUCA1 pGEN1 construct was chosen for further study as it provided a 
large quantity of protein and only a single band was observed on western blot; it 
was expected that the multiple bands observed for other constructs were due to 
degradation of the protein.   
149 
 
 
Figure 5.8. Expression levels of FUCA1 and FUCA2 constructs in HEK-293T and 
CHO-K1 cells. Expression levels were determined by Western blotting using an 
anti-His:HRP monoclonal antibody. Protein from both the soluble and insoluble 
phases was visualised; the samples run were of secreted protein from HEK -293T 
(A) and CHO-K1 (C) and protein isolated from cells of HEK-293T (B) and CHO-K1 
(D). M is a low range molecular weight marker (Biorad). Samples 1-9 are, 
respectively, pGEN1, pGEN2, pGEN3, pGEC1 and pGEC2 constructs of FUCA1 
and pGEN1, pGEN2, pGEN3 and pGEC1 constructs of FUCA2.  
 
Subsequently, expression of the FUCA1 pGEN1 construct was carried out using 
different transfection reagents (linear polyethylenimine, polyethylenimine “Max”) 
at a range of transfection reagent:DNA ratios, in both HEK-293T and CHO-K1 cells 
in order to determine the optimal transfection reagent (data not shown). Linear 
polyethylenimine was chosen for subsequent experiments as this transfection 
reagent and ratio seemed to give the highest yield of FUCA1 as observed by 
western blot.  
Expression of the FUCA1 pGEN1 construct in HEK -293T cells was scaled up to ca.  
450 mL in 15 T175 flasks. Two harvests were conducted, at 3 and 5 days after cell 
transfection. Conditioned media was concentrated by tangential -flow filtration and 
protein was purified using Ni
2+
 affinity chromatography followed by size exclusion 
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chromatography to yield 1 mg of protein from a total volume of 900 mL  
conditioned media (Figure 5.9). This purified protein was observed to be active 
against 2-chloro,4-nitrophenyl-α-ʟ-fucopyranoside on bench tests, causing a colour 
change in the reaction solution due to formation of a yellow 2-chloro,4-
nitrophenolate product . The purified protein produced by cultured mammalian cells   
was observed to run higher on SDS-PAGE gels than that produced recombinantly by 
Eshcerichia coli , indicating the presence of N-linked glycans (Figure 5.9, D vs. e.g. 
Figure 5.4, E). Curiously, when expression of this construct in otherwise similar 
conditions (the same HEK-293T cell line albeit with a higher passage number, 
similar cell confluency at the time of transfection etc.) but using roller bottles for 
cell culturing, a ca. 10-fold lower yield of 100 µg L
-1
 purified protein was obtained.   
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Figure 5.9. Expression and purification of  FUCA1 pGEN1 construct  in cultured 
HEK-293T cells. A: Western blots of FUCA1 expression, His-tagged proteins were 
visualised using an anti-His:HRP monoclonal antibody (M: biorad broad range 
molecular weight marker 1: first 450 mL harvest, 3 days after transfection 2: second 
450 mL harvest, 5 days after transfection). B: Immobilised metal affinity 
purification of FUCA1 pGEN1; A280 response is shown in blue while the percentage 
of high imidazole in the mixed buffer sample is shown in orange. C: Size exclusion 
chromatography of FUCA1 pGEN1; A 280 response is shown in blue. D: Samples 
from purification were visualised on an SDS-PAGE gel (M: biorad broad range 
molecular weight marker, 1: Protein concentrated by tangential -flow filtration. 2: 
sample from protein that had been run through the 1 mL Hi -Trap Excel column a 
single time, 3-4: samples from Ni
2+
-affinity chromatography purification of FUCA1 
pGEN1, 5: Concentrated FUCA1 pGEN1 sample loaded on the size exclusion 
column). Unfortunately, while samples from the size exclusion purification of 
FUCA1 pGEN1 were loaded on the gel, the intensity of the protein bands was too 
low to visualise.  
 
5.3.2.2 Assays on purified FUCA1 pGEN1 
Enzymatic assays were run on FUCA1 pGEN1 after Ni
2+
-affinity and size exclusion 
purification. As the pGEN1 construct contains an N-terminal His8 affinity tag that 
is cleavable by TEV protease, cleavage of the affinity tag was tested using TEV 
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protease (Figure 5.10); further, assays using the deglycosylating enzymes EndoH 
and PNGase were conducted (Figure 5.10).  
Treatment of FUCA1 pGEN1 with TEV protease yielded no visible gel shift (Figure 
5.10, 1, 5-7), making it unlikely that proteolytic cleavage was catalysed by this 
enzyme. The protein bands on treatment with EndoH using both standard an d 
denaturing reaction conditions appear similar (Figure 5.10, 2-4, 8), and show the 
presence of heterogeneous species. This stands to reason as EndoH is not capable of 
accepting complex glycans as substrate; these species comprise a proportion of the 
glycans produced by mammalian cells. Treatment with PNGase however (Figure 
5.10, 1, 9-10) yielded a visible gel shift towards an apparently homogenous species 
which is perhaps the fully deglycosylated enzyme (less its innermost GlcNAc 
residues). 
 
 
Figure 5.10. Enzymatic assays on purified FUCA1 pGEN1.  Gels displayed are 12 % 
SDS-PAGE gels. Molecular weight ladders (Biorad broad range, M) are shown 
along with the molecular weight of the protein standards in kDa. Lane 1: native 
FUCA1. Lanes 2-4: FUCA1 treated with native EndoH f assays for 1, 2 and 4 hours, 
respectively. Lanes 5-7: FUCA1 treated with AcTEV protease for 1, 2 and 4 hours 
respectively. Lane 8: FUCA1 treated with EndoH f in a denaturing assay. Lane 9: 
FUCA1 treated with PNGase F in a native assay. Lane 10: FUCA1 treated with 
PNGase F in a denaturing assay.  
 
Expression of the FUCA1 pGEN1 construct in HEK-293T cells allowed the 
purification towards seemingly pure protein (Figure 5.9, B-D). The pGEN1 
construct however contains a long (32 residues) region co mprising a His8 affinity 
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tag, Strep tag, attB1 sequence and TEV proteolysis site prior to the start of the 
FUCA1 gene product (Figure 5.3); long linker regions tend to hinder 
crystallogenesis and must typically be cleaved prior to crystal formation. As 
proteolysis of FUCA1 pGEN1 could not be achieved using TEV protease (Figure  
5.10, 1, 5-7), and in order to reduce the number of steps taken for purification of a 
crystallisable construct,  constructs were designed with minimal octahistidine tags at 
the N-terminus of the FUCA1 gene product.   
 
5.3.2.3 FUCA1 constructs containing minimal octahistidine affinity tags  
Three FUCA1 constructs were designed containing minimal, non -cleavable His-
Tags either directly upstream of the FUCA1 coding sequence (8His_FUCA1), o r 
containing one (8HisSG_FUCA1) or two (8HisSGSG_FUCA1) SG dipeptides before 
start of the FUCA1 coding sequence (for methodological details, see 5.2.2.3). 
Small scale expression tests were conducted on each of the constructs ( Figure 5.11) 
in both HEK-293T and CHO-K1 cells, using both linear polyethylenimine and 
polyethylenimine “Max” as transfection reagents. As only a single protein band was 
observed on anti -His western blot for the 8His_FUCA1 construct, while multiple 
bands were seen for the 8HisSG_FUCA1 and 8HisSGSG_FUCA1 constructs (Figure 
5.11), subsequent scale-up was carried out using 8His_FUCA1.  
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Figure 5.11. Small scale expression testing of FUCA1 constructs with minimal His -
Tags. Molecular weight ladders (M) are shown along with the molecular weight of 
the protein standards in kDa. Constructs and cell lines are as displayed in braces. 
Odd lane numbers correspond to expression after transfection with a ratio of 1.7:1 
linear polyethylenimine while even lane numbers correspond to expression after 
transfection with a ratio of 3.5:1 polyethylenimine “Max”. Pairs of samples ( 1 and 
2, 3 and 4 etc.) represent duplicate expression tests with plasmid DNA isolated 
from unique colonies formed after transformation of bacterial cells; two colonies 
were tested for each octahistidine-tagged construct.   
 
Expression was thus scaled up to 90 mL (three T175 flasks). Unlike previously with 
FUCA1 pGEN1, transfection was effected when cells had reached ca. 90 % 
confluency (for previous tissue culture experiments, trans fection was carried out at 
ca. 50-70 % confluency). Two cell harvests were conducted, each of 90 mL 
conditioned media. Harvested protein was clarified and purified using immobilised 
metal affinity chromatography, yielding 1.2 mg of 8His_FUCA1 in total; 
conditioned media from the first and second harvests were purified separately and 
less protein was purified from the second harvest (Figure 5.12).  
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Figure 5.12. Expression and purification of 8His_FUCA1 expressed in cultured 
HEK-293T cells. The sample run on the first lane of each gel figure (C, E) is a 
Biorad broad range molecular weight marker  (M), with molecular weights of 
protein standards displayed. A and B: Immobilised metal affinity purification of 
8His_FUCA1; A280 response is shown in blue while the  percentage of high 
imidazole in the mixed buffer sample is shown in orange ( A is from the first 90 mL 
harvest while B is from the second). C: SDS-PAGE gel of samples from Ni
2+
 
purification of the first harvest of 8His_FUCA1 (A, also representative of the 
second harvest, B). M: Biorad broad range molecular weight marker (molecular 
weights of protein standards are displayed), 1-7: samples from increasing run 
volume, encompassing each fraction across the peak in A.  
Expression was scaled up to 450 mL (fifteen  T175 flasks), with transfection at ca. 
50-70 % confluency. Purification of the 450 mL clarified conditioned media by 
immobilised metal affinity chromatography only yielded a further 1.4 mg 
8His_FUCA1, however. This dramatic difference in expression yield may be due to 
the confluency of cultured cells at the time of transfection. While a number of 
transfection protocols cite confluencies for optimal transfection efficiency in the 
approximate range 40-80%, Aricescu et al . noted that “optimal transfection 
efficiency is achieved when adherent cells reach about 90% confluency”. 346  
Nevertheless, the two samples of 8His_FUCA1 were pooled, concentrated and 
further purified by gel filtration chromatography to yield the enzyme at high purity 
(Figure 5.13).  
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Figure 5.13. Purification of 8His_FUCA1 by size exclusion chromatography. A: 
Size exclusion chromatography of 8His_FUCA1; A 280 response is shown in blue. B: 
SDS-PAGE gel of sample from size-exclusion chromatography of 8His_FUCA1. M:  
Biorad broad range molecular weight marker (molecular weights of protein 
standards are displayed), 1-6: samples from increasing run volume across the large 
peak in A.  
 
5.3.2.4 Assays and crystallisation of minimal octahistidine FUCA1 construc t 
The Michaelis-Menten parameters for CNP-fucoside hydrolysis by purified 
8His_FUCA1 were determined;  KM = 0.099 ± 0.01 mM ,  Vmax = 1305 ± 47 min
-1
,  
Figure 5.14. These values correlate well with those determined previously by Liu et 
al. using purified FUCA1 expressed recombinantly in Escherichia coli  (KM = 0.23 
mM, Vmax = 17.1 s
-1
).
334
 The KM value observed for 8His_FUCA1 is slightly lower; 
this could be due to the difference in substrate (2 -chloro,4-nitrophenyl-α-ʟ-
fucopyranoside rather than 4-nitrophenyl-α-ʟ-fucopyranoside), or due to differences 
in the experimental pH and buffer system.  It is unlikely that the presence of glycans 
in the tissue-culture derived sample has any effect on substrate binding as treatment 
of human liver derived FUCA1 with N-glycanase has previously been shown not to 
affect its KM value.
312
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Figure 5.14. Michaelis-Menten kinetics of CNP-α-ʟ-fucopyranoside hydrolysis by 
8His_FUCA1. 
 
Crystallisation screens were also set up with purified 8His_FUCA1, using the 
sitting drop vapour diffusion method. In order to improve the pro pensity for the 
enzyme to crystallise, it was incubated with α-ʟ-fucosidase inhibitor 2 (see 2.2 and 
Table 2.2) for ca. 1 hour before crystallisation experiments.  Initial crystallisation 
screens were kindly optimised by Wendy Offen to yield crystals which appeared 
visually promising (Figure 5.15); these crystals were tested for diffraction in -house. 
Unfortunately, diffraction of these crystals resulted in only a few, highly intense 
diffraction spots, interpreted as being due to the diffraction of small mole cule 
crystals. As the crystallisation mother liquor contained only buffer and 
polyethylene glycol (optimised from PACT condition D1, Molecular Dimensions; 
this condition contains 0.1 M ᴅʟ-malic acid, MES monohydrate, Tris buffer system 
pH 4.0, 25 % w/v PEG 1500), it seems unlikely that the spots are due to mother 
liquor, but may be due to crystals of 2 that formed in the crystallisation drop.  
 
158 
 
 
Figure 5.15. Crystals formed in optimisation trays from the incubation mixture of 
8His_FUCA1 and inhibitor 2. On diffraction studies, these crystals appeared to be 
salt crystals.   
 
The α-ʟ-fucosidase sample was not deglycosylated prior to crystallogenesis 
experiments. The presence of N-glycans in a protein sample is known to interfere 
with crystallisation due to the structural and conformational heterogeneity N -
glycans introduce to a protein, and few crystal structures have been determined of 
proteins containing extensive N-glycosylation.
325
 Therefore, these proteins are 
typically deglycosylated enzymatically prior to crystallisation experiments.  
325
 The 
deglycosylating enzyme PNGase, which accepts as substrate pr oteins with all types 
of N-glycan structure, converts the Asn residue forming an N -glycosidic bond to an 
Asp residue, thereby altering the surface charge of the enzyme, and this is also 
known to interfere with crystallogenesis and the polydispersity of the  enzyme 
sample, causing its aggregation
325
. Unfortunately, the EndoH enzyme, which leaves 
a single GlcNAc monosaccharide at each glycosylation site, does not alter the 
surface charge of the protein, interfere with crystallogenesis or cause aggregation, 
does not act to cleave the complex-type N-glycans which comprise a portion of the 
N-glycans produced during the mammalian N-glycan biosynthetic pathway. It was 
shown previously that EndoH-catalysed deglycosylation of FUCA1 pGEN1 led to a 
heterogenous reaction product (5.3.2.2, Figure 5.10).  
EndoH is thus the structural biologists’ preferred deglycosylating enzyme, however 
means must be taken to avoid the biosynthesis of complex -type N-glycans during 
protein expression. Knowledge of the N-glycan biosynthetic pathway can be 
exploited to yield N-glycosylated proteins lacking complex-type modifications. For 
example, the α-mannosidase inhibitors kifunensine or swainsonine can be 
introduced to media in order to inhibit glycan N-glycan biosynthesis, limiting N-
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glycan biosynthesis at the stage of oligomannose -type or hybrid-type N-glycans 
respectively.
325
 Alternatively, a glycosylation deficient cell line  such as HEK-293S 
GnTI
- / -328
 could be used for the expression of human α-ʟ-fucosidases with a higher 
propensity to crystallise.  
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5.4 Conclusions 
The α-ʟ-fucosidases FUCA1 and FUCA2 were expressed recombinantly in 
Escherichia coli ; FUCA1 was further purified by immobilised metal affinity 
chromatography and size-exclusion chromatography with a yield of 3.5 mg L
-1
 
active protein, however this was not the case for FUCA2, which could not be 
purified. For both enzymes, most of the expressed protein was present in inclusion 
bodies. Attempts to further solubilise the proteins by using constructs both with an 
N-terminal SUMO module and pelB leader peptide to facilitate solubility and 
disulfide bond formation did not appear to improve protein solubility. While 3.5 mg 
L
-1
 purified enzyme is not a high yield for recombinant expression of a soluble 
protein in Escherichia coli , it may be possible to use this method to yield enough 
protein for crystallisation studies .  
FUCA1 and FUCA2 were also expressed in cultured CHO-K1 and HEK-293T cells. 
A number of constructs containing the gene transcripts for FUCA1 and FUCA2 
received from the Moremen Lab (Complex Carbohydrate Research Centre, 
University of Athens, Georgia) were expressed. Transfection of the shortest N -
terminal construct, comprising both octahistidine and Strep -II affinity tags, into 
cultured CHO-K1 and HEK-293T was observed to allow expression of the most 
stable α-ʟ-fucosidase transcripts for both proteins from those tested, while the level 
of FUCA2 expression was lower than that of FUCA1. FUCA1 was further purified 
from conditioned media using a combination of immobilised metal affinity 
chromatography and size-exclusion chromatography to yield high purity protein 
which was active against the synthetic substrate 2 -chloro,4-nitrophenyl-α-ʟ-
fucopyranoside, however at low yield (ca. 1.1 mg L
-1
).  
For FUCA1 an additional construct comprising just an octahisti dine affinity tag at 
the N-terminus of the FUCA1 gene transcript was cloned and used to transfect both 
CHO-K1 and HEK-293T cells. Transfection of highly confluent (ca. 90 %) HEK-
293T cells using this construct allowed purification of active α-ʟ-fucosidase at 
greater than 6 mg L
-1
 yield. The Michaelis-Menten parameters of this purified 
enzyme were determined (KM = 0.099 mM, Vmax = 1305) and are in agreement with 
literature values. Crystallisation screens were set up with this purified enzyme 
complexed with a competitive α-ʟ-fucosidase inhibitor, however the only crystals 
that formed from these experiments were likely formed by the inhibitor itself. It is 
unsurprising that crystals of the enzyme did not form as at the time of 
crystallogenesis, the sample still  contained a heterogenous pattern of N-glycans, 
which is known to interfere with crystallogenesis. Further attempts towards the 
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realisation of the crystal structure of human GH29 enzymes from a tissue culture 
source would benefit from either expression in glycosylation deficient cell lines  or 
the introduction of inhibitors of the N-glycan biosynthetic pathway to the culture 
media during transfection. The yield of purified FUCA1 from transfected cultured 
HEK-293T cells was observed to be maximised when trans fection was conducted at 
high (ca. 90%) confluency, and when expression was carried out in T175 flasks 
rather than by using the less labour-intensive roller bottle system.  
FUCA2, which could not be purified in an active form by expression in a 
heterologous system, could be expressed and purified in cultured mammalian cells, 
however at lower yield than FUCA1. While FUCA1 perhaps has more significance 
in the clinical setting, the structural characteristics of FUCA2 may be advantageous 
in the study and treatment of host-pathogen interactions due to its documented role 
in Helicobacter pylori  virulence.
4
 
While the transient transfection system employed herein can be employed rapidly 
for the testing of new plasmid DNA clones, it is not the most ideal for large scale 
protein expression, as is likely to be required for structural studies. The generation 
of stable clones expressing GH29 fucosidases with relevant affinity tags for 
purification may provide a better long-term alternative for protein production; as it 
is likely that many studies downstream of an initial structure determination would 
be carried out, the realisation of a robust protein expression system for these 
enzymes would be ideal.
347
 
Hopefully, the work documented herein will pave the way for the successful 
structural characterisation of these important enzymes in the near future.  
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Chapter 6: Conclusions and future perspectives 
 
ʟ-fucose has vital importance to the correct functioning of a number of biological 
species in a wide range of contexts, inter alia, in the formation of durable 
extracellular matrices, molecular adhesion and signalling events, fertility and 
development. α-ʟ-fucosidases act to cleave ʟ-fucose residues from these biological 
species and these enzymes have a relationship with disease phenotypes in mammals. 
Genetic factors leading to lack of lysosomal α -ʟ-fucosidase activity cause the 
neurodegenerative lysosomal storage disorder fucosidosis. Further, the enzymes 
have a relationship with cancer, as many neoplastic cells differentially express 
fucosylated glycans such as the sialyl -Lewis
x
 antigen on their cell surface and may 
also upregulate expression of α -ʟ-fucosidase. Finally, molecular adhesion and 
infectivity by the stomach pathogen Helicobacter pylori  has been shown to 
correlate with plasma α-ʟ-fucosidase activity. α-ʟ-fucosidases are thus critically 
important enzymes, and it may be envisioned that the inhibiti on of these enzymes 
may provide clinical routes to treatment of the illnesses discussed above. As such, 
there has been generous research interest in developing inhibitors of α -ʟ-fucosidase. 
As enzyme function is largely related to the 3 -dimensional structure adopted in 
solution, the design of potent enzyme inhibitors may be aided by prior knowledge 
of the 3-dimensional structure of the enzyme in question along with understanding 
of its reaction mechanism and transition-state(s). Unfortunately, while the 3 -
dimensional structures of a number of bacterial α -ʟ-fucosidases were known at the 
onset of this work, no structure for either mammalian α -ʟ-fucosidase (lysosomal or 
plasma) was known.  
Throughout this work, the 3-dimensional basis for the inhibition of GH29 family α-
ʟ-fucosidase enzymes by 5-membered iminosugars was probed by a combination of 
X-ray crystallography and kinetic methods. The conformation adopted by these 
inhibitors when complexed with a bacterial α -ʟ-fucosidase from Bacteroides 
thetaiotaomicron  (BtFuc2970) was observed crystallographically to be E3 (equating 
to E4 for a pyranoside), supporting the catalytic mechanism of this class of enzyme, 
which proceeds through a 
3
H4 transition state; this conformation was concluded to 
occur due to hydrogen bonds made to key residues in the enzymatic active site.  
Through these studies, a hydrophobic ridge was also observed in GH29 -A subfamily 
α-ʟ-fucosidases which appears to provide a hydrophobic interaction motif for 
glycosidic aglycon moieties.   
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5-membered iminocyclitols have proven a versatile system for the inhibition of 
glycoside hydrolases, particularly of GH38 golgi α-mannosidase-II222, 348, 349 , and α-
ʟ-fucosidase as presented in this work. These heterocycles have the advantage that 
their conformation is dictated not by ring energe tics but by the ring substituents, 
allowing greater design of substituents in order to fill pockets in the enzymatic 
active site to yield inhibitors which may be less promiscuous than 6 -membered ring 
inhibitors. While these compounds have much potential fo r glycoside hydrolase 
inhibition in the clinical setting, they have only been applied to a small number of 
glycoside hydrolase families, and their more widespread use may provide access to 
powerful, selective inhibitors for treatment of a range of conditio ns including 
lysosomal storage disorders and cancer.  
Irreversible enzyme inhibitors can be powerful tools for molecular imaging. Such 
compounds which comprise fluorophores or other moieties may be utilised in a 
process known as activity-based protein profiling, whereby the catalytic mechanism 
of an enzyme is exploited to yield highly specific and bio -orthogonal molecular 
imaging reagents. The 3-dimensional crystal structures of compounds upon which 
α-ʟ-fucosidase activity-based probes can be appended were determined when 
complexed with BtFuc2970. These structures serve to show unequivocally the 
covalent bond formed between the enzymatic nucleophile residue and the fucose -
mimic ring, after trans-diaxial ring-opening of the aziridine moiety present in these 
compounds, and represent the first crystal structures reported of a glycoside 
hydrolase ligated with such an aziridine compound. Compounds such as these may 
have utility in discovering novel enzymes with α -ʟ-fucosidase activity, and as 
reporters of this activity, most prominently in studies related to fertility.  
Activity-based probes like those discussed in the current work provide a powerful 
system for the study of enzyme activity and the dynamics of enzyme biosynthesis, 
trafficking and degradation. This technique has been applied in the past to a range 
of glycoside hydrolases such as glucocerebrosidase and other β-glucosidases, 274,350,  
β-galactosidases269 and hexosaminidases273, and will likely be expanded to other 
retaining glycoside hydrolases in the coming years, likely including clinically 
important enzymes. One shortcoming is that the covalent trapping of glycoside 
hydrolases to report on their activity has thus far only been applied against 
retaining glycoside hydrolases. Given a suit able synthetic chemistry framework, it 
should be possible to apply the techniques developed for retaining glycoside 
hydrolases to their inverting counterparts. For example, recent research reported the 
synthesis of N-bromoacetylglycosylamines and bromoketone-C-glycosides to target 
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inverting endo-xyloglucanases
351
, and it may be envisaged that these compounds 
could be synthesised to include reporter moieties for use as activity -based probes.   
Another potential use for activity-based probes such as those described herein is in 
the labelling of glycosyltransferases. While the glycosylation occurring during N-
glycan biosynthesis has previously been tracked using labelled nucleoside 
sugars,
268,352
 individual glycosyltransferases involved in this pathway or other 
glycosyl transfers have not yet been visualised by activity -based protein profiling. 
Many glycosyltransferases have clinical relevance, such as 
oligosaccharyltransferase which transfers a dolichol-linked precursor N-glycan to 
nascent glycoproteins on the luminal side of the endoplasmic reticulum and is thus 
critical for the correct maturation and folding of many proteins
353
 and O-GlcNAc 
transferase, which transfers GlcNAc in a β-linkage to many proteins in the nuclear 
compartment; dysregulation of this enzyme is linked to diabetes
354
, cancer
355
 and 
neurodegenerative disorders
356
. Fucosyltransferases, meanwhile, are important due 
to their generation of fucosylated glycans which have been linked to cancer
73
, the 
immune response
44,45
 and host-pathogen interactions
5,6
. The development of 
activity-based probing techniques for trapping of glycosyltransferases thus has 
exciting prospects for improving our understanding of glycosylation in d isease.  
The results discussed above further our understanding of the enzymatic mechanism 
of α-ʟ-fucosidases and may further aid in the design of more potent inhibitors of the 
enzyme class, however they do nothing to address a critical lack of understandin g 
by the field, namely that the 3-dimensional structures of human α -ʟ-fucosidases are 
still unknown. As these are the enzymes that are important to human health, this 
represents a bottleneck to growth of the field and the potential development of 
therapeutics for fucosidosis, cancer and infection by Helicobacter pylori . As such, a 
number of methods were carried out to attempt the expression of human fucosidases 
FUCA1 and FUCA2. While these enzymes have previously been expressed and 
purified to apparent homogeneity, the yield of purified enzyme obtained using these 
methods was not suitable for crystallographic experiments.  
Expression of both human α-ʟ-fucosidases was attempted using Escherichia coli , 
Pichia pastoris , and cultured mammalian cells as expression vectors. The most 
success was observed when the GH29 enzymes were obtained by transient 
transfection of highly confluent human embryonic kidne y cells. For FUCA1 at least, 
the expression yield and purity after a two -step purification procedure leaves the 
author optimistic that a structural solution to this clinically important enzyme is on 
the horizon.  
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The human α-ʟ-fucosidases are each clinical ly important, however it is currently 
unknown to what extent the GH29 inhibitors described in the literature inhibit each 
enzyme, or what the structural features which may allow more selective inhibition 
of each enzyme may be. This may be clinically import ant however as, e.g., whilst 
inhibition of FUCA2 may allow clearance of Helicobacter pylori  from the stomach, 
the inhibition of FUCA1 in vivo is likely to cause a number of side -effects due to 
the importance of the enzyme in glycan catabolism. The availabi lity of crystal 
structures for these enzymes could potentially inform the design of selective 
inhibitors for each human α -ʟ-fucosidase. 
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Appendix 1: Alignment of α-ʟ-fucosidase sequences 
from various organisms 
 
 
Appendix 1.1. Alignment of α-ʟ-fucosidase protein sequences. Protein sequences of 
Bacteroides thetaiotaomicron  2970 (Bt2970), Thermotoga maritima  GH29 
(TmGH29), Homo sapiens  FUCA1 (HsFUCA1) and FUCA2 (HsFUCA2) and Bos 
Taurus GH29 (BtaGH29) are aligned. Amino acids are coloured according to 
sequence similarity; 100% similarity in green, 80-10% in light green, 60-80% in 
yellow. Alignment was performed using Geneious R8 (http://www.geneious.com, 
Kearse et al., 2012).
357
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Appendix 2: BtFuc2970 gene sequence and transcript 
in pET-YSBLIC3C vector 
 
A2.1 BtFuc2970 gene sequence in pET-YSBLIC3C 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGT
TCCAGGGACCAGAAGCAAAGAAGGAAATTCCTTTGAAATATGGAGCTACGA
ATGAAGGTAAACGGCAAGACCCTGCCATGCAGAAGTTCCGTGACAATCGTTT
GGGTGCCTTCATCCACTGGGGACTGTATGCTATCCCCGGGGGAGAGTGGAAT
GGAAAAGTATATGGCGGAGCTGCCGAATGGCTGAAAAGCTGGGCAAAAGTA
CCTGCTGATGAATGGCTGAAACTGATGGATCAATGGAACCCTACGAAATTTG
ATGCGAAGAAATGGGCAAAGATGGCCAAAGAAATGGGTACTAAGTATGTCA
AGATTACAACGAAACATCATGAAGGCTTCTGTCTGTGGCCTAGTAAGTAT AC
TAAATATACCGTAGCAAATACCCCATATAAGCGTGATATATTGGGCGAGTTG
GTGAAAGCCTATAATGACGAAGGAATTGATGTACACTTCTATTTCTCAGTGA
TGGACTGGAGTAATCCGGATTATCGTTATGATATAAAATCCAAAGAAGATAG
CATCGCCTTCAGCCGTTTCCTTGAATTTACCGACAATCAACTGAAAGAACTG
GCAACACGTTACCCGACCGTTAAGGACTTCTGGTTTGATGGTACGTGGGATG
CCAGCGTTAAAAAGAATGGTTGGTGGACAGCTCATGCAGAACAAATGTTGA
AGGAACTCGTTCCGGGTGTTGCCATCAATAGCCGCTTACGTGCTGATGACAA
AGGAAAGCGACATTTTGATAGCAATGGTCGTCTGATGGGTGACTACGAATCC
GGCTACGAACGCCGCTTGCCCGATCCGGTGAAAGATCTCAAAGTTACACAGT
GGGACTGGGAAGCCTGCATGACTATACCCGAAAATCAATGGGGATATCACA
AAGACTGGTCATTGAGCTATGTGAAAACTCCGATTGAAGTCATTGACCGCAT
TGTACACGCTGTTTCCATGGGTGGAAACATGGTTGTCAACTTCGGGCCTCAG
GCAGATGGTGATTTCCGTCCCGAAGAGAAAGCAATGGCTACAGCGATTGGTA
AGTGGATGAATCGTTACGGAAAAGCTGTTTATGCTTGCGATTATGCCGGATT
TGAAAAACAAGACTGGGGATATTATACACGTGGTAAAAACGATGAAGTTTAT
ATGGTAGTATTCAATCAGCCTTATAGTGAACGGTTGATTGTAAAGACTCCGA
AAGGCATTACAGTAGAAAAAGCCACTTTGCTGACTACCGGTGAAGATATCAC
TGTTGTTGAGACAACCCGCAATGAATATAACGTATCTGTTCCTAAAAAGAAT
CCGGGTGAACCTTATGTAATTCAGCTTAAAGTTCGTGCAGCTAAAGGAACAA
AAAGTATTTATCGAGATGCTTTAACATAA 
 
168 
 
A2.2 BtFuc2970 transcript in pET-YSBLIC3C 
MGSHHHHHHSSGLEVLFQGPAEAKKEIPLKYGATNEGKRQDPAMQKFRDNRLG
AFIHWGLYAIPGGEWNGKVYGGAAEWLKSWAKVPADEWLKLMDQWNPTKFD
AKKWAKMAKEMGTKYVKITTKHHEGFCLWPSKYTKYTVANTPYKRDILGELV
KAYNDEGIDVHFYFSVMDWSNPDYRYDIKSKEDSIAFSRFLEFTDNQLKELATR
YPTVKDFWFDGTWDASVKKNGWWTAHAEQMLKELVPGVAINSRLRADDKGK
RHFDSNGRLMGDYESGYERRLPDPVKDLKVTQWDWEACMTIPENQWGYHKD
WSLSYVKTPIEVIDRIVHAVSMGGNMVVNFGPQADGDFRPEEKAMATAIGKWM
NRYGKAVYACDYAGFEKQDWGYYTRGKNDEVYMVVFNQPYSERLIVKTPKGI
TVEKATLLTTGEDITVVETTRNEYNVSVPKKNPGEPYVIQLKVRAAKGTKSIYR
DALT 
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Appendix 3: FUCA1 and FUCA2 gene sequences and 
transcripts in pET30a
+
 vector 
 
A3.1 FUCA1 gene sequence in pET30a
+
 
ATGCACCATCATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCTGGTAT
GAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCCCAGA
TCTGGGTACCGACGACGACGACAAGGCCATGGGCGGTGCCGCCGAATCAGT
GCGTCGTGCCCAACCGCCGCGTCGCTACACCCCGGATTGGCCGTCGCTGGAT
AGTCGCCCGCTGCCGGCTTGGTTTGATGAAGCAAAATTTGGCGTGTTCATTC
ATTGGGGTGTCTTTAGCGTGCCGGCTTGGGGCTCTGAATGGTTCTGGTGGCA
CTGGCAGGGTGAAGGTCGTCCGCAGTATCAACGTTTTATGCGCGATAACTAT
CCGCCGGGCTTCAGCTACGCAGACTTTGGTCCGCAGTTCACCGCTCGCTTTTT
CCATCCGGAAGAATGGGCCGACCTGTTTCAAGCCGCGGGTGCAAAATACGTG
GTTCTGACCACGAAACATCACGAAGGTTTCACCAACTGGCCGAGCCCGGTTT
CTTGGAACTGGAATTCCAAAGATGTGGGTCCGCATCGTGACCTGGTTGGCGA
ACTGGGTACGGCGCTGCGTAAACGCAATATTCGCTATGGCCTGTACCATTCT
CTGCTGGAATGGTTTCACCCGCTGTATCTGCTGGATAAGAAAAACGGTTTTA
AAACCCAGCACTTCGTTAGTGCCAAAACGATGCCGGAACTGTATGATCTGGT
CAATAGTTACAAACCGGATCTGATCTGGTCCGACGGCGAATGGGAATGCCCG
GACACCTATTGGAACAGCACGAATTTCCTGTCTTGGCTGTACAACGATAGTC
CGGTGAAAGACGAAGTCGTGGTTAACGATCGTTGGGGTCAGAATTGCTCCTG
TCATCACGGCGGTTACTACAACTGCGAAGATAAATTCAAACCGCAATCACTG
CCGGACCATAAATGGGAAATGTGTACCAGTATTGACAAATTCTCCTGGGGCT
ATCGTCGCGATATGGCACTGTCGGACGTTACCGAAGAATCAGAAATTATCTC
GGAACTGGTTCAGACGGTCAGCCTGGGCGGTAACTACCTGCTGAATATCGGC
CCGACCAAAGATGGTCTGATTGTCCCGATCTTTCAAGAACGTCTGCTGGCCG
TGGGCAAATGGCTGTCAATTAACGGTGAAGCAATCTATGCTTCGAAACCGTG
GCGCGTCCAGTGGGAGAAAAACACCACGTCTGTGTGGTATACCAGTAAAGG
CTCCGCGGTTTACGCCATTTTTCTGCACTGGCCGGAAAACGGTGTGCTGAATC
TGGAATCACCGATCACCACGTCGACCACGAAAATTACCATGCTGGGCATCCA
GGGTGATCTGAAATGGAGCACGGATCCGGACAAAGGTCTGTTCATCTCTCTG
CCGCAACTGCCGCCGAGTGCTGTTCCGGCAGAATTTGCTTGGACGATTAAAC
TGACGGGTGTGAAATGA  
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A3.2 FUCA1 transcript in pET30a
+
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMGGAAES
VRRAQPPRRYTPDWPSLDSRPLPAWFDEAKFGVFIHWGVFSVPAWGSEWFWW
HWQGEGRPQYQRFMRDNYPPGFSYADFGPQFTARFFHPEEWADLFQAAGAKY
VVLTTKHHEGFTNWPSPVSWNWNSKDVGPHRDLVGELGTALRKRNIRYGLYHS
LLEWFHPLYLLDKKNGFKTQHFVSAKTMPELYDLVNSYKPDLIWSDGEWECPD
TYWNSTNFLSWLYNDSPVKDEVVVNDRWGQNCSCHHGGYYNCEDKFKPQSLP
DHKWEMCTSIDKFSWGYRRDMALSDVTEESEIISELVQTVSLGGNYLLNIGPTK
DGLIVPIFQERLLAVGKWLSINGEAIYASKPWRVQWEKNTTSVWYTSKGSAVY
AIFLHWPENGVLNLESPITTSTTKITMLGIQGDLKWSTDPDKGLFISLPQLPPSAV
PAEFAWTIKLTGVK 
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A3.3 FUCA2 gene sequence in pET30a
+
 
ATGCACCATCATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCTGGTAT
GAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCCCAGA
TCTGGGTACCGACGACGACGACAAGGCCATGGGCGCTCACTCAGCGACCCGT
TTCGACCCGACCTGGGAATCACTGGATGCGCGTCAACTGCCGGCGTGGTTCG
ATCAAGCAAAATTTGGCATTTTTATCCATTGGGGCGTGTTTAGCGTCCCGTCA
TTCGGTTCGGAATGGTTTTGGTGGTATTGGCAGAAAGAAAAAATCCCGAAAT
ACGTGGAATTCATGAAAGATAACTATCCGCCGAGCTTTAAATACGAAGACTT
TGGTCCGCTGTTCACCGCGAAATTTTTCAACGCAAATCAGTGGGCTGATATCT
TCCAAGCGAGTGGCGCCAAATATATTGTTCTGACCTCCAAACATCACGAAGG
CTTTACGCTGTGGGGTAGCGAATATTCTTGGAACTGGAATGCGATTGATGAA
GGTCCGAAACGTGACATCGTTAAAGAACTGGAAGTCGCCATTCGTAATCGCA
CCGATCTGCGCTTCGGCCTGTATTACTCTCTGTTTGAATGGTTCCATCCGCTG
TTTCTGGAAGACGAAAGCTCTAGTTTCCACAAACGTCAGTTTCCTGTGAGTA
AAACCCTGCCGGAACTGTATGAACTGGTGAACAATTACCAACCGGAAGTTCT
GTGGAGCGATGGTGATGGCGGTGCACCGGATCAGTATTGGAACAGCACGGG
TTTCCTGGCTTGGCTGTACAATGAATCTCCGGTTCGTGGCACCGTGGTTACGA
ACGATCGCTGGGGCGCGGGTAGTATCTGCAAACATGGCGGTTTTTATACCTG
TTCCGACCGCTACAACCCGGGTCATCTGCTGCCGCACAAATGGGAAAATTGC
ATGACGATTGATAAACTGTCATGGGGCTATCGTCGCGAAGCCGGTATTTCGG
ACTACCTGACCATCGAAGAACTGGTGAAACAACTGGTGGAAACGGTTAGCTG
TGGCGGTAACCTGCTGATGAATATCGGCCCGACCCTGGATGGTACGATTTCA
GTCGTGTTTGAAGAACGTCTGCGCCAAATGGGCTCGTGGCTGAAAGTTAACG
GTGAAGCAATTTATGAAACCCACACGTGGCGTAGCCAGAATGATACCGTCAC
GCCGGACGTGTGGTATACCTCTAAACCGAAAGAAAAACTGGTCTACGCTATC
TTCCTGAAATGGCCGACCAGTGGCCAGCTGTTTCTGGGTCATCCGAAAGCGA
TTCTGGGTGCCACGGAAGTCAAACTGCTGGGCCACGGTCAGCCGCTGAACTG
GATTAGCCTGGAACAAAATGGCATCATGGTGGAACTGCCGCAGCTGACGATT
CATCAAATGCCGTGTAAATGGGGCTGGGCTCTGGCTCTGACCAATGTCATCT
AA 
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A3.4 FUCA2 transcript in pET30a
+
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMGAHSAT
RFDPTWESLDARQLPAWFDQAKFGIFIHWGVFSVPSFGSEWFWWYWQKEKIPK
YVEFMKDNYPPSFKYEDFGPLFTAKFFNANQWADIFQASGAKYIVLTSKHHEGF
TLWGSEYSWNWNAIDEGPKRDIVKELEVAIRNRTDLRFGLYYSLFEWFHPLFLE
DESSSFHKRQFPVSKTLPELYELVNNYQPEVLWSDGDGGAPDQYWNSTGFLAW
LYNESPVRGTVVTNDRWGAGSICKHGGFYTCSDRYNPGHLLPHKWENCMTIDK
LSWGYRREAGISDYLTIEELVKQLVETVSCGGNLLMNIGPTLDGTISVVFEERLR
QMGSWLKVNGEAIYETHTWRSQNDTVTPDVWYTSKPKEKLVYAIFLKWPTSG
QLFLGHPKAILGATEVKLLGHGQPLNWISLEQNGIMVELPQLTIHQMPCKWGW
ALALTNVI 
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Appendix 4: Generation of FUCA1 constructs with 
minimal N-terminal octahistidine affinity tags 
A4.1 Oligonucleotide primers for generation of plasmids with only N-
terminal octahistidine affinity tags  
 
8His_FUCA1 
Forward primer  CAGCCTCCGCGCCGCTAC 
Reverse primer  GTGATGATGGTGATGGTGGTG 
8HisSG_FUCA1 
Forward primer  CAGCCTCCGCGCCGCTAC 
Reverse primer  GCCGCTGTGATGATGGTGATGGTGGTG 
8HisSGSG_FUCA1 
Forward primer  CAGCCTCCGCGCCGCTAC 
Reverse primer  GCCGCTGCCGCTGTGATGATGGTGATGGTGGTG 
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Abbreviations 
 
µg   Microgram 
µL   Microlitre 
µM   Micromolar 
µmol   Micromole 
A. thaliana  Arabidopsis thaliana   
ABP   Activity-based probe 
ABPP   Activity-based protein profiling 
ADAM  A disintegrin and metalloproteinase 
Arg   Arginine 
Asn   Asparigine 
Asp   Aspartic acid 
Bi   Bifidobacterium longum subsp. Infantis  
BODIPY  Boron-dipyrromethene 
BSA   Bovine serum albumin 
Bt   Bacteroides thetaiotaomicron 
C. jejuni  Campylobacter jejuni 
C   Celsius 
CAZy   Carbohydrate Active Enzymes database  
cDNA   Chromosomal deoxyribonucleic acid 
CHO   Chinese Hamster Ovary (cell strain)  
CMV   Cytomegalovirus 
CNP   2-chloro,4-nitrophenol 
CNP-fucoside 2-chloro,4-nitrophenyl-α-ʟ-fucopyranoside 
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Da   Dalton  
DFJ   Deoxyfuconojirimycin 
DLS   Diamond Light Source 
DMEM  Dulbecco’s Modified Eagle’s Medium  
DMJ   Deoxymannonojirimycin 
DNA   Deoxyribonucleic acid 
EDTA   Ethylenediaminetetraacetic acid 
EndoH   Endoglycosidase H 
ESRF   European Synchrotron Research Facility 
FBS   Foetal Bovine Serum 
Fg   Fuasrium graminearum 
FPLC   Fast protein liquid chromatography 
Fuc   Fucose 
FUCA1  α-ʟ-fucosidase 1 (Homo sapiens) 
FUCA2  α-ʟ-fucosidase 2 (Homo sapiens) 
FucCS   Fucosylated chondroitin sulfate 
fucR   ʟ-Fucose operon activator 
FUT1-11  GDP-α-ʟ-fucosyltransferases 1-11 
Gal   Galactose 
GalNAc  N-acetyl-galactosamine 
GDP   Guanine disphosphate 
GH   Glycoside hydrolase family 
GH29-A  Subfamily A from glycoside hydrolase family 29  
GH29-B  Subfamily B from glycoside hydrolase family 29  
GlcNAc  N-acetyl-glucosamine 
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Gln   Glutamine 
Glu   Glutamic acid 
GTP   Guanine triphosphate 
h   Hours 
HEK   Human embryonic kidney (cell strain)  
H. pylori  Helicobacter pylori 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His   Histidine 
HTCS   Hybrid two-component sensor/regulator  
IPTG   Isopropyl β-ᴅ-1-thiogalactopyranoside 
Ka    Acid dissociation constant  
kDa   Kilodalton 
K i   Inhibition constant 
KM    Michaelis constant 
L   Litre 
LADII   Leukocyte adhesion deficiency type II  
LB   Lysogeny Broth 
m    Minutes 
M   Molar 
MES   2-(N-morpholino)ethanesulfonic acid 
mg    Milligram 
mL   Millilitre 
mM   Millimolar 
mPES   Modified polyethersulfone 
mRNA   Messenger ribonucleic acid 
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MUC1   Cell surface-associated mucin 1 
nL   Nanolitre 
nm   Nanometre 
nM   Nanomolar 
P. aeruginosa Pseudomonas aeruginosa 
PAGE   Polyacrylamide gel electrophoresis 
PBS    Phosphate-buffered saline 
PDB   Protein databank 
PEG   Polyethylene glycol 
PEI   Polethylenimine 
pelB   Pectate lyase B 
PL   Polysaccharide lyase family 
PNGase  Peptide-N-glycosidase  
POFUT1-2  Protein-O-fucosyltransferases 1-2 
PUL   Polysaccharide utilisation locus 
RCF   Relative centrifugal force 
RCSB   Research Collaboratory for Structural Bioinformatics  
RMSD   Root-mean-square deviation 
ROS   Reactive oxygen species 
RPM   Revolutions per minute   
s   Seconds 
SDS   Sodium dodecyl sulfate 
Ser   Serine 
Sia   Sialic acid 
SUMO   Small ubiquitin-like modifier 
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Sus   Starch utilisation system 
TE   Trypsin-EDTA 1x working stock, Life Technologies  
TEV   Tobacco etch virus 
Thr   Threonine 
TIM   Triosephosphate isomerase 
Tm   Thermotoga maritima 
Tris   Tris(hydroxymethyl)aminomethane  
Trp   Tryptophan 
Vmax   Maxmial enzyme velocity 
w/v   Weight / volume 
Xyl   Xylose 
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